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1 SUMMARY 
The  origins  of  the  "population  approach"  to  pharmacokinetic  (PK)  and  pharmacodynarnic 
(PD)  data  analysis  owes  much  to  its  use  as  a  tool  for  understanding  the  variability  in  data 
collected  during  routine  therapeutic  drug  monitoring.  Subsequent  promotion  by  leading 
regulatory  scientists  led  the  impetus  that  resulted  in  its  regular  and  successful  application 
in  the  analysis  of  the  sparse  data  gathered  during  the  later  phases  of  drug  development. 
Nevertheless,  it  is  recognised  that  assessment  of  its  full  potential  requires  prospective 
application  from  the  beginning  of  drug  development  process.  This  concept  is  embodied  by 
the  definition  of  "PK/PD  as  a  general  conceptual  framework  for  drug  development". 
However,  early  studies  are  inherently  data  rich  and  therefore  lend  themselves  to 
noncompartmental  analyses  and  conclusions  based  on  standard  statistical  hypothesis 
testing.  Furthermore,  due  to  the  high  degree  of  experimental  constraint  and  the 
homogeneity  of  the  subjects  under  investigation,  the  benefits  from  the  "population 
approach"  in  its  traditional  sense  are  not  clearly  evident.  The  potential  advantages  of 
applying  the  population  approach,  and,  in  particular,  nonlinear  mixed  effects  modelling 
(NONMEM),  to  data  representative  of  those  typically  encountered  in  early  drug 
development  are  explored  in  this  thesis. 
Normally,  the  safety  of  chronic  drug  treatment  is  assessed  by  measuring  drug  accumulation 
during  multiple  dosing  to  steady  state.  However,  for  drugs  with  long  terminal  half-lives 
dosing  to  steady  state  is  not  always  practically  possible,  and  model  based  predictions  are 
often  used.  In  the  presented  example,  a  previous  standard  two  stage  approach  (STS) 
detected  an  equality  between  the  absorption  (Ka)  and  distribution  ((x)  rate  constants. 
However,  using  a  nonlinear  mixed  effect  model  both  rate  constants  were  separately 
charactensed.  Subsequently,  the  model  was  shown  to  be  useful  in  the  prediction  of 
2 variability  in  steady  state  concentrations  and  in  deducing  that  continuous  treatment  was 
unlikely  to  lead  to  chronic  toxicity. 
The  standard  bioequivalence  study  has  one  of  the  strictest  experimental  designs.  However, 
due  to  drug  toxicity  or  expected  clinical  biolnequivalence,  there  may  be  reason  to  establish 
bioequivalence  in  the  target  population.  In  these  circumstances  the  number  of  samples  that 
can  be  ethically  or  practically  taken  from  each  subject  may  be  limited.  A  population 
pharmacokinetic  approach  to  bioequivalence  testing  was  compared  to  the  standard 
noncompartmental  approach  using  data  from  two  routine  studies.  The  point  and  90% 
confidence  interval  estimate  for  relative  difference  in  the  area  under  the  concentration  time 
curve  (AUC)  and  Ka  was  estimated  directly  from  a  two  compartment  model  with  first 
order  absorption.  After  utilising  the  Wagner  Nelson  approximation  the  point  and 
confidence  interval  for  the  relative  difference  in  (the  maximum  concentration)  Cmax  was 
also  directly  calculated  using  a  novel  approach.  The  conclusion  of  bioequivalence  in  AUC 
and  bioinequivalence  in  Cmax  was  consistent  between  the  two  approaches.  After  randomly 
reducing  the  dataset  to  20%  of  the  its  original  size,  the  point  and  confidence  interval 
estimates  for  the  relative  difference  were  still  similar  to  those  originally  estimated.  This 
conclusion  was  influenced  by  the  sample  design  and  whether  an  additive  or  multiplicative 
bioequivalence  model  was  utilised.  It  was  also  shown  that  advanced  knowledge  of  the  PK 
model  was  most  likely  to  allow  the  bioinequivalence  in  Cmax  to  be  identified. 
It  has  been  proposed  that  the  use  of  cross-over  or  dose  escalation  designs  for  dose  ranging 
studies  in  combination  with  more  informative  analysis  could  lead  to  a  better 
characterisation  of  the  dose  response  relationship.  In  the  example  presented,  the  dose 
response  relationship  for  the  3-hydroxy-3-methylglutaryl  Coenzyme  A  inhibitors  (FMG 
COA)  inhibitor,  simvastatin,  was  estimated  from  a  cross-over  study  which  covered  the 
current  recommended  dose  range  (10  to  40  mg).  Analysis  using  nonlinear  mixed  effects 
modelling  approach  demonstrated  that  the  selected  doses  only  covered  20%  (70  to  90%)  of 
3 the  upper  part  of  the  estimated  dose  response  relationship.  It  was  concluded  that  a  lower 
dose  strength  would  be  required  to  allow  adjustment  within  the  log-linear  portion  of  the 
dose  response  relationship.  The  clinical  implications  of  potential  relationships  between  the 
pre-treatment  cholesterol  level  and  the  model  parameters  were  explored  through  prediction 
and  simulation.  On  simulating  the  relationship  between  dose  and  the  percentage  of  patients 
who  would  achieve  reductions  to  below  a  recognised  target  concentration,  it  was  found  that 
a  different  set  of  dosages  may  better  optimise  clinical  response. 
Where  strict  experimental  design  is  invalidated  by  study  design  or  restricted  recruitment, 
the  resulting  data  can  be  unbalanced  and  not  easily  analysed  by  standard  statistical 
methods.  In  the  example  presented,  the  number  and  size  of  doses  of  dofetilide  used  to  test 
for  PK/PD  differences  between  patients  with  ischaernic  heart  disease  (ISH)  and  healthy 
volunteers  were  different.  A  population  PK/PD  modelling  approach  was  implemented, 
and  no  difference  between  the  two  groups  could  be  detected.  The  Cmax  and  peak  QTc 
ranges  were  predicted  to  be  narrower  following  a  fixed  dose  regimen  in  comparison  to  a 
dose  per  kilogram  regimen.  However,  after  incorporating  the  PK/PD  variability,  this  was 
not  predicted  to  manifest  into  an  overall  increase  in  the  risk  of  Torsades  de  POintes. 
Nevertheless,  there  was  evidence  to  suggest  that  an  upper  total  dose  lirMt  would  be  needed 
if  a  dose  per  kilogram  regimen  was  to  be  adopted  in  future  studies. 
Although  early  drug  development  is,  by  nature,  a  piece-wise  process,  the  application  of 
more  intuitive  methods  of  analysis,  such  as  nonlinear  mixed  effects  modelling,  was  shown 
to  provide  a  better  understanding  of  the  dose  concentration  response  relationship  and  a 
useful  tool  with  which  to  investigate  study  designs  issues.  On  the  basis  of  the  analyses 
presented,  the  early  prospective  application  of  these  techniques  should  have  benefits  in  the 
optimisation  of  drug  development. 
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.1 
The  phased  approach  to  drug  development 
The  term  "drug  development"  covers  the  wide  variety  of  activities  required  to  take  new 
chemical  entities  from  discovery  through  to  regulatory  approval.  The  process  is  time- 
consuming,  very  costly  and  has  a  high  failure  rate.  Only  about  one  or  two  from  every 
10,000  compounds  synthesised  finally  become  licensed  pharmaceuticals,  so  it  is  important 
that  the  process  is  optimally  managed  and  controlled.  The  risk  to  healthy  volunteers  and 
patients  taking  part  in  clinical  trials  is  minimised  by  reassessing  the  proposed  therapeutic 
advantage  of  each  chemical  entity  throughout  the  development  process.  A  phased 
approach  is  most  often  applied  to  both  streamline  the  development  process  and  improve 
decision  making.  The  commonly  defined  phases  of  drug  development  are  briefly  described 
below: 
Preclinical 
Identification  of  candidate  drugs  by  comparing  the  activity  and  safety  profiles  via  in  vitro 
and  animal  models  is  the  goal  of  the  preclinical  phase.  Pharmacokinetic  and 
pharmacodynamic  data  gathered  during  this  phase  are  also  used  to  guide  human  dosage 
regimen  development  and  dose  escalation  strategies.  The  accuracy  of  predictions  from  in 
vitro  and  animal  models  can  vary  substantially,  so  expeditious  progression  to  a  point 
where  human  investigation  can  be  initiated  at  minimum  risk  is  the  primary  focus  of  the 
preclinical  phase. 
Phase  I  studies 
The  primary  aim  of  Phase  I  is  to  determine  safety  and  tolerability  of  a  new  drug  in  human 
volunteers.  A  secondary  aim  is  to  provide  infon-nation  on  the  absorption,  distribution, 
metabolism  and  excretion  and,  in  some  cases,  early  proof  of  the  therapeutic  concept  i.  e. 
demonstration  of  the  blood  pressure  reduction  effects  of  a  new  ant1hypertensive. 
22 Phase  11  studies 
Progression  from  Phase  I  to  Phase  11  represents  the  transition  from  healthy  volunteers  to 
patients  with  the  disease  state(s)  of  interest.  Similar  factors  are  explored  in  both  settings, 
but,  the  focus  of  Phase  11  is  to  establish  that  the  new  drug  is  effective.  A  secondary  aim  is 
to  establish  a  dose  range  which  provides  benefit  while  rrunin-ýsing  the  risk  of  adverse 
effects.  This  information  is  used  in  the  design  of  the  Phase  III  studies. 
Phase  III  studies 
These  are  comparative  studies  designed  to  assess  the  safety  and  effectiveness  of  the  drug  in 
conditions  approximating  those  in  which  the  drug  would  be  used  in  clinical  practice.  The 
best  dosage  form  and  dose  or  range  of  doses  from  Phase  II  are  administered  to  a  larger  and 
more  varied  patient  population.  One  of  the  additional  aims  is  the  detection  of  groups  of 
patients  who  may  be  at  increased  risk  of  adverse  eftects  or  who  require  a  higher  dose  to 
achieve  an  adequate  therapeutic  response. 
1.2  Role  of  pharmacokinetic  and  pharmacodynamic  modelling  in 
drug  development 
The  overall  understanding  of  a  complex  system  can  be  considered  to  be  the  sum  of  the 
knowledge  of  its  component  parts.  The  components  underlying  the  relationship  between 
dose  and  response  (Figure  1.1)  are  more  fully  described  below. 
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1.2.1  Pharmacokinetics  and  pharmacokinetic  modelling 
The  term  Pharmacokinetics  was  defined  by  WHO  as  "the  study  of  the  absorption, 
distribution  metabolism  and  elimination  of  drugs"  (World  Health  Organisation,  1970).  An 
apt  definition  by  Wagner  describes  it  as  "the  study  of  the  time  courses  of  drug  and 
metabolite  concentrations  and  amounts  in  biological  fluids,  tissues  and  excreta  .....  and  the 
construction  of  suitable  models  to  interpret  the  data  "  (Wagner,  1968).  The  latter 
highlights  the  need  to  model  or  reduce  the  data  to  a  set  of  meaningful  parameters  which 
can  be  used  to  make  predictions  for  future  experiments.  The  functional  form  of  the 
pharmacokinetic  model  is  dependent  upon  both  the  processes  to  be  modelled  and  the  future 
24 predictions  required,  but  usually  involves  relating  dose,  dose  frequency,  and  route  of 
administration  to  the  change  in  plasma  concentration  (Cp)  over  time. 
1.2.2  Pharmacodynamics  and  pharmacodynamic  modelling 
The  principles  surrounding  the  establishment  of  an  appropriate  dosage  regimen  rest  heavily 
on  the  assumption  that  a  functional  relationship,  albeit  complex,  exists  between  the 
concentration  at  the  site  of  action  (Ce)  and  the  response  ultimately  produced. 
Pharmacodynamics  is  the  study  of  this  relationship  and  PD  modelling  involves  the 
mathematical  expression  of  the  inhibition,  activation  or potentiation  of  the  biological  signal 
(biosignal)  which  underlies  the  drug  response.  Therefore,  drug  potency  and  tissue  or organ 
sensitivity  can  be  usefully  summarised  by  using  models  linking  concentration  to  clinical 
effect  (Holford  &  Sheiner,  1982a,  b).  While  the  benefits  of  a  new  drug  cannot  be  fully 
established  until  large  scale  efficacy  trials  are  conducted,  the  relationships  between 
surrogate  markers  of  response  to  dose  or  concentration  can  be  used  to  indicate  therapeutic 
potential  and  guide  future  dosing.  The  measurement  of  drug  effect  and  its  interpretation 
through  the  principles  of  pharmacodynamics  is  now  considered  to  be  a  very  important  part 
of  early  drug  development. 
1.2.3  The  linking  of  pharmacokinetics  and  pharmacodynamics:  Past  and 
present  approaches 
The  full  potential  of  PK/PD  modelling  was  not  fully  realised  until  the  effect  compartment 
or  link  model  was  popularised  in  the  late  1970's  early  1980's  (Kelman  &  Whiting,  1979; 
Sheiner  et  al.,  1979;  Whiting  et  al.,  1980;  Holford  &  Sheiner,  1982b)  which  was  some 
years  after  the  seminal  paper  by  Segre  (Segre,  1968).  It  has  now  become  the  standard 
methodology  in  modelling  the  temporal  displacement  between  concentration  and  effect 
(hysteresis),  a  complexity  which  can  often  anse  in  non-steady  state  PK/PD  studies  (Hudson 
25 et  al.,  1983;  Meredith  et  al.,  1983;  Guy  et  al.,  1984;  Fisher  et  al.,  1985;  Hinderling  et  al., 
1985;  Kelman  et  al.,  1986). 
Elaboration  of  the  basic  models  has  also  led  to  the  development  of  sen-ý-parametnc 
approaches,  where  the  PD  and/or  PK  relationship  is  characterised  non-parametrically,  but  a 
parametric  link  model  is  used  to  account  for  the  hysteresis  (Unadkat  et  al.,  1986;  Verotta  & 
Sheiner,  1988;  Fuseau  &  Sheiner,  1989).  Moreover,  convolution  techniques  which  allow 
the  temporal  delay  to  be  characterised  by  poly-exponential  and  non-parametric  spline 
functions  have  also  been  proposed  (Verotta  &  Sheiner,  1991;  Gumbleton  et  al.,  1994). 
Other  physiological  approaches  to  describing  the  relationships  between  concentration  and 
effect  have  more  recently  been  proposed.  Protein  binding  (Pedraz  et  al.,  1992) 
, 
formation 
of  competitive  or  non-competitive  agonists  and  antagonists  (Gupta  et  al.,  1993)  and  arteno- 
venous  drug  concentration  differences  (Gumbleton  et  al.,  1994)  have  been  proposed  as 
alternative  pharmacokinetic  mechanisms  by  which  both  displacement  of  effect  from 
concentration  (counterclockwise  -hysteresis  loop  )  or  displacement  of  concentration  from 
effect  (clockwise  -proteresis  loop  )  could  occur. 
A  physiological  modelling  approach  to  PK/PD  was  used  some  time  ago  to  describe  the 
effect  of  warfarin  on  prothrombin  complex  activity  (Nagashima  et  al.,  1969;  Sheiner,  1969) 
and  further  described  by  Holford  and  Sheiner  (1982b).  More  recently  it  has  been  applied  to 
study  the  pharmacodynarnics  of  corticosteriods  (Kong  et  al.,  1989;  Wald  et  al.,  1991;  Wald 
&  Jusko,  1992;  Lew  et  al.,  1993)  and  prolactin  suppression  (Francheteau  et  al.,  1991).  By 
way  of  these  and  other  examples,  Jusko  and  co-workers  characterised  a  family  of  indirect 
response  models  for  stimulation  or  inhibition  of  the  production  or  loss  of  endogenous 
substances  or  mediators  (Dayneka  et  al.,  1993)  and  proposed  their  utility  in  charactensation 
of  the  lag-time  between  concentration  and  effect  for  other  therapies  (Jusko  &  Hui,  1994). 
They  also  demonstrated  that  mi  s-  specification  of  an  effect  compartment  model  in  place  of 
26 an  indirect  model  would  result  in  erroneous  conclusions  i.  e.  that  Ce5o  and  Emax  were  dose 
dependent  (Dayneka  et  al.,  1993;  Jusko  &  Hui,  1994). 
The  establishment  of  appropriate  methods  for  undertaking  a  PK/PD  modelling  approach 
has  subsequently  led  to  its  extensive  application  in  many  therapeutic  areas  i.  e.  (Swerdlow 
&  Holley,  1987;  Dingernanse  et  al.,  1988;  Donnely  et  al.,  1989;  Reid  &  Meredith,  1990; 
Manderna  &  Danhof,  1992)  and  has  been  the  focus  of  specialist  symposia  i.  e.  (Danhof  & 
Peck,  1994).  More  recently  the  importance  of  these  approaches  have  gained  favour  within 
the  drug  industry  (Steimer  et  al.,  1993;  Van  Peer  et  al.,  1993)  and  the  drug  regulatory 
agencies  (Peck  &  Collins,  1990;  Peck,  1992a,  1993).  A  more  detailed  discussion  of  the 
advantages  of  PK/PD  modelling  in  the  area  of  antiarrhythmic  drug  therapy  is  shown  below, 
and  serves  as  the  background  to  PK/PD  analysis  described  in  Chapter  7. 
Hysteresis  in  the  concentration  versus  ECG  time  intervals  has  been  commonly  shown  for 
many  antiarrhythmic  drugs  after  intravenous  administration  i.  e.  amiodarone  (Rodden, 
1993),  ajmaline  (Padrini  et  al.,  1993)  diltiazem  (Schwartz  &  Abernethy,  1987),  flecainide 
(Wang  et  al.,  1988),  procainanude  (Galeazzi  et  al.,  1976),  and  verapamil(Abemethy  et  al., 
1986).  Consequently,  one  of  the  initial  applications  of  the  effect  compartment  theory  was 
in  the  PK/PD  modeling  of  antiarrhythmics  i.  e  quinidine  (Holford  et  al.,  1981)  digoxin 
(Kelman  &  Whiting,  1979)  and  disopyrarrude  (Whiting  et  al.,  1980). 
As  an  alternative,  the  slopes  of  the  concentration  ECG  interval  relationship  can  be  obtained 
from  the  post  infusion  data  (Echizen  et  al.,  1985;  Abernethy  et  al.,  1986;  Schwartz  & 
Abernethy,  1987).  However,  Schwartz  et.  al.  (1989)  demonstrated  that  this  technique 
resulted  in  biased  slope  estimates,,  which  over  predict  the  steady  state  QTc.  Furthermore, 
since  the  descending  limb  of  the  hysteresis  loop  (data  post  end  of  infusion)  can  often 
approximate  a  sigmoid  relationship,  dose  dependent  Emax  and  CE50  parameter  estimates 
have  in  some  cases  been  wrongly  reported  (Echizen  et  al.,  1985;  Schwartz  &  Abernethy, 
1987). 
27 1.3  Pharmacokinetic  and  pharmacodynamic  variability 
The  factors  which  are  commonly  found  to  influence  the  pharmacokinetics  and 
pharmacodynamics  and,  therefore,  help  explain  the  variability  in  the  PK/PD  model  are  also 
shown  in  Figure  1.1.  In  the  following  two  sections  the  components  of  the  overall 
variability  are  discussed  with  reference  to  these  factors: 
Interindividual  variability 
The  interindividual  variability  in  drug  response  can  result  from  either  pharmacokinetic  or 
pharmacodynamic  differences  between  subjects.  Differences  in  diet  and  disease  state  can 
affect  the  rate  and  extent  of  drug  absorption.  Similarly,  differences  in  body  size,  body 
weight,  tissue  composition  and  tissue  binding  can  account  for  interindividual  differences  in 
drug  distribution.  The  variability  in  elimination  often  depends  on  both  genetic  and 
environmental  factors.  Metabolic  rates  can  be  either  or  both  genotypically  or 
phenotypically  different.  Differences  in  overall  elimination  can  be  further  altered  by  the 
effect  of  ageing  or  disease.  Both  pathophysiological  and  genetic  differences  are  major 
factors  influencing  the  interindividual  variability  in  phannacodynamics. 
Intraindividual  Variability 
Residual  or  intraindividual  variability  is  related  to  several  sources.  "True"  intraindividual 
variability  is  most  often  obscured  by  the  variability  inherent  in  the  measurements  of 
concentration  or  response  i.  e.  assay  error  or  the  error  in  the  recordings  of  dosing  and 
sampling  times.  "True-  intraindividual  variability  results  from  moment  to  moment  or 
occasion  to  occasion  changes  in  physiology,  in  some  cases  these  have  a  rhythm  and  can  be 
modelled  i.  e.  diurnal  variation  in  blood  pressure. 
28 1.3.1  Population  approach 
The  aim  of  the  population  approach  is  to  assess  the  central  tendency  of  the 
pharmacokinetic  and  pharmacodynamic  response  and  to  quantify  the  variability  around  it. 
Although,  the  concept  of  measuring  and  accounting  for  variability  in  pharmacokinetics  is 
not  new,  the  development  of  novel  statistical  methods  has  allowed  PKIPD  modelling  to 
implemented  across  all  phases  of  drug  development.  An  outline  of  the  available  statistical 
methodologies  and  the  development  of  the  population  approach  are  described  below. 
1.3.2  Statistical  methodologies  used  in  population  pharmacokinetics 
The  standard  two  stage  approach  (STS)  is  often  used  to  obtain  estimates  of  the  average 
pharmacokinetic  parameters  and  their  associated  variability  from  rich  experimental  data. 
With  this  approach  the  estimation  of  interindividual  variability  and  the  investigation  of 
covariate  relationships  are  undertaken  in  a  separate  step  to  the  nonlinear  regression  used  to 
estimate  the  individual  model  parameters.  Provided  that  the  study  design  is  reasonably 
balanced,  the  average  parameter  estimates  should  theoretically  agree  with  the  "True" 
values.  However,  it  would  be  expected  that  the  interindivIdual  variabilities  would  be 
upwardly  biased  since  they  include  the  uncertainty  in  the  estimation  of  the  individual 
parameter  estimates.  Furthermore,  particular  problems  arise  with  the  STS  approach  when 
the  data  per  individual  is  sparse,  since  obtaining  parameter  estimates  for  every  individual 
may  become  difficult.  In  such  circumstances  naive  pooling  of  data  (NPD)  can  be  used  to 
obtain  average  parameter  estimates.  However,  this  approach  ignores  the  concept  of  the 
individual,  and  estimates  of  interindividual  vanability  are  not  available. 
Statistically,  a  non-linear  mixed  effect  model,  allowing  for  repeated  measurements  ,  is 
necessary  to  allow  estimation  of  parameters  in  a  single  stage.  "Mixed  effects"  refers  to  the 
combination  of  both  fixed  effects  (parameters  and  covariate  relationships)  and  random 
29 effects  (intra-  and  inter-  individual  variability).  A  parametric  approach  to  the  estimation 
problem  was  developed  by  Sheiner  and  Beal  and  first  implemented  as  the  first  order  (FO) 
method  within  the  program  NONMEM  (Beal,  SL  &  Sheiner,  1980).  The  ten-n  "parametric 
refers  to  the  assumption  that  the  variability  in  both  parameter  estimates  and  measurements 
follows  a  Gaussian  distribution.  The  first  order  method  utilises  the  first  term  of  the  Taylor 
series  expansion  of  the  nested  (intraindividual  within  interindividual)  random  effects.  The 
resultant  linearisation  simplifies  the  problem  to  one  which  is  more  easily  estimated. 
Despite  this  approximation,  the  method  has  been  shown  to  be  superior  to  the  NPD  method 
in  estimating  the  population  mean  (structural)  parameter  estimates  and  superior  to  the  STS 
in  estimating  interindividual  variability  of  mean  parameters  when  the  data  is  simulated  as 
either  sparse  clinical  (Sheiner  &  Beal,  1980;  Sheiner,  1984;  Steimer  et  al.,  1984; 
Hashimoto  et  al.,  1994)  or  rich  experimental  (Sheiner  &  Beal,  1981,1983;  Beal,  1984) 
from  a  linear  (Sheiner  &  Beal,  1981,1983;  Sheiner,  1984;  Steimer  et  al.,  1984)  or 
nonlinear  (Sheiner  &  Beal,  1980;  Hashimoto  et  al.,  1994)  PK  (PD)  model.  Nevertheless, 
the  algorithm  is  prone  to  inaccuracies  when  interindividual.  variation  is  large  (White  et  al., 
1990)  or  when  the  parameter  estimates  are  highly  correlated  (Steimer  et  al.,  1984). 
Other  approaches  have  also  been  developed.  Mallet  (1986)  introduced  the  non-parametric 
maximum  likelihood  method  which  differs  from  NONMEM  in  that  it  is  not  dependent  on 
any  prior  assumptions  about  the  distribution  of  the  parameter  estimates  within  the 
population.  A  Bayesian  method  has  also  be  suggested  (Racine-Poon  &  Smith,  1990)  and 
developed  using  Gibbs  Sampling  into  several  exportable  packages. 
An  EM  (  expectation  maximisation)  -algorithm  developed  to  analyse  linear  models 
(Dempster  et  al.,  1977;  Laird  &  Ware,  1982)  has  been  further  developed  for  estimation  of 
non-linear  models  by  utilising  different  linearisation  methods  (Amisaki  &  Tatsuhara,  1988; 
Aarons,  1993).  A  Bayesian  approach  implementing  the  EM-algonthm  has  also  been 
proposed  (Racine-Poon,  1985). 
30 More  recent  versions  of  NONMEM  have  developed  along  similar  lines  and  now  include  a 
first  order  conditional  (FOCE)  algorithm  which  is  similar  to  the  Lindstrom  and  Bates 
method  (Lindstrom  &  Bates,  1990).  Details  of  statistical  aspects  of  the  NONMEM 
software  are  discussed  in  chapter  3. 
1.3.3  The  population  approach  -Past  and  present  developments 
It  was  the  FDA  who  first  raised  concerns  that  the  pharmacokinetics  of  new  drugs  were  not 
being  sufficiently  investigated  during  the  drug  development  process.  In  particular,  to  aid  in 
the  selection  of  appropriate  doses,  they  outlined  the  need  for  the  pharmacokinetics  of  new 
drugs  to  be  studied  in  the  elderly  population  (Temple,  1983,1985).  In  these  documents 
they  introduced  the  concept  of  the  pharmacokinetic  screen,  where  trends  between  patient 
demographics  and  steady  state  trough  plasma  concentrations  were  investigated.  This 
simplistic  approach  was  first  adopted  for  practical  reasons,  since  extensive 
pharmacokinetic  sampling  in  elderly  patients  was  not  ethically  permissible.  The  data  was 
often  sparse  and  biased  as  the  number  and  frequency  of  samples  could  vary  between 
patients  and  visits.  A  formalised  approach  adopting  more  sophisticated  methodology  was 
required  to  deal  with  these  data.  Sheiner  et  al.  had  earlier  alluded  to  methodology  which 
could  be  used  in  these  situations  and  highlighted  the  clear  rationale  for  their  development 
as  an  aid  to  both  drug  development  and  clinical  evaluation  (Sheiner  et  al.,  1972,1977). 
Despite  this  obvious  need,  the  application  of  the  population  approach  was  for  many  years 
quite  limited.  Underlying  this  was  a  degree  of  healthy  scepticism  within  the  drug  industry 
(Darrow,  1985;  Colburn,  1989).  The  main  reasons  for  this  was  complexity  of  the 
methodology,  the  lack  of  general  acceptance  of  the  statistical  techniques,  and  the 
explorative  nature  of  the  analyses.  However,  at  that  time  therapeutic  drug  monitoring  xvas 
at  its  peak,  and  retrospective  analysis  using  the  population  approach  was  used  to 
31 investigate  actors  which  influenced  the  pharmacokinetics  of  drugs  with  a  narrow 
therapeutic  index  (Whiting  et  al.,  1986).  These  analyses  provided  information  for  both 
dose  initiation  and  subsequent  adjustment  via  Bayesian  feedback  (Kelman  et  al.,  1982; 
Sheiner  &  Beal,  1982). 
As  a  result  of  the  continued  acadernic  interest,  the  approach  slowly  gained  favour  within 
the  drug  industry.  During  the  1990's  there  has  been  an  explosion  of  interest,  as  reflected 
by  the  large  increase  in  publications  and  the  formation  of  specific  user  groups  (i.  e.  PAGE). 
The  support  through  the  COST  BI  initiative  has  been  pivotal  in  both  the  further 
development  and  wider  application  of  the  approach  within  the  drug  industry  (Bechtel  & 
Alvan,  1998).  As  well  as  two  conferences,  specialist  meetings  on  PK/PD  software  (Aarons 
et  al.,  1994)  and  performing  population  PK/PD  studies  (Aarons  et  al.,  1996)  have  added 
greatly  to  the  developments  in  this  areas.  The  first  conference  entitled  "New  strategies  in 
drug  development  and  clinical  evaluation;  the  population  approach"  highlighted  the  short- 
comings  to  be  overcome  in  order  for  the  approach  to  become  more  acceptable.  Jochemsen 
(1992)  revealed  that  the  European  pharmaceutical  industry  was  beginning  to  employ  the 
population  approach  and  incorporate  it  into  study  design.  However  there  had  only  been  a 
limited  amount  of  prospective  application  and  it  was  felt  that  a  conceptual  shift  within  the 
industry  was  required  if  the  approach  was  to  become  established  (Olson,  1992).  While 
individuals  within  FDA  continued  to  champion  the  approach  (Peck,  1992a),  the  European 
guidelines  did  not  reflect  the  growing  interest  (Gundert-Remy,  1992). 
The  second  COST  BI  "Conference  on  the  population  approach:  measuring  and  managing 
variability  in  resPonse,  concentration  and  dose"  in  Geneva  in  1997  demonstrated  that  many 
advances  had  been  made.  The  five  intervening  years  had  seen  an  appreciable  development 
addressing  theoretical  issues  around  estimation  methods,  statistical  models  and  design.  A 
staggering  growth  in  both  awareness  and  interest  in  the  approach  was  exemplified  by  the 
three  fold  increase  in  the  number  of  scientific  publications  (Vozeh,  1997).  The  present  day 
32 value  of  the  approach  was  highlighted  by  the  growth  in  prospectively  planned  population 
PK/PD  analyses  (Bruno,  1997;  Fuseau  et  al.,  1997;  Jorga  et  al.,  1997;  Manderna,  1997), 
and  the  number  of  subsequent  submissions  to  the  FDA  which  had  included  the  approach 
(25%)  (Ette,  1997).  Furthermore,  the  FDA  and  NTA  regulators  presented  a  number  of 
cases  where  population  PK  was  being  used  as  evidence  for  labelling  statements  (Ette, 
1997;  Wade,  1997). 
Now,  the  potential  of  population  pharmacokinetic  and  pharmacodynan-&  modelling  and  its 
application  to  the  drug  development  process  receives  similar  attention  from  academic 
(Aarons,  1992;  Sale  &  Blaschke,  1992;  Sheiner  &  Ludden,  1992;  Grasela  &  Antal,  1993; 
Rosenbaum  et  al.,,  1995)  industry  (Samara  &  Granneman,  1997)  and  regulatory  agencies 
(Peck  et  al.,  1992b). 
1.3.4  Application  of  PK/PD  modelling  in  the  early  phases  of  drug 
development 
The  application  of  PK/PD  modelling  to  data  obtained  from  the  early  phases  (1/11)  of  drug 
development  and  its  the  subsequent  use  in  the  design  of  the  Phase  III  studies  has  been 
discussed  in  several  papers  (Steimer  et  al.,  1993;  Van  Peer  et  al.,  1993;  Peck,  1997).  In 
particular,  Sheiner,  who  previously  questioned  the  adequacy  of  the  current  practices  used  in 
drug  development  (Sheiner,  1991),  has  proposed  an  alternative  strategy  with  PK/PD 
modelling  as  the  cornerstone  of  the  optimised  process.  By  partitioning  Phases  1/11  and  III 
into  cycles  of  "leaming"  and  "confirming",  respectively,  he  highlighted  that  early 
development  should  serve  to  fully  evaluate  the  "therapeutic  response  surface"  (Sheiner, 
1997);  a  mandate  that  requires  a  greater  flexibility  both  in  the  design  and  analysis  of  the 
early  studies  (Sheiner  &  Rubin,  1995).  Although  some  examples  showing  the  advantages 
of  using  PK/PD  modelling  with  rich  experimental  data  have  been  highlighted  (Sambol, 
33 1991;  Karlsson  et  al.,  1995;  Schoemaker  &  Cohen,  1996),  further  work  exploring  the 
advantages  and  disadvantages  of  utilising  these  methodologies  in  the  early  phases  of  drug 
Zý 
development  is  required  to  support  conceptual  change  proposed  by  Sheiner  and  others. 
34 CHAPTER  2 
OUTLINE  AND  GENERAL  AIMS 
35 The  general  aim  of  this  thesis  is  to  explore  how  nonlinear  mixed  effects  modelling  can  be 
used  in  the  analysis  of  data  taken  from  the  early  stages  of  drug  development.  The 
advantages  and  disadvantages  of  applying  these  techniques  are  examined  through  a  series 
of  examples- 
Drug  safety  analysis  -  Chapter  4 
Bioequivalence,  testing-  Chapter  5 
Dose  response  analysis  -  Chapter  6 
Dose  concentration  response  analysis  -  Chapter  7 
The  order  or  presentation  represents  the  transition  from  the  application  of  pharmacokinetic 
modelling  (Chapters  4  and  5)  to  pharmacodynamic  modelling  (Chapter  6)  and  finally  to  an 
example  of  integrated  PK/PD  modelling  (Chapter  7).  The  common  pharmacokinetic  and 
statistical  methods  are  outlined  in  Chapter  3.  Each  subsequent  chapter  is  an  integral  piece 
of  work;  with  aims,  methods,  results,  discussion  and  conclusions.  While  Chapters  4,6  and 
7  are  focused  towards  the  drug  under  investigation,  all  Chapters  assess  the  potential 
advantages  of  applying  a  rnixed  effect  modelling  approach  to  standard  early  drug 
development  problems. 
Conclusions  from  the  four  separate  analysis  are  presented  in  Chapter  8. 
36 CHAPTER  3 
GENERAL  METHODS 
37 This  chapter  describes  the  pharmacokinetic  and  statistical  methods  which  are  common  to 
the  analyses  presented  in  the  later  Chapters.  Analysis  specific  methods  are  presented 
within  each  subsequent  Chapter. 
3.1  The  nonlinear  mixed  effects  model 
As  previously  discussed,  a  non-linear  mixed  effects  model  can  be  used  to  describe  the  fixed 
and  random  effects  associated  with  a  model  based  approach  to  a  PK/PD  problem  (Chapter 
1).  In  the  sections  below,  the  intraindividual  and  interindividual  submodels  are  descnbed 
along  with  the  methods  used  to  estimate  both  simultaneously. 
3.1.1  Intraindividual  submodel 
In  PK/PD  analyses,  it  is  usually  assumed  that  observations  can  be  described  by  the 
following  model 
yi  f 
(pi 
7x 
ii,  -Fid 
Eq  (3.1) 
Where  yij  is  the  jth  observation  (concentration  and  /or  response)  from  the  ith  individual, 
is  a  general  function  of  all  arguments  listed  which  includes  a  structural  model  that 
relates  the  independent  variables,  Xij  (e.  g.  time  and  dosage  history),  to  the  observations 
given  the  ith  individuals  vector  of  model  parameters  p,  (such  as  CL,  V,  D5o  and  Emax). 
The  term  ej  accounts  for  the  error  between  the  observations  yj  and  model  predictions  yj, 
and  is  normally  assumed  to  be  independently  symmetrically  distributed  with  an  expected 
mean  value  of  zero  and  van  ance  V  a'  . 
The  parameter  V  represents  the  dependence 
between  model  predictions  ý  and  the  intraindividual  error  variance.  Changes  to  v  alter  Yjj 
how  the  intraindividual  variability  model  is  implemented.  If  there  is  no  dependence  i.  e.  the 
variance  remains  constant  irrespective  of  the  magnitude  of  the  predictions,  the  error  model 
38 is  said  to  homoscedastic  or  additive.  In  this  case,  V  (described  above)  equals  I  and  07  is 
the  standard  deviation  (SD).  However,  in  many  PKIPD  cases  the  error  model  is  found  to 
be  heteroscedastic  i.  e.  the  error  variance  changes  with  the  magnitude  of  the  prediction.  A 
limited  heteroscedastic  case  is  where  the  error  vanance  is  proportional  to  the  magnitude  of 
^. Y  In  this  case,  V  equals 
2 
the  variance  of  cj  becomes  or  2y2  and  or  is  the  ij  yij  I  ^ij 
coefficient  of  variation  (%CV). 
In  NONMEM  additive  and  proportional  intraindividual  error  models  are  defined  as  follows 
Y=F+  EPS(l) 
Y=F*  (1  +EPS  (1)) 
Eq  3.1 
Eq  3.2 
where  Y  is  y,  F  is  ^  and  EPS(I)  is  E,  . 
An  exponential  expression,  as  shown  below 
ij  Yjj  j 
can  also  be  used 
Y=F  *EXP  (EPS(l))  Eq  3.3 
However,  with  the  FO  approximation  (see  section  3.2)  this  is  operationally  identical  to  the 
proportional  error  model  (Eq  3.2). 
More  complex  intraindividual  error  models  can  also  be  defined.  In  the  general 
heteroscedastic  case  the  error  variance  is  equal  too7'  ^ýi,  where  ýj  is  an  estimated  variance  Y  ij 
parameter.  The  advantage  of  this  is  model  is  that  it  can  smoothly  interpolate  between  a 
homoscedastic  model  (Ci=O)  and  the  proportional  model  (Ci=2). 
Unfortunately,  observations  at  or  around  zero  cause  estimation  problems.  Often  the 
combined  exponential  (or  proportional)  and  additive  model  is  used.  In  this  case  two 
^2 
independent  errors,  cj,  and  and  therefore  two  independent  variances  2  and  Eij  2 
yij  U  EXp 
2  are  estimated.  The  is  expressed  as  a  (%CV)  and  is  expressed 
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39 as  a  standard  deviation  (SD).  In  NONMEM,  the  van  ances  and  covari  ances  for  theFj  's  are 
estimated  as  a  block  matrix  (1). 
In  NONMEM  the  combined  exponential  and  additive  intraindividual  error  model  is written 
as  follows 
Y=F  *EXP(l)  +  EPS(2)  Eq  3.4 
This  was  the  most  complex  model  tested  in  this  thesis  and  has  the  advantage  that  it  can  be 
easily  reduced  to  an  additive  or  exponential  error  model. 
3.1.2  Interinclividual  model 
The  individual  structural  parameter  estimates  p,  's  are  distributed  around  their  typical 
values  0.  The  following  describes  the  general  relationship 
Pik  :::::  9k  (Ok 
" 
Zi 
7 
Ilki)  Eq  (3.5) 
Where  PiK'S  the  kth  parameter  in  the  vector  of  individual  parameters 
P, 
9  Ok  is  a  parameter 
of  ()  which  singly  (or  in  combination  with  other  parameters  from  ()  )  describes  the 
population  average  or  typical  value  Pk  . 
The  term  Z.  represents  the  vector  of  covariates 
for  the  ith  individual.  e.  g.  the  ith's  individuals  demographics,  biochemistry  or  concomitant 
medication.  The  function  9k  Ois  a  general  function  of  all  arguments  listed,  and  relates 
Pk  to  z.  throughOk  ,  while  estimating  the  difference 
(11ki  )between  Pk  and  Pik,  The 
flki  9s  are  assumed  to  be  independently,  multivariately  distnbuted,  with  mean  expected 
2 
values  of  zero  and  variances  of  0),,.  The  variances  and  covariances  for  the 
TL  's 
are 
estimated  in  NONMEM  as  a  block  matrix  (Q).  In  comparison  to  the  additive  model,  the 
exponential  error  model  prevents  individual  parameter  estimates  (see  section  3.2.2)  from 
becoming  negative. 
40 Examples  of  additive,  proportional  and  exponential  interindividual  error  models  for 
clearance  (CL)  are  described  as  follows 
CL  =  TVCL  +  ETA(l) 
Eq  3.6 
CL  =  TVCL  *(I+  ETA(l)) 
Eq  3.7 
CL  =  TVCL  *EXP  (ETA(l)) 
Eq  3.8 
where  TVCL  is  the  typical  value  (PK)  of  CL  and  ETA(1)  is  71, 
i 
3.1.3  General  nonlinear  mixed  effects  model 
On  suppressing  9k  () 
,  the  nesting  of  the  intefindividual  and  the  intraindividual  models  can 
be  expressed  by  the  general  model: 
yi.  = 
,7 
S(Xij 
9zi  q()q  Ili  ýEjj)  Eq  3.9 
where  S(  becomes  a  general  function  incorporating  the  terms  of  both  submodels. 
3.2  Estimating  the  nonlinear  mixed  effects  model 
As  discussed  in  section  1.3.2,  estimation  of  the  nonlinear  mixed  effects  has  been 
implemented  in  a  number  of  software  packages  (Aarons  et  al.,  1994).  However,  since  only 
NONMEM  was  used  in  this  thesis  only  the  methods  related  to  this  package  are  presented. 
3.2.1  First  Order  estimation  method  (FO) 
NONMEM  minimises  the  extended  least  squares  objective  function  (Eq  3.10) 
Oels 
=ý 
[Iogjvar(y,  ý 
+ 
(y, 
-  E(y,  ))var(y,  )-'(y, 
-  E(y,  ))']  Eq  3.10 
where  0,1,  is  the  extended  least  squares  objective  function,  var(y)  is  the  variance- 
covariance  of  the  ith  individual's  vector  of  observations,  E  (Y) 
is  the  expectation  of  yi  i.  e. 
^  and  the  subscript  t  denotes  the  transpose  of  the  matrix.  The  log  term  included  in  the 
Yi 
41 Oels 
can  be  viewed  as  a  penalty  to  avoid  continuous  increases  in  the  variance  which  would 
decrease  the  objective  function  without  a  decrease  in  residuals.  Under  Gaussian  conditions 
Oels  is  only  different  to  -2log-likelihood  of  the  fit  (-2LL)  by  a  constant.  This  attribute  is 
utilised  in  model  development  and  the  testing  of  covariate  relationships  (3.4.1). 
Closed  form  solutions  of  E 
(Y) 
and  var(y)  can  only  be  obtained  in  the  special  case  when 
the  general  model  (Eq  3.9)  is  linear  in  its  random  effects.  However,  a  linearisation  can  be 
used  as  an  approximate  solution  when  this  is not  the  case.  This  approximation  uses  a  first 
order  Taylor  series  expansion  about  the  expected  values  of  flki  1)  s  and  cj  's  i.  e.  zero. 
If  the  general  function  (3.9)  is  simplified  to  the  vector  M,  (E),  Tl,,  c)  ,  such  that 
Eij  Yi  11  ,  Ei)  = 
(Mil  (E)l"li"dFil)'Mi2 
iEi2)'Mi3 
(0  "li'Ei3) 
Eq  3.11 
where  the  ith  individual's  dosing  history,  covariates  and  j  individual  observations  are 
suppressed,  and  the  TI,  is  the  ith  individual's  vectors  of  Tj  -values  and  cj  is  the  ith 
individual's  vectors  of  E  's  for  observation  J.  The  expectation  of  the  partial  derivatives  of 
with  respect  to  TI,  and  E,  can  be  denoted  by  matrices  Gi  and  Hi, 
respectively  i.  e. 
dM.  Eq  3.12 
Gi  = 
ýý  i  ((),  0,0) 
d  11, 
Hi  = 
dMi 
(0,0,0)  Eq  3.13 
dEi 
As  a  result,  E(Y)  is  approximately  given  by 
E(y)  =  M,  (E),  O,  O)  +  Gill  i+ 
HiF,  Eq  3.14 
42 and  if  Gj'  and  Hi'correspond  to  the  transpose  of  Gi  and  Hi,  respectively,  var(y)  is 
approximately  given  by 
Si  (0,  Q,  1)::  ý  Gi  QGi'  +  DiagHi  EH,  '  Eq  3.15 
where  Q  is  the  variance  covariance  matrix  of  the  I  's,  and  I  is  the  variance  covariance  of 
the  Ej  's  as  discussed  previously.  Diag  is  the  matrix  diagonal 
The  use  of  the  linear  approximation  to  estimate  E  (Y) 
and  var(y)  in  the  extended  least 
squares  (ELS)  objective  function  is  known  as  the  first  order  (FO)  estimation  method  and 
was  the  first  method  implemented  with  NONMEM.  The 
Oels  for  the  population  model 
under  the  FO  approximation  becomes: 
I 
log  S2(0ýQý,: 
)J+(Yi_Mi(090ý0))  (S2(jq, 
Q,  j)ýI(yi_Mi(E),  O,  O)) 
, 
Eq  3.16 
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ii 
'I 
The  resultant  objective  function  value  (OFV)  can  be  used  to  compare  models  (see  section 
3.3.1). 
3.2.2  Individual  parameter  estimates 
With  the  FO  estimation  method,  individual  posterior  Bayes  parameter  estimates  can  be 
obtained  after  the  ELS  problem  has  been  minimised.  The  objective  function  which  is 
minimised  with  respect  to  the  il,  -values  is  as  follows 
2 
(E)qjZ. 
90)) 
(S2(OqQqE)  1(yi-mi 
logsi(OQqx)  +(Yi-mi  i 
(o 
I 
q. 
90)  Eq 
77'Q  -'  77 
3.17 
The  population  parameters 
(E),  Q,  1)  are  fixed  to  that  obtained  from  the  fit  so  only  the 
second  (or  Bayesian)  term  is  estimated.  Since  the  individual  parameter  estimates  are 
43 obtained  after  the  objective  function  has  been  minirn-Ised  the  tenn  "Posthoc"  is  used  to 
describe  them. 
3.2.3  First  order  conditional  estimation  FOCE 
When  the  model  is  highly  non-linear  in  11,  the  FO  method  may  under  certain 
circumstances  produce  biased  estimates.  Bias  can  occur  with  non-linear  PK  or  PD  models 
and  may  be  exacerbated  by  multiple  dose  models.  Additional  estimation  methods  are 
available  to  reduce  the  bias  with  the  FO  method.  The  conditional  estimation  methods 
produce  both  estimates  of  population  parameters  and  estimates  of  random  interindividual 
effects,  simultaneously.  The  FOCE  methods  are  two  stage  processes,  at  each  iteration 
conditional  estimates  of  11,  are  obtained  using  the  current  estimates  of  E),  Q,  I.  The 
estimates  of  Q. 
) 
I  are  then  updated  based  on  The  following  objective  function  is 
minirMsed 
log  S2  + 
(y, 
M, 
(E),  ^,,  0)) 
s  2(6  Q,  j)ýI(yi_Mi  0 
i'O  i 
TI  i(  Ti 
Eq  3.18 
Two  FOCE  methods  exist,  by  default  the  "no  interaction"  method  is  specified.  In  this  case 
I  is  estimated  based  on  the  mean  parameter  model.  When  "interaction"  is  specified  the 
prediction  of  I  is  based  on  the  conditional  estimates  of  fi Tli 
When  the  intraindividual  error  is  independent  of  the  predicted  value  i.  e.  additive  error, 
there  can  be  no  interaction  between  the  "',  's  and  E.  's.  Therefore,  specifying  an  interaction  TI 
can  only  give  different  parameter  estimates  when  a  heteroscedastic  error  model  is  utilised. 
There  is  a  dramatic  increase  in  computation  time  with  the  FOCE  methods,  so  the  FO 
method  is  usually  used  by  default. 
44 3.3  Model  building 
The  process  of  model  building  involves  balancing  the  need  to  obtain  the  best  description  of 
a  set  of  observations  against  the  convenience  and  utility  of  the  model.  While  the  individual 
observations  are  themselves  the  most  accurate  representation  of  the  data,  they  are  not  very 
easy  to  use.  The  arithmetic  mean,  on  the  other  hand,  is  convenient  to  use  but  is  not  a  good 
description  of  the  majority  of  the  data.  The  "best"  model  lies  somewhere  between  these 
two  extremes.  The  stepwise  process  for  determining  the  most  appropriate  structural, 
variance  and  covariate  models  is  outlined  below. 
3.3.1  Structural  model  identification 
The  structural  models  employed  for  the  characterisation  of  the  pharmacokinetic  and 
pharmacokinetic/pharmacodynamic  relationships  may  or may  not  utilise  knowledge  from 
previous  analyses.  Refinement  of  previous  models  by  fixing  or  deleting  parameters  from 
the  model  may  be  necessary  where  the  data  is  insufficient  to  support  the  full  model. 
Difficulties  in  obtaining  satisfactory  minimisation  or  poor  parameter  precision  (i.  e.  large 
SE)  may  be  used  to  identify  when  models  are  overly  complex  i.  e.  not  supported  by  the  data. 
If  the  underlying  model  is  not  known  or  found  to  be  insufficient,  knowledge  from  the  basic 
pharmacology  and  phannacokinetics  can  be  used  to  propose  suitable  alternative  models. 
Selection  of  the  final  structural  model  is  based  on  a  combination  of  the  following  criteria  : 
1)  Significant  decrease  in  objective  function  value  (OBV).  This  is  deten-nined  using  either 
the  likelihood  ratio  test  (LRT),  if  competing  models  form  a  full/reduced  pair  (see  section 
4.1),  or  the  Akaike  information  criterion  (AIC)  (Yamaoka  et  al.,  1978) 
i.  e.  for  two  models  a  and  b 
AAIC=  OFVa-OFVb+2(Pa-Pb) 
where  P  is  the  number  of  free  parameters 
45 If  AAIC  >0  model  b  is  choosen  over  a 
2)  Improvement  in  the  goodness  of  fit  (GOF)  plots  i.  e.  observed  (DV)  vs  predicted  (PRED) 
plots;  residual  (RES)  and  weighted  residual  (WRES)  versus  time  after  dose  plots. 
Subjectively  assessed  by  looking  for  patterns  and  bias  in  the  residuals. 
3)  Improvement  in  the  goodness  of  fit  (GOF)  plots  for  the  individual  data  i.  e.  observed 
(DV)  vs  individual  predicted  (IPRED)  plots;  individual  residual  (IRES)  and  individual 
weighted  residual  (IWRES)  versus  time  after  dose  plots. 
4)  Parameter  precision  calculated  based  on  the  SE  of  the  parameter  estimates  which  are 
obtained  using  a  quadratic  approximation.  As  stated  above,  a  model  may  be  considered 
too  complex  if  one  or  more  of  the  parameter  estimates  is  not  statistically  significantly 
different  from  zero  i.  e.  95  % CI  includes  zero.  This  is  approximately  equivalent  to  the 
SE  (%)  (SE  as  a  percentage  of  the  population  parameter  estimate)  being  greater  than 
50%. 
3.3.2  Variability  model  identification 
The  combined  additive  and  exponential  error  model  (section  3.1.1)  was  the  most  complex 
intraindividual  vanability  model  used.  The  significance  of  each  component  was  tested 
using  the  LRT.  Either  a  proportional  or  an  exponential  interindividual  error  model  was 
used. 
3.3.3  Covariate  identification  and  selection 
Graphical  analysis  was  used  to  detect  potential  relationships  between  covanates  and 
Posthoc  or  FOCE  derived  individual  parameter  estimates.  The  trends  in  the  plots  were 
used  to  determine  whether  the  relationship  was  likely  to  be  linear  or  nonlinear.  The 
significance  of  each  relationship  was  formally  tested  by  comparing  the  objective  function 
obtained  with  and  without  the  additional  parameter(s)  used  to  describe  the  relationship. 
The  likelihood  ratio  test  was  used  (LRT)  to  compare  the  difference  in  the  objective 
46 function  values  between  the  two  models  (  known  as  the  "full"  and  the  "reduced"  model 
21 
pair).  The  difference  is  approximately  X  distribution  with  degrees  of  freedom  (df)  equal  to 
the  difference  in  the  number  of  free  parameters.  When  one  parameter  is  fixed  in  the 
reduced  model  a  decrease  in  objective  function  value  3.84  is  significant  at  p<0.05. 
After  testing  all  covariates  univariately  a  step-wise  procedure  was  used  to  incorporate  all 
the  significant  covariates.  In  the  analyses  presented  there  were  only  a  small  number  of 
covariates  of  interest,  so  all  combinations  of  covariates  from  the  univanate  analyses  were 
tested  multivariately.  After  the  full  models  were  built,  the  final  models  were  obtained  by 
removing  each  of  the  covariates  in  turn  and  performing  a  LRT.  Since  the  aim  of  these 
analyses  was  to  generate  hypotheses  for  testing  in  subsequent  studies,  the  same  p-value 
(p<0.05)  was  used  to  include  and  exclude  covanates. 
47 CHAPTER  4 
APPLICATION  OF  NONLINEAR  MIXED 
EFFECTS  MODELLING 
IN  THE  DRUG  SAFETY  ANALYSIS  OF 
RANITIDINE  BISMUTH  SUBCITRATE  (RBS) 
48 In  this  chapter  a  nonlinear  mixed  effects  analysis  of  the  distribution  /  elimination 
pharmacokinetics  of  bismuth  following  multiple  dosing  with  ranitidine  bismuth  subc1trate 
(RBS)  is  described.  The  results  are  compared  to  a  previous  analysis  where  individual 
fitting  was  carried  out  using  models  which  assume  that  the  absorption  rate  Ka  is  equal  to 
initial  distribution  rate  constant  (x.  Predictions  of  steady  state  bismuth  accumulation  are 
performed  and  the  safety  of  extended  courses  of  RBS  treatment  is  assessed. 
4.1  Introduction 
4.1.1  Ranitidine  bismuth  subcitrate  (RBS) 
RBS  is  a  novel  salt  of  ranitidine  formed  from  ranitidine  hydrochloride  and  bismuth  citrate 
complex.  It  therefore  possesses  both  the  antisecretory  actions  of  ranitidine  (Prewitt  et  al., 
1991),  and  the  mucosal  protective  (Hudson  et  al.,  1993)  and  Anti-helicobacter  pylori 
(Fraser  et  al.,  1993;  Webb  et  al.,  1995)  properties  of  bismuth.  RBS  was  developed  for 
treatment  of  relapse  of  benign  gastric  ulcer,  duodenal  ulcer  and  eradication  of  Helicobacter 
pylori. 
4.1.2  Bismuth  pharmacokinetics 
The  absorption  of  bismuth  depends  on  the  solubility  of  the  salt  in  which  it  is  administered. 
The  most  commonly  used  are  the  salicylate  (Peptobismol  @)  or  subcitrate  salt  ( 
tripotassium  dicitrato  bismuthate)  (De-nol  @).  While  only  trace  amounts  are  absorbed 
from  the  relatively  insoluble  subnitrate  and  salicylate  salts  (Nwokolo  et  al.,  1990a,  b), 
absorption  from  the  more  soluble  subcitrate  salt  has  been  demonstrated  (Wagstaff  et  al., 
1988;  Froomes  et  al.,  1989;  Gavey  et  al.,  1989;  Nwokolo  et  al.,  1989;  Benet,  1991;  Madaus 
et  al.,  1991)  and  a  bioavailability  of  -  0.28%  has  been  estimated  based  upon  urinary 
measurements  (Benet,  1991). 
A  pictorial  representation  of  the  processes  governing  the  pharmacokinetics  of  absorbed 
49 bismuth  after  oral  bismuth  subcitrate  (BS)  administration  is  shown  in  Figure  4.1.  The 
primary  route  of  elimination  is  by  urinary  excretion.  While  biliary  clearance  may  be  as 
much  as  90%  of  renal  clearance,  hepato-biliary  re-circulation  may  reduce  the  net  bi  Ii  ary 
loss  (Mclean  et  al.,  1989). 
Figure  4.1  Schematic  diagram  of  bismuth  pharmacokinetics  and  pharmacodynamic 
characteristics  (adapted  from  Benet  1991) 
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Previously,  the  multiple  distribution  phase  pharmacokinetics  of  bismuth  have  been  shown 
to  require  at  least  a  tri-eponential  model  for  the  post  peak  decline  in  plasma  concentration 
(Benet,  1991).  Bismuth  accumulation  following  regular  dosing  has  been  well  documented 
with  apparent  steady  state  levels  being  achieved  in  30-40  days  (Froomes  et  al.,  1989-, 
Gavey  et  al.,  1989;  Nwokolo  et  al.,  1989).  However,  a  general  ellrYUnation  half-life  of  21 
days  (Froomes  et  al.,  1989)  and  terminal  elimination  half-life  of  21-72  days  (Benet,  1991) 
have  been  estimated,  so  accumulatlon  may  continue  for  up  to  4-12  months. 
The  presence  of  food  can  reduce  the  percentage  absorbed  (Nwokolo  et  al.,  1989)-,  and  co- 
50 administration  of  H2-antagonists  can  increase  the  absorption  of  bismuth  from  certain 
formulations  by  decreasing  gastric  pH  (Nwokolo  et  al.,  1991).  Since  it  is  primarily 
eliminated  via  the  renal  route,  caution  is  advised  in  the  treatment  of  patients  with  renal 
impairment.  In  particular,  a  meta-analysis  of  several  bismuth  studies  demonstrated  a 
negative  correlation  between  trough  concentration  and  creatinine  clearance  (Lacey,  1994). 
The  small  increase  in  trough  levels  was  not  deemed  to  be  clinically  significant.  Most  of  the 
intra-  and  inter-indi  vi  dual  variability  in  bismuth  levels  remains  largely  unexplained  and 
considered  to  be  the  result  of  variable  absorption  and  low  intrinsic  bioavailability  (Benet, 
1991). 
4.1.3  Bismuth  toxicity 
While  gastro-intestinal  side-effects  i.  e.  blackening  of  the  stools  are  the  most  commonly 
reported  side-effect  with  bismuth,  more  severe  CNS  toxicity  has  also  been  reported. 
During  the  1970's,  oral  administration  of  bismuth  salts  resulted  in  over  a  thousand  reported 
cases  of  neurological  disorders  which  were  characterised  by  myoclonic  jerks,  severe 
confusion,  hallucination  and  epileptic  seizures  (Martin-Bouyer  et  al.,  1981).  Hillemand 
and  co-workers  proposed  average  steady  state  blood  concentrations  greater  than  50ng.  mll 
and  lOOng.  ml-  I  (equivalent  to  plasma  levels  of  77.5  and  155,  respectively)  to  be  "safety'9 
and  "alann"  levels  for  bismuth  toxicity,  respectively  (FEllemand  et  al.,  1977).  However, 
these  have  more  recently  been  shown  to  be  over  cautious  (Benet,  1991).  Furthermore, 
previous  episodes  of  CNS  toxicity  have  mainly  been  associated  with  salts  other  than 
subcitrate  and  treatment  duration  extending  beyond  that  required  clinically  (Martin-Bouyer 
et  al.,  1981). 
Nevertheless,  the  delay  from  the  onset  of  therapy  until  the  appearance  of  toxicity  may  be 
due  to  the  slow  accumulation  into  the  CNS.  A  full  understanding  of  the  pharmacokinetics 
51 of  bismuth  following  treatment  with  RBS  is  required  to  help  understand  the  potential  for 
toxicity  upon  prolonged  treatment. 
4.1.4  Drug  and  therapeutic  safety  evaluation 
The  primary  focus  of  the  initial  healthy  volunteer  studies  is  to  determine  the  relationship 
between  dose/concentration  and  adverse  events.  For  a  new  product  containing  a 
combination  of  drugs,  these  relationships  may  have  previously  been  established. 
Nevertheless,  when  the  combination  has  the  potential  to  interact,  these  relationships  will 
have  to  be  reassessed.  In  multiple  dose  safety  and  tolerability  studies  it  is  desirable  that 
dosing  continue  until  steady  state  levels  have  been  achieved.  However,  with  drugs  which 
have  a  long  terminal  half-life  this  is  not  always  practical. 
4.2  Data  and  previous  results 
4.2.1  Study  design&  data 
A  double  blind  randomised  multiple  dose  study  in  healthy  volunteers,  was  undertaken  to 
investigate  the  pharmacokinetics  of  bismuth  and  ranitidine  following  administration  of  the 
RBS  fonnulation.  The  randomisation  assigned  one  third  of  subjects  to  placebo,  and  the 
remainder  to  800mg  of  RBS  twice  daily  for  28  days.  After  the  morning  doses  on  days  1, 
14,  and  28,  plasma  samples  were  taken  pre-dose  and  at  0.25,0.5,1.0,2.0,3.0,4.0,5.0,6.0, 
8.01,10.0,12.0  hours  post  dose.  During  the  intervening  weeks,  trough  samples  were 
collected  on  days  4,7,10,14,18,21  and  25.  After  day  28,  the  subjects  in  the  active  group 
entered  into  an  open  phase  where  further  samples  were  measured  daily  for  one  week,  twice 
weekly  for  the  following  three  weeks  and  then  weekly  until  either  plasma  levels  fell  below 
the  assay's  limit  of  quantification  or  28  weeks  had  elapsed  from  the  final  dose. 
Subjects  had  a  mean  age  and  weight  of  32.3  (SD  8.8  )  years  and  77.7  (SD  6.7  )  kg, 
respectively. 
52 One  subject  was  lost  to  follow  up  before  the  last  full  profile  study  day,  the  other  17 
subjects  completed  the  initial  study  phase.  Two  subjects  (5  &  7)  were  lost  to  follow  up 
after  one  week  post  final  dose  and  had  plasma  bismuth  levels  of  1.2  and  2.31  ng.  ml-1  at  this 
time.  The  rest  of  the  subjects  were  monitored  for  an  average  of  58  (SD  24.2)  days  post 
dosing,  at  which  point  the  bismuth  concentration  was  0.24  (SD  0.04)  ng.  ml-1.  In  total  the 
eighteen  patients  provided  977  bismuth  concentrations. 
4.2.2  Drug  assay 
Plasma  bismuth  concentration  measurements  were  determined  using  a  validated 
inductively  coupled  plasma  mass  -  spectroscopy  method  which  had  a  lower  limit  of 
quantification  of  0.2  ng.  ml-I  and  precision  of  13.2%  (Tye  et  al.,  1992). 
4.2.3  Previous  results  using  a  Standard  Two  Stage  (STS)  approach 
Koch  et  al  have  previously  modelled  the  data  individually  using  PC-NONLIN  version  3 
(Koch  et  al.,  1996).  In  this  analysis,  the  most  appropriate  distribution  model  was  initially 
determined  from  the  following  models  using  the  AIC  (  Chapter  3)  to  select  between 
models. 
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Eq  4.3 
The  equations  describe  plasma  concentration  (C)  as  a  function  of  time  (t),  coefficient 
constants  (A,  B,  C  and  D),  absorption/  distribution/  elirnýination  rate  constants  (Ka,  cc,  0,  y7 
8)  and  the  standard  multiple  dose  function  (I  -e  -NxT  )/  (I  -e-x');  where  x  represents  the 
respective  rate  constant  (Ka,  (x,  P,  X,  8),  N  is  the  number  of  equal  doses  administered  by 
time  t,  andr  is  the  dosing  interval. 
However,  it  was  reported  that  on  fitting  these  models,  the  standard  errors  for  Ka  and  cc 
were  found  to  be  very  large  i.  e.  >100%.  Inaccurate  and  imprecise  estimates  can  occur  when 
the  absorption  rate  constant  value  is  similar  to  that  of  a  distribution  or  elimination  rate 
constant  (this  is  considered  further  in  the  discussion-section  4.6.2).  To  overcome  this 
problem,  models  for  the  special  case  where  the  absorption  rate  is  equal  to  a  distribution  or 
elirMnation  rate  have  been  derived  for  the  one  (Dost,  1968)  and  two  compartment  models 
(Wijnand,  1988).  These  were  extended  by  Koch  et  al  to  allow  the  fit  of  up  to  4 
compartments  after  multiple  doses  i.  e. 
2-Compartment 
Ct  =  Ate  -kt 
-I-e 
-Nkr 
+  Are  -kt  e 
-ki- 
_e 
-Nkr 
-Ne 
-Nki-  +e  -Nki- 
I-e  -kr  1-e  -k-r' 
-1-e 
-kr 
-Pt  I-e  -Nor 
-kt  I-e  -Nkr 
+Be  .1- 
e-p'r 
--Be  . 
1-e  -kr 
-  Eq  4.4 
54 3-Compartment 
Ct=Ate  -kt  I-e  -Nkr 
+  Are  -kt  e 
-k-r 
_e 
-Nkr 
-N 
-Nk-r  -Nk-r 
* 
I-e  -ki-  I-e  -kr  *- 
I-e  -kr  e+e 
e  e- 
Nyr 
-kt  I-  e- 
Nkz- 
Be  +  Ce 
(B+C)e 
-kr 
Eq  4.5 
I-e  I-e  I-e 
4-Compartment 
Ct=Ate  -kt 
- 
I-e  -A  -r 
+  A-re  -kt 
-Ie 
-kr 
_e 
-Nki- 
I-e  -kr  1-e  -kr 
L- 
I-e  -kz- 
-  Pt  I-e  -Npr 
-yt  I-e  -Nyr 
-8t  I-e  -N8,  r 
+Be 
I-e 
+  Ce 
e-yr 
+  De 
I-e  -8T- 
-(B+C+D) 
-kt  I-e 
-  Nkr 
e.  I-e 
-kT 
-Ne 
-Nk-r  +e  -Nk-c 
Eq  4.6 
where  k  is  the  combined  absorption  and  distribution  rate  constant.  The  individual 
parameter  estimates  for  the  best  fit  model  using  this  approach  are  shown  in  Table  4.1. 
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0 u 4.3  Aims 
The  aim  of  this  analysis  was  to: 
1)  Determine  the  disposition  characteristics  of  bismuth  following  multiple  oral  dosing  in 
healthy  volunteers  using  nonlinear  mixed  effect  modelling 
2)  Compare  the  population  modelling  approach  to  the  standard  two  stage  approach  with 
regard  to  estimation  of  (x  and  Ka 
3)  Predict  the  steady  state  levels  and  therefore  assess  the  potential  for  toxicity  from 
prolonged  treatment  with  RBS 
4.4  Methods 
4.4.1  Noncom  partmental  analysis 
The  area  under  the  plasma  time  curve  for  the  first  12  hours  post  dose  (AUCO-12)was 
calculated  for  each  full  profile  day  using  the  linear  trapezoidal  rule.  The  maximum 
concentration  post  dose  (Cmax)  and  minimum  concentration  after  12  hours  (Cmin)  were 
determined  directly  from  the  data.  Ratios  of  the  individual  parameters  were  used  to 
assess  the  accumulation  from  day  I  to  day  14  and  from  day  14  to  day  28. 
4.4.2  Population  pharmacokinetic  analysis  using  micro  or  macro  rate 
constant  models 
Micro  rate  constant  model 
An  initial  population  analysis  was  undertaken  utilising  the  ADVAN5  subroutine  from 
the  PREDPP  library  of  pharmacokinetic  models  available  within  NONMEM.  Two  and 
three  compartment  models  with  first  order  input  were  fitted  using  the  FO  and  FOCE 
methods  (Chapter  3). 
57 Macro  rate  constant  model 
Due  to  problems  in  obtaining  appropriate  model  fits  (see  results  and  discussion),  a 
second  population  analysis  was  undertaken  using  the  coefficient  and  macro  rate  constant 
models  Eq  4.1  to  4.3.  For  comparison,  the  adapted  Wijnand  compartment  models  were 
also  fitted  Eq  4.4  to  4.6.  Interindividual  variability  was  estimated  on  all  parameters 
using  an  exponential  error  model.  Intraindividual  variability  was  estimated  using  a 
combined  exponential  and  additive  error  model  (Chapter  3).  The  NMTRAN  user 
supplied  PRED  records  for  implementation  of  equations  4.2  and  4.5  are  shown  in 
Appendix  I.  I- 
Model  dependent  estimation  of 
AUCO-129  Cmax  and  Cmin 
The  population  mean  and  individual  model  dependent  estimates  of  Cmax  and  Cmin  on 
days  1,14  and  28  were  obtained  by  setting  N  to  1,27  or  55  in  Eq.  4.1  to  4.6  and 
substituting  in  the  corresponding  population  and  individual  pharmacokinetic  parameter 
estimates.  While  Cmin  was  obtained  by  directly  substituting  t=12,  Cmax  was  obtained 
by  varying  t  until  a  maximum  was  reached.  This  process  was  automated  using  the 
solver  routine  in  EXCEL  (version  5).  AUCO-12on  days  1,14  and  28  were  obtained  by 
integrating  the  equations  over  the  12  hour  dosing  interval.  For  the  standard  three 
compartment  model  (Eq  4.2)  the  following  equation  is  obtained 
A  Nar  B  -Nrr)  A+B+C  -NKar) 
e-  )+ 
. 
(I-e-N'6)+-c.  (I-e  -  K,  . 
('-e 
Eq  4.7 
The  values  of  Cmin  and  Cmax  at  steady  state  were  obtained  from  the  equivalent  steady 
state  equations  i.  e.  for  the  three  compartment  model 
58 -  c(t  I 
Ctss=  Ae 
.I  -al,  +Be  18t 
- 
(A+ 
B+  C)  e-Kat  -  I-e 
I 
Ka  -r 
I 
-X 
I 
e-'8r 
Ce  . 
e-yr 
Eq  4.8 
AUCO-12at  steady  state  was  determined  by  taking  the  integral  of  these  equations  over  the 
12  hour  dosing  interval  i.  e.  for  the  three  compartment  model 
A  UCss  =A  .+B+C- 
A+B+C 
a8y  Ka 
The  prediction  intervals  for  AUC,  Cmin  and  Cmax  from  day  1  up  to  steady  state  dosing 
(i.  e.  (median  and  25-75th  and  5-95th  percentiles)  were  obtained  by  simulating  for  1000 
patients  using  the  final  population  mean  and  variability  estimates. 
4.4.3  Assessment  and  comparison  of  the  noncom  partmental  and 
population  model  dependent  estimates  of  accumulation. 
Model  based  predictions  of  accumulation  in  AUCo-12)  Cmin  and  Cmax  were  compared 
to  the  noncompartmental  estimates.  The  noncompartment  estimates  were  log-normally 
distributed,  so  the  geometric  mean  was  compared  to  the  average  population  estimates 
obtained  using  the  exponential  interindividual  variability  model. 
4.5  Results 
4.5.1  Noncompartmental  analysis 
The  individual  and  geometric  mean,  AUCO-12,  Cmin  and  Cmax  for  days  1,14  and  28  are 
shown  in  Table  4.2.  The  average  measures  indicated  that  noncompartmental  parameters 
increased  during  the  course  of  the  study.  The  standard  deviations  were  large  across  all 
parameters  and  days.  All  subjects  except  individuals  3,7,8  and  11  demonstrated  a 
progressive  increase  in  both  AUCO-12and  Cmin  during  treatment. 
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"0 The  relationship  between  Cmax  and  duration  of  treatment  was  highly  variable  for  all 
individuals.  This  was  exemplified  by  the  largest  measured  concentration  being  sampled 
on  day  14  in  9  individuals.  The  accumulation  of  bismuth  during  the  treatment  course  is 
shown  in  terms  of  the  ratios  of  the  parameters  on  day  14  to  day  I  and  on  day  28  to  day 
14  (Table  4.3).  As  expected,  the  geometric  mean  accumulation  in  Cmax,  Cmin  and 
AUCO-12  during  the  first  two  weeks  (2.07,6.00  and  3.61,  Table  4.3)  was  much  greater 
than  that  during  the  second  two  weeks  (1.07,1.29  and  1.16,  Table  4.3).  Although 
further  significant  increases  would  not  be  expected,  predictions  of  the  final  steady  state 
estimates  require  the  application  of  modelling  techniques. 
4.5.2  Population  analysis 
Micro  rate  constant  model 
The  summary  of  runs  made  using  the  micro  rate  constant  models  is  shown  in  Table  4.4. 
Using  FO  estimation  and  an  exponential  error  model,  the  objective  function  for  the  three 
compartment  model  (Run2)  was  significantly  smaller  than  that  for  a  two  compartment 
model  (Runl).  The  combined  additive  plus  exponential  intraindividual  vanability 
model  (Run3)  was  significantly  better  than  when  the  exponential  error  model  alone  was 
used  (Run2).  Figure  4.2  shows  plots  of  population  predicted  concentration  versus  the 
observed  concentration  for  a  three  compartment  model  using  the  FO  and  FOCE 
estimation  methods  (Run  3  and  Run  5).  The  fit  with  the  FOCE  method  was  less  biased 
than  with  the  FO  method.  However,  the  run  terminated  unsuccessfully  due  to  rounding 
errors,  even  after  rerunning  with  new  starting  estimates.  A  successful  termination  and 
lower  objective  function  was  obtained  by  reducing  the  number  of  (o  terms  in  the  model 
(Run  6).  This  suggested  that  the  model  with  the  full  interindividual  variability  structure 
had  terminated  at  a  local  minimum  (Run  5). 
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42 Table  4.4  Model  development  for  the  micro  rate  constant  models 
Run 
no 
Estimation 
method 
No 
compartments 
Objective 
function 
No  0 
Parameters 
No  w 
parameters 
No  cy 
parameters 
Successful 
minimisation 
No 
significant 
figures 
Standard 
errors 
estimated 
1  FO  2  1191.3  5  5  1  yes  3.3  ne 
2  FO  3  405.1  7  7  1  yes  3.1  ne 
3  FO  3  313.0  7  7  2  yes  3.1  ne 
4  FOCE  2  830.8  5  5  1  yes  3.5  ne 
interaction 
5  FOCE  3  188.0  7  7  2  No  -0.5  ne 
interaction 
6  FOCE  3  35.7  7  4  2  yes  3.3  yes 
interaction 
ne  indicates  where  the  standard  errors  were  not  estimable 
63 Figure  4.2  Predicted  concentration  versus  observed  concentration  plots  for  a)  Run  3  (3 
compartment  model  using  the  FO  estimation)  and  b)  Run  5  (3  compartment  model  using 
the  FOCE  estimation) 
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64 Macro  rate  constant  model 
Model  development  of  the  macro  rate  constant  population  models  is  shown  in  Table  4.5 
and  the  corresponding  population  parameter  estimates  are  shown  on  Table  4.6.  Run 
times  were  much  shorter  with  this  parameterisation  (12  to  24  hours)  and  the  objective 
functions  for  equivalent  models  were  substantially  lower.  There  was  a  large  decrease  in 
objective  function  upon  fitting  a3  compartment  model  in  comparison  to  a2 
compartment  model  (Run  8  vs  Run  7).  The  decrease  in  objective  function  upon  fitting  a 
4  compartment  model  was  smaller  but  still  statistically  significant  (P<0.005),  (Run  9  vs 
Run  8).  However,  the  covanance  step  was  not  successful  and  therefore  standard  errors 
could  not  be  estimated.  Figure  4.3  shows  the  weighted  residuals  versus  time  plots  for 
the  2,3  and  4  compartment  models.  While  the  bias  in  the  weighted  residuals  indicates 
that  there  was  mi  s-  specification  of  the  washout  phase  (times  >  672  hours)  when  the  two 
compartment  model  was  fitted  (Figure  4.3a),  there  was  no  evidence  of  a  bias  with  the 
three  and  four  compartment  models  (Figure  4.3  b  and  c  ).  Plots  of  the  individual 
predictions  are  shown  on  Figure  4.4.  While  there  was  a  large  difference  between  the 
individual  predictions  from  the  two  and  three  compartment  models,  the  individual 
predictions  for  the  three  and  four  compartment  model  were  very  similar  i.  e.  only  26  of 
977  individual  predictions  using  the  four  compartment  model  were  >+25%  or  <-25%  of 
corresponding  three  compartment  model  individual  predictions.  Thirteen  of  these 
predictions  were  for  three  individuals  where  the  individual  fitting  demonstrated  that  a 
four  compartment  model  was  better.  Therefore,  while  for  some  individuals  the 
concentration  time  profile  was  better  characterised  by  a  four  compartment  model,  a 
three  compartment  model  was  most  appropriate  across  the  majority  of  the  subjects. 
Precise  population  average  estimates  of  Ka  and  cc  were  obtained  (Table  4.6).  In  general, 
interindividual  variability  estimates  were  large  and  imprecisely  estimated  (Table  4.6). 
65 Table  4.5  Model  development  of  the  macro  rate  constant  models 
Run 
no 
Estimation 
method 
No 
compartments 
&  model  type 
Objective 
function 
No  0 
Parameters 
No  TI 
parameters 
No  E 
parameters 
Successful 
minimisation 
No 
significant 
figures 
Standard 
errors 
estimated 
7  FOCE  2  293.7  5  5  2  yes  4.2  yes 
interaction  standard 
8  FOCE  3  15.6  7  7  2  yes  4.1  yes 
interaction  standard 
9  FOCE  4  -1.58  9  9  2  yes  4.5  no 
interaction  standard 
10  FOCE  2  554.2  4  4  2  yes  4.4  yes 
interaction  Wijnand 
11  FOCE  3  25.9  6  6  2  yes  4.0  yes 
interaction  Wijnand 
12  FOCE  4  2.7  8  8  2  yes  4.7  no 
interaction  . 
Wijnand 
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Individual  predicted  C)Mvjitration  for  a  drm  colqmrbMlt Individual  patient  parameters  for  the  standard  macro  rate  constant  three  compartment 
model  are  shown  in  Table  4.7.  A  selection  of  individual  patient  fits  using  the  standard 
macro  rate  constant  model  is  shown  in  Figure  4.5. 
The  model  development  and  parameter  estimates  using  the  Wijnand  macro  rate  constant 
models  are  also  shown  in  Tables  4.5  and  4.6,  respectively.  On  comparing  equivalent 
models,  the  objective  functions  were  larger  than  for  the  standard  macro  rate  constant 
models.  For  the  two  compartment  (  Run  2  vs  Run  10)  and  three  compartment  (Run  8  vs 
Run  11)  models  the  differences  in  objective  function  were  statistically  significant 
(P<0.001  and  P<  0.01,  respectively).  A  comparison  of  the  individual  predictions  for  the 
three  compartment  models  is  shown  in  Figure  4.6.  Only  4  of  the  977  Wijnand  model 
predictions  were  >+25%  or  <-25%  of  the  standard  model  predictions. 
For  the  three  compartment  model,  the  estimates  of  B,  P,  C,  y  estimates  were  similar  for 
the  standard  and  Wijnand  models  (Run  8  and  Run  11,  Table  4.6).  The  combined 
au  I  ab-sorption/distribution  rate  constant,  k,  was  estimated  to  be  2.3  hr-  I  (Run  11),  and 
I 
therefore,  in  between  the  values  of  1.2  and  4.4hr- 
,  estimated  for  (x  and  Ka,  respectively. 
The  estimate  of  the  exponential  component  of  intraindividual  vanability  was  the  same 
for  Runs  8  and  11. 
The  individual  patient  parameters  for  the  Wijnand  macro  rate  constant  three 
compartment  model  are  also  shown  in  Table  4.7.  The  individual  estimates  of  B,  P,  C, 
and  y  estimates  were  similar  for  the  standard  and  Wijnand  macro  rate  constant  models. 
Therefore,  while  using  the  Wijnand  macro  rate  constant  model  increased  the  objective 
functions,  it  did  not  affect  the  estimate  of  the  intermediate  and  terminal  rate  constants. 
The  magnitude  of  k  in  comparison  to  (x  and  Ka,  was  consistent  with  that  shown  with 
population  parameters.  Since  separate  estimates  of  oc  and  Ka  were  discernible  there  was 
no  requirement  to  further  utilise  the  Wijnand  macro  rate  constant  model. 
70 Table  4.7  Individual  parameter  estimates  and  calculated  half-lifes  for  the  macro  rate 
constant  models 
Standard  (Run8) 
ID  A  cc  B  c  y  Ka  T  1/2  TI/2  T  1/2  TI/2 
ng.  ml-  I  hr-1  ng.  ml-1  hr-'  ng.  ml-'  hr-1  hr-1 
cc 
mins 
0 
hrs 
y 
days 
Ka 
mins 
2  5.6  1.2  0.45  0.057  0.025  0.0014  2.7  35  12  20  17 
3  11  1.0  0.76  0.045  0.024  0.0015  4.6  40  15  19  9.1 
4  7.9  1.1  0.43  0.035  0.082  0.0011  3.8  36  20  27  11 
5  6.8  1.5  0.63  0.032  0.046  0.0010  4.7  28  22  29  8.8 
7  12  0.52  0.75  0.046  0.040  0.0018  3.5  80  15  16  12 
8  11  1.7  3.4  0.097  0.034  0.0013  7.5  25  7  22  5.6 
10  6.6  2.4  0.33  0.041  0.021  0.0013  2.6  17  17  22  16 
11  13  0.76  0.51  0.043  0.031  0.0015  3.9  55  16  19  11 
13  5.9  1.6  0.47  0.056  0.053  0.0014  4.3  26  12  21  9.7 
14  6.9  1.1  0.75  0.046  0.040  0.0011  5.3  36  15  26  7.9 
15  6.8  1.2  0.84  0.072  0.029  0.0012  5.2  34  10  24  8.0 
17  6.7  1.4  0.78  0.065  0.016  0.00046  3.7  29  11  63  11 
19  5.7  1.6  0.36  0.040  0.030  0.0020  3.6  27  18  14  11 
21  7.3  1.7  0.38  0.037  0.071  0.0013  6.0  24  19  22  6.9 
23  6.9  1.0  0.66  0.034  0.056  0.0013  3.6  42  20  22  12 
24  6.4  1.6  0.26  0.058  0.29  0.0019  4.4  26  12  15  9.5 
25  8.3  1.8  0.46  0.028  0.078  0.0015  5.8  23  24  20  7.1 
27  5.8  1.1  0.59  0.045  0.083  0.0023  2.9  37  15  12  14 
Population  7.0  1.2  0.57  0.046  0.044  0.0014  4.4  35  15  21  9.6 
(NONMEM) 
Wij  nand  (Run  11) 
]D  A  k  B  c  y 
TI/2  TI/2  TI/2 
k  P  y 
ng.  mI-1.  hr-1  hr-1  ng.  ml-1  hr-1  ng.  mI-1  hr-1  mins  hrs  days 
2  6.9  1.7  0.48  0.061  0.025  0.0015  24  11  20 
3  31  2.0  0.85  0.048  0.025  0.0015  20  14  19 
4  31  2.0  0.48  0.039  0.083  0.0011  21  18  27 
5  31  2.5  0.66  0.033  0.046  0.0010  16  21  29 
7  31  1.3  1.0  0.049  0.042  0.0019  32  14  15 
8  31  3.2  3.4  0.096  0.034  0.0013  13  7.2  22 
10  4.0  3.3  0.32  0.042  0.022  0.0013  12  16  22 
11  29  1.5  0.63  0.048  0.032  0.0016  28  14  18 
13  15  2.6  0.51  0.060  0.054  0.0014  16  11  21 
14  24  2.4  0.88  0.053  0.040  0.0011  18  13  25 
15  23  2.4  0.97  0.080  0.029  0.0012  17  8.6  24 
17  15  2.3  0.81  0.067  0.016  0.00045  18  10  64 
19  11  2.4  0.39  0.043  0.031  0.0021  17  16  14 
21  26  3.0  0.42  0.041  0.073  0.0013  14  17  21 
23  16  1.8  0.73  0.038  0.058  0.0013  23  18  22 
24  17  2.6  0.29  0.064  0.29  0.0019  16  11  15 
25  29  3.1  0.48  0.030  0.079  0.0015  14  23  20 
27  10  1.8  0.65  0.050  0.085  0.0023  23  14  12 
Population  18  2.3  0.64  0.050  0.045  0.0014  18  14  21 
(NONMEM) 
71 Figure  4.5  Individual  predictions  from  the  standard  population  macro  rate  constant 
model  (Run  8)  versus  time 
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Model  dependent  estimates  of  AUCO-12qCmax  and  Cmin  and  comparison  with  the 
noncompartmental  estimates  of  accumulation 
The  predicted  estimates  of  AUCO-12,  Cmax  and  Cmin  for  days  1,14  and  28  and  at  steady 
state,  using  the  population  and  individual  estimates  from  Run  8  are  shown  in  Table  4.8. 
The  ratios  of  day  14  to  day  I  estimates,  and  day  28  to  day  14  estimates  and  SS  to  day  28 
estimates  are  shown  in  Table  4.9.  Figure  4.7  shows  a  comparison  of  the  geometric 
mean  estimates  of  AUCO-12,  Cmax  and  Cmin  on  days  1,14  and  28  from  the 
noncompartmental  analysis  and  the  corresponding  population  typical  estimates  from  the 
population  analysis  . 
The  ratios  of  the  AUCO-12  indicate  that  the  model  based  estimate 
of  accumulation  was  smaller  from  day  1  to  day  14  (2.94  Table  4.9  vs  3.61  Table  4.3) 
and  greater  from  day  14  to  day  28  (1.28  Table  4.9  vs  1.16  Table  4.3).  However,  the 
resultant  estimates  of  AUCO-12  on  day  28  were  very  similar  (  36.1  ng.  ml-l.  hr  Table  4.8 
vs  36.4ng.  ml-l.  hr  Table  4.2). 
73 
10  12 coo 
u  4-4 
a3 
E 
4-J 
cn 
10 
U 
03 
(1) 
M 
cl 
o6 
cl 
7j 
1-4 
as 
a: E 
U 
Cý 
6 
C4ý  0 
cn a) 
(73 
cn U 
-0  U 
-.  4 
0 
-cj 
C) 
00 
NOW 
cn  re  -  E 
býG 
ý,  0 
rn 
CD 
oo 
cý 
CD 
- 
r- 
rn 
oo 
tf) 
CD 
- 
- 
rIJ 
- 
lf) 
rfý 
rJ 
CD 
ýo 
c> 
M 
CD 
￿0 
- 
CD 
oo 
r- 
￿0 
".  o 
￿0 
00 
rn 
oo 
oo 
\m 
oo 
ri 
- 
v) 
cý 
- 
￿0 
" 
ý6 
00 
rý 
CD 
CD 
rn 
CD 
00 
r- 
M 
r- 
r- 
V') 
m 
ýb 
'%.  0 
cý 
0., 
￿o 
r- 
- 
cý 
cý 
oo 
￿o 
r- 
e  ýe  1f) 
rn 
C-1 
ýi 
',  M 
e 
m 
- 
r, 
ýb 
---f m 
￿0 
￿o 
, 
- 
e 
V) 
r- 
"0 
c-i 
v-) 
= 
00 
vi 
Mt 
--.  d  E 
"0  e  m  In  -e  cý  .  v)  c>  c> 
"0 
- 
00 
00 
le 
-ý 
ON 
"0 
rn 
- 
le 
e 
IZ 
e 
ýo 
r- 
kn 
--ý  c--1  r-  ýo  v-)  cý  -  -  oo  rn  in  v-i  rn  rn  vi  'z  oo  ￿0  ￿+  &Z 
CD  cq  kf)  CD  Cl\  1.  r)  00  00 
00  r- 
r,  -  1,0  kf) 
"0 
(-li 
r- 
le 
le 
v)  m  m  v-)  oo  CD  r-  (N  le  m  cq  m  rn  c-i  m  rq  fli 
cn 
cn 
*g 
U 
E 
= 
00  CD 
￿t 
C-11 
r- 
- 
r_ 
CD 
cq 
vi 
00 
Co 
cq 
\M 
￿0 
rn 
00 
oo 
- 
Ilt 
-e 
cq 
le 
￿0 
rn 
rf) 
ä-, 
CI) 
"0 
Z 
(-J  v-) 
r1)  oo 
-  ---1 vi 
rn 
00 
-i 
kr) 
r, - 
Mt 
V) 
kr) 
c> 
r- 
(n 
cý 
qt 
roi 
00  -  E  rn  Cl\  CD 
CD 
cli 
cq 
(n 
t-- 
r-- 
CD 
m 
rn 
00 
00 
rf) 
in 
tr) 
rq 
r-- 
CD 
le 
00 
le 
r- 
rq 
1,0 
rn 
cý 
CD 
r,  - 
00 
le 
- 
t- 
m) 
le  c,  v) 
00 
￿p  -e 
Irý 
00 
00 
cq 
00 
cý 
m 
-e 
rn 
￿0  cý,  C-1  CD  -  rý  v-)  cý  00  m  r- 
ÖG  (,  i  cq  --,  c-i  CD  cq  cq  v-i  c-i  C-q 
cq  r- 
"t  r- 
m  oo  e  c> e  - 
-  c9 
rq  t 
rn  cý 
ri  r- 
ýt  00 
rn  00 
in  kn 
cq  c,  -I  m  CD 
kn  e  (n  e  r', 
en 
bij  CD  CD  CD  CD  CD  -  CD  CD  CD  CD  CD  c)  CD  CD  CD  CD  CD  CD  cý 
rq 
"0  (N  r- 
r_ 
rn 
kn 
r,  -  rn 
kn  00  lz 
't 
CD 
00 
00 
r- 
tf) 
(> 
"0 
00 
IC)  c-,  cl, 
(11  Z 
9 
e 
C:  ) 
(zý 
llt 
r- 
e 
t- 
C) 
V') 
Ilt 
In 
r-, 
00 
r_ 
(N 
rn  cý 
(vý 
00 
ýt 
m 
00 
- 
C,  1 
le 
00 
00  --4 
C:  ) 
C-ý 
C:  ) 
le 
< 
c.  D  M  nt  -  ir)  tn  rý  r-  00  CD  et  1,0  ￿0  rn  -  CD  -  CD  Wý  CD  rn 
ýD 
cý  vn  lf)  00  rn  m  m  cý  00  cq  cl  ýlo  cý  kr)  (Dd 
ZD  9 
rn 
￿o 
kf) 
- 
CD 
CD 
- 
CD 
00 
C> 
e 
110 
cq 
cý 
(1,1 
(11 
V) 
rn 
ri 
00 
- 
0 
cý 
IZ 
cý 
- 
- 
(N 
- 
- 
M 
rn 
C> 
(1) 
r- 
kf) 
CD 
In 
r- 
CD 
c-, 
- 
cý 
00 
t 
110 
00  Cý  C> 
< 
00  CD  r-  C>  e 
N / 
(1)  4-A 
(73 
03 
+-j 
m 
06 CIA 
r- 03 
Iýt 
4--4 
00 
4-4 
C) 
-E1 
cu  C'l 
rIn 
cý 
4 
\M 
CD 
- 
't 
c,  -I  \M 
CD 
00 
CD 
e  r- 
CD 
r- 
rq 
- 
r,  1 
r-  CD  cý 
CD 
oo 
C-1 
e 
rf) 
CD 
(n 
rn 
(-,  j 
oo  = 
E  4 
e 
CD 
rA 
Cq 
￿t 
- 
gý 
CD 
v'ý 
CD 
c9 
cýI 
v) 
CD 
cý 
-  -1 
g 
CD 
g 
CD 
cD 
---1 
oo 
---4 
cn 
CD 
oo 
rn 
r- 
--4 
cD 
ý 
mý 
P-1 
U 
C;  6 
C-ý  -ý  -ý  -ý  -ý  -ý  -ý  __;  __;  -ý  -ý  -ý  -ý  -ý  -ý  -4  -4  "  -ý  -4 
m  1,0  \M  CD  e  00 
kn 
\Z 
cýI 
C\ 
cý 
c>  ý,  0 
1,0 
v) 
4 
- 
rn 
V) 
rn 
C,  1 
oo 
-e  oo  oo  e  kr)  cý 
r-  00 
ýi 
r-) 
le 
1,0 
cli 
OC 
r- 
rn 
ýo 
e 
cli 
cýJ 
M 
In 
Ilt 
rn 
rn 
m 
V') 
e 
V') 
V) 
V') 
- 
V_ý 
- 
c"i 
1,0 
(n 
ýt 
Igt 
00 
rn 
r') 
le 
- 
rq 
t- 
qe 
V-) 
rn 
CD 
cq 
C> 
V) 
rn 
m 
kn 
IN 
C-1 
cli 
rý 
r1) 
00 
clq 
\Z 
Ilt 
rn 
rf) 
ýIM 
rn 
rn 
rn 
IM ri 
\Z 
le 
rý 
rn 
M 
tr) 
00 
rn 
C,  4 
rn 
r,  -  en 
00 
m 
rn 
rn 
r- 
CD 
r- 
r- 
"0 
CD 
C> 
rn 
cý 
--.  i 
rý 
ý,  0 
V'ý 
CD 
CD 
rn 
- 
oo 
00 
ý,  c) 
1-0 
CD 
Clý 
- 
, 
"0  00 
oo 
c\ 
V-ý 
vý 
ýc 
U 
oo 
Cq  C)  -4  ￿o  tfi 
ýt 
--4 
C) 
cq  -t 
CD 
rý 
IM 
e 
M 
zt 
CD 
e 
cý 
CD  -  kn  M  M 
CD 
`t  ,  n 
c2  .  .  .  .  .  .  .  . 
.; 
(Z  e  v-)  c-i  CD  ￿0  r,  1  cq  r--  ýr)  ￿0  e  rn  -  CD  00  't  Cý  rq  ￿0  00 
(:  ý 
ýD 
-4 
-4 
0-% 
cq 
VI 
CD 
Cq 
r- 
c> 
rn 
(-,  l 
rn 
ý 
- 
ý,  0 
- 
--4 
m 
---4 
- 
rn 
rn 
V') 
(-q 
--4 
ci 
r- 
ci 
tf) 
rn 
r- 
e 
CD 
r) 
't 
a',  e  rn  ei 
CD  le  in  r-  C> 
II 
N Figure  4.7  Comparison  of  population  model  dependent  estimates  (Run  8)  of  a)  AUCo-12, 
b)  Cmax  and  c)  Cmin  with  the  equivalent  geometric  mean  estimates  from  the 
noncompartmental  analysis  on  days  1,14  and  28,  and  at  steady  state  (SS) 
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Days The  model  dependent  estimates  of  Cmin  on  days  1,14  and  28  (  0.37,1.74  and  2.37 
ng.  m  I  Table  4.8,  respectively)  were  very  similar  to  the  observed  values  (0.30,1.77  and 
2.24  ng.  ml-1  Table  4.2,  respectively).  Although  the  model  dependent  estimate  of  Cmax 
was  substantially  greater  on  day  1  (3.47 
, 
Table  4.8  vs  2.45  Table  4.2),  the  model 
dependent  estimates  of  accumulation  in  Cmax  over  the  first  14  days  was  smaller,  so  the 
actual  estimates  on  day  14  (  5.15  Table  4.8  vs  5.33  Table  4.2)  and  subsequently  day  28  ( 
5.80  Table  4.8  vs  5.78  Table  4.2)  were  similar  for  the  noncompartmental  and 
compartmental  approaches. 
It  was  predicted  that  the  accumulation  from  day  28  to  the  steady  state  levels  would  on 
average  result  in  a  further  36%,  47%  and  20%  increase  in  AUCO-12,  Cmin  and  Cmax, 
respectively.  The  predicted  estimates  of  AUCO-12.,  Cmin  and  Cmax  at  steady  state  were 
49.1  ng.  ml-1.  hr,  3.49  ng.  ml-1  and  6.94  ng.  ml-1,  respectively  (Table  4.8). 
The  prediction  intervals  (median  and  25-75th  and  5-95th  percentiles)  for  AUC,  Cmin 
and  Cmax  from  day  I  up  to  steady  state  are  shown  in  Figure  4.8.  At  steady  state  the 
upper  limit  for  Cmax  was  predicted  to  be  well  below  the  previously  proposed  "safety" 
limits  (50  ng.  ml-1,  section  4.1.3). 
77 Figure  4.8  Predicted  estimates  of  a)  AUCo-12,  b)  Cmax  and  c)  Cmin  following  a  255  day 
treatment  course  of  RBS. 
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78 4.6  Discussion 
4.6.1  Safety  assessment  of  RBS  treatment 
As  previously  highlighted  (4.1.3),  most  incidences  of  toxicity  have  been  due  to 
treatment  periods  which  extended  beyond  those  currently  used  in  routine  management 
of  relapsed  gastric  or  duodenal  ulcer.  It  is  therefore  unlikely  that  episodes  of  CNS 
toxicity  would  occur  with  any  bismuth  formulation  given  in  accordance  with  current 
clinical  practice.  Nevertheless,  the  drug  regulatory  agencies  require  that  the  safety  of  an 
individual  drug  product  be  demonstrated.  Furthermore,  since  alteration  of  intra-gastric 
acidity  has  been  shown  to  increase  the  absorption  of  bismuth  from  RBS  (Nwokolo  et  al., 
1991),  plasma  levels  could  theoretically  increase  upon  co-administration  with  ranitidine. 
The  noncompartmental  geometric  mean  estimates  of  AUCO-12,  Cmax  and  Cmin  on  day 
14  (31.7  ng.  ml.  hr-  I,  5.3  ng.  ml  -1  and  1.8  ng.  ml  -1,  respectively)  were  comparable  with 
levels  previously  reported  on  day  10  of  a  500  mg  twice  daily  "S  study  (34ng.  ml.  hr-1, 
5  ng.  mI  -1  and  2  ng.  ml  -I,  respectively)  (Lacey  et  al.,  1994).  However,  since  the 
equivalent  elemental  bismuth  doses  were  240.8  mg  and  150.5  mg,  respectively,  it  would 
be  expected  that  in  the  present  study  the  average  AUCO-12.,  Cmax  and  Cmin  would  be 
significantly  higher.  The  differences  may  be  an  artefact  of  the  small  sample  sizes  in 
each  study  and  the  large  interindividual  variability  in  general  (Table  4.2).  The  three  12 
hour  profiles  allowed  the  estimation  of  bismuth  accumulation  via  noncompartmental 
techniques  (Table  4.3).  Since  accumulation  ratios  were  a  lot  smaller  over  the  second 
two  weeks  of  dosing  it  would  be  expected  that  further  accumulation  upon  dosing  to 
steady  state  would  be  limited.  In  fact,  it  was  predicted  that  the  accumulation  from  day 
28  to  the  steady  state  levels  would  on  average  result  in  a  further  increase  in  AUQ-12, 
Cmin  and  Cmax  of  36%,  47%  and  20%,  respectively. 
All  plasma  concentrations  measured  over  the  28  day  dosing  period  were  lower  than 
19ng.  ml-  I,  a  value  which  is  approximately  one  quarter  of  the  proposed  77.5  ng.  ml-1 
79 safety  limit.  Similarly,  the  5th  to  95th  percentile  range  for  the  predictions  of  Cmax  at 
steady  state  were  shown  to  be  much  lower  than  this  limit.  Furthermore,  there  has  been 
no  clinical  evidence  that  the  transitory  nature  of  the  Cmax  values  relate  to  toxIcity,  and 
the  limits  as  previously  discussed  have  themselves  been  considered  to  be  overcautious 
(Benet,  1991). 
4.6.2  Model  dependent  methods 
Due  to  the  necessity  for  at  least  a  three  compartment  model  to  describe  the  typical 
healthy  volunteers  pharmacokinetics,  ADVAN  5  (for  general  linear  models)  from  the 
PREDPP  library  was  utilised.  However,  the  complexity  of  the  models,  the  use  of 
ADVAN  5  and  the  requirement  for  FOCE  increased  computation  time  considerably  (3-7 
days  per  run  ).  In  addition,  neither  successful  minimisation  or  standard  error  estimation 
could  be  obtained  using  the  full  off-diagonal  interindividual  error  structure.  In 
comparison,  the  coefficient  and  macro  rate  constant  parameterisation,  implemented 
using  a  PRED  subroutine,  was  found  to  decrease  computation  time  and  provide 
successful  termination.  Avoiding  ADVAN  5  was  probably  the  main  reason  for  the 
improvement  in  run-times. 
As  previously  stated,  the  combined  exponential  and  additive  models  allowed  the 
variance  to  be  calculated  as  separate  homogenous  and  heterogenous  components 
(Chapter  3).  Often,  both  the  heterogenous  and  homogenous  intraindividual  variability 
are  estimated.  In  this  analysis,  the  additive  variance  was  fixed  to  0.04  (LO&  due  to  the 
protracted  nature  of  the  terminal  phase  at  or  around  the  LOQ  and  the  inability  to  obtain 
a  precise  estimate. 
The  population  approach  determined  that  a  three  compartment  model  would  best 
describe  the  pharmacokinetics  of  bismuth.  This  confirms  the  results  of  the  individual 
fitting  and  is  consistent  with  a  Bayesian  analysis  of  this  data  which  has  recently  been 
80 reported  (Bennett  et  al.,  1997).  The  population  typical  parameter  estimates  for  both 
population  methods  i.  e.  A,  B,  C,  cc,  P,  y  and  Ka  were  (Bayesian  /  NONMEEM,  Run  8 
Table  4.6  )  4.5/  7.0  ng.  ml-1,0.59  /  0.57  ng.  ml-1,0.051  /  0.044  ng.  ml-1,0.87  /  1.20  hr-1, 
0.035  /  0.046hr-1  and  0.0013  /  0.0014  hr-1  and  4.76  /  4.4  hr-1,  respectively.  The  small 
differences  may  be  due  to  the  random  effects  being  assumed  to  be  normal  and  log 
normal  for  this  analysis  and  the  Bayesian  analysis,  respectively.  The  estimated  half- 
lives  from  this  analysis  are  similar  to  those  from  the  Bayesian  analysis  i.  e.  (Bayesian  / 
NONMIEM)  TI/2(x,  TI/2p  TI/2y  and  Tl/2Ka  were  48  /  35  mins,  20  /  15  hours  and  22.2/21 
days,  respectively.  However,  they  do  not  coincide  with  the  range  in  the  half-lives 
previously  reported  by  Benet  (1991)  i.  e.  I  to  4  hours,  5  to  II  days  and  21  to  72  days. 
Nevertheless,  the  washout  curve  available  with  this  dataset  should  allow  the  distribution 
and  elimination  phases  to  be  appropriately  characterise. 
As  previously  discussed,  the  inflated  standard  errors  when  the  data  was  individually 
modelled  using  a  two,  three  and  four  compartment  model  with  PC-NONLIN  was 
perceived  to  be  due  to  an  equality  between  absorption  and  initial  distribution  parameter 
estimates  (x  (Koch  et  al.,  1996).  Previous  investigations  of  this  phenomena  have 
focused  on  the  problems  of  estimating  an  equality  between  Ka  and  Ke  parameters  of  a 
one  compartment  model  with  first  order  absorption.  Application  of  regular  residual 
methods  (Gibaldi  &  Perrier,  1982b) 
,  curve  stripping  programmes  i.  e.  (R-Stnp  & 
Minsq.,  1987)  and  the  Wagner  Nelson  method  have  been  shown  to  give  inaccurate 
parameter  estimates  when  Ka  <3  Ke  or  3  Ka  <Ke  (Chan  &  Miller,  1982;  Gibaldi  & 
Perrier,  1982a;  Garrett,  1993).  The  failure  of  these  methods  is  due  to  overlap  with  the 
absorption  phase  preventing  the  determination  of  a  "true"  terminal  elimination  phase. 
In  comparison,  nonlinear  regression  has  previously  been  shown  to  provide  accurate 
estimates  of  Ka  and  Ke  when  there  is  at  least  a  small  difference  between  the  values 
(Chan  &  Miller,  1982;  Patel,  1984).  However,  the  closer  the  parameter  estimates  the 
81 greater  the  potential  for  computational  problems.  Depending  on  the  parameter 
estimation  algorithm  utilised,  both  slow  and  failed  convergence  can  occur,  and  standard 
errors  can  become  greatly  inflated  when  the  correlation  between  Ke  and  Ka  approaches 
1  (Purves,  1993).  In  the  cases  where  parameters  can  be  considered  to  be  identical,  the 
models  derived  by  Dost  (1968)  and  Wijnand  (1988)  can  be  applied.  Several 
noncompartmental  techniques  have  been  proposed  to  aid  in  the  identification  of  whether 
this  assumption  can  be  made,  however,  all  are  limited  to  the  one  compartment  single 
dose  case  (Bialer,  1980;  Macheras,  1985;  Garrett,  1993).  In  comparison,  the  application 
of  nonlinear  regression  allows  both  identification  of  an  equality  in  the  rate  constants  and 
subsequent  estimation  of  the  combined  parameter  regardless  of  the  underlying  data  or 
compartmental  model.  While  there  was  evidence  in  the  individual  fitting  approach  that 
the  large  standard  errors  on  the  parameter  estimates  arose  from  a  similarity  between  the 
(x  and  Ka,  the  population  typical  rate  constants  were  determined  to  be  3.7  fold  different 
and  precisely  estimated  (Table  4.6).  The  combined  absorption  and  initial  distribution 
rate  constant  k  (from  the  Wijnand  model)  was  equivalent  to  the  average  of  the  separate 
estimates  of  Ka  and  cc  (from  the  standard  model).  This  result  is  consistent  with  previous 
comparisons  of  these  models  (Patel,  1984). 
Ka  and  cc  equality  has  previously  been  induced  by  adding  small  amounts  of  random 
error  to  data  simulated  using  distinct  values  for  Ka  and  cc  (Purves,  1993).  As  part  of  this 
investigation,  it  was  shown  that  the  WLS  (Weighted  Least  Squares  )  method  used  by 
Koch  et  al  (1996)  erroneously  concluded  equality  of  rate  constants  more  often  than  the 
more  complex  IRLS  (Iteratively  Reweighted  Least  Squares)  method.  To  this  regard,  the 
application  of  the  ELS  (Extended  Least  Squares  )  method  with  individual  data  requires 
further  investigation. 
82 There  may  be  other  reasons  why  the  SE  of  cc  and  Ka  were  found  to  be  inflated  upon 
individual  fitting.  The  highly  variable  absorption  which  is  inherent  with  drugs  of  low 
bioavailability  (Hellriegel  et  al.,  1996)  may  have  prevented  accurate  estimation  of  Ka 
and  cc.  Since  different  and  precise  estimates  of  Ka  and  oc  were  also  obtained  using  the 
Bayesian  approach  (Bennett  et  al.,  1997),  the  application  of  population  methods  has 
been  shown  to  be  beneficial  in  characterising  the  underlying  model  which  was  otherwise 
difficult  when  using  an  individual  fitting  approach. 
Despite  the  significant  reduction  in  the  objective  function  upon  estimating  separate  cc 
and  Ka  parameters,  the  comparison  of  the  standard  three  compartment  model  with  the 
corresponding  Wijnand  model  showed  that  assuming  equality  did  not  greatly  change  the 
predictions  (Figure  4.6).  This  is  consistent  with  the  previous  work  which  showed  the 
predictions  from  the  two  types  of  model  could  be  very  similar  (Wijnand,  1988)  and  that 
mis-  specification  of  the  absorption  phase  does  not  affect  the  estimation  of  other 
population  model  parameters  (Wade  et  al.,  1993). 
For  the  three  compartment  model  in  this  study  the  initial,  intermediate  and  terminal 
phases  accounted  for  7%,  27%  and  66%  of  steady  state  AUQ-12,  respectively. 
Therefore,  inaccurate  estimation  of  the  initial  phase  would  not  greatly  affect  the 
estimation  of  exposure.  In  a  simulation  analysis  Bennett  et  al  (1997)  showed  that  on 
fitting  a  simple  one  compartment  model  to  data  simulated  using  the  three  compartment 
model,  there  was  bias  in  the  estimate  of  CL/F.  However,  it  was  less  than  the  bias  in  the 
estimate  of  V/F.  This  result  is  consistent  with  the  majority  of  AUC  and  hence  CL/F 
being  associated  with  a  single  elimination  phase  but  Cmax  and  hence  V/F  being 
dependent  on  charactensing  the  full  absorption  and  distribution  profile  for  bismuth. 
83 4.7  Conclusions 
While  the  noncompartmental  approach  allowed  appropriate  estimates  for  accumulation 
during  the  28  day  treatment  course,  estimation  of  expected  steady  state  levels  requires 
the  application  of  modelling  techniques.  While  individual  patient  accumulation  is  of 
ultimate  clinical  importance,  the  typical  healthy  volunteer  accumulation  and  variability 
is  important  in  the  extrapolation  to  the  later  phases  of  drug  development.  The 
application  of  the  population  approach  has  been  shown  in  this  chapter  to  be  useful  in 
this  respect. 
The  initial  STS  approach  suggested  that  distinct  Ka  and  (x  rate  constants  could  not  be 
determined.  In  resolving  the  problem,  the  dual  absorption  and  elimination  rate  constant 
was  estimated  using  adaptations  of  derived  models  for  the  special  case  where  Ka  equals 
cc.  However,  precise  population  estimates  of  both  Ka  and  cc  could  be  obtained  using  the 
FOCE  method  implementing  user  supplied  PRED  codes. 
The  problems  associated  with  the  population  modelling  of  complex  distribution 
functions  and  extensive  multiple  non  steady  state  dosing  were  exemplified.  For  these 
complex  cases  the  benefits  of  the  FOCE  over  the  FO  estimation  method  was 
demonstrated.  The  resulting  extraordinary  CPU  times  were  largely  overcome  by 
avoiding  PREDPP,  and  by  employing  simpler  user  supplied  PRED  routines. 
The  results  indicate  that  the  population  approach  provided  an  appropriate  description  of 
healthy  volunteer  data  and  a  suitable  base  model  for  future  patient  investigations.  It  was 
shown  that  accumulation  to  toxic  levels  was  unlikely  with  the  present  formulation  and 
dosage  regimen. 
84 CHAPTER  5 
APPLICATION  OF  NONLINEAR  MIXED 
EFFECTS  MODELLING 
TO  BIDEQUIVALENCE  TESTING 
85 In  this  chapter,  the  application  of  the  mixed  effects  modelling  to  bioequivalence  testing  is 
investigated.  A  compartmental  modelling  approach  is  compared  to  the  standard  non- 
compartmental  analysis.  The  robustness  of  the  mixed  effect  modelling  approach  is 
assessed  by  testing  the  hypotheses  of  bioequivalence  before  and  after  the  datasets  have 
been  reduced  by  80%.  Both  additive  and  multiplicative  bioequivalence  models  are  utilised 
in  the  analysis.  Finally,  the  potential  role  of  the  population  pharmacokinetic  approach  in 
the  assessment  of  bioequivalence  is  discussed. 
5.1  Introduction 
5.1.1  The  concept  of  bioavailability  and  bioequivalence 
Bioavailability,  an  abbreviated  tenn.  for  biological  availability,  has  been  defined  by  the 
FDA  as  "the  rate  and  extent  to  which  the  active  ingredient,  or  therapeutic  moiety,  is 
n  t.. 
absorbed  and  becomes  available  at  the  site  of  action".  In  practical  terms,  the  proportion  of 
a  drug  which  becomes  systemically  available  is  known  as  the  absolute  bioavailability  (F), 
and  all  intravascular  doses  are,  by  convention,  100%  bioavailable.  The  relative 
bioavailability  of  an  extra-vascular  drug  product  is  estimated  by  comparing  the 
concentration  time  profiles  after  intra-vascular  and  extra-vascular  administration.  This 
value  is  dependent  on  both  the  physiochernical  properties  of  the  drug  and  the  release 
characteristics  of  the  formulation. 
In  comparative  bioavailability  studies,  the  concentration  time  profiles  of  different 
formulations  of  the  same  drug,  or  different  drug  products,  are  compared.  In 
bioequivalence  studies  the  average  concentration  time  profiles  from  different  formulations 
are  compared  to  ensure  that  the  products  are  interchangeable.  Bioequivalence  is  concluded 
when  the  two  formulations  are  shown  to  be  equivalent  in  terms  of  both  the  "rate"  and 
66  extent"  of  absorption. 
86 5.1.2  Parameters  used  to  determine  bioequivalence 
Many  different  pharmacokinetic  parameters  can  be  used  to  describe  and  assess  the  drug 
concentration  time  profiles,  e.  g.  TI/2  Ke,  Mean  residence  time  (MRT)  etc.  The  preferred 
parameters  are;  AUCO-.  to  assess  the  total  amount  of  drug  which  becomes  bloavallable 
(i.  e.  the  44extent"  of  absorption);  Cmax,  the  maximum  observed  concentration;  and  Tmax, 
the  time  at  which  the  maximum  concentration  is  observed.  Together  Cmax  and  Tmax  are 
used  to  assess  the  rate  at  which  the  drug  becomes  bioavailable. 
5.1.3  Background  and  history  of  bioequivalence  studies 
After  the  innovating  company's  patent  has  expired,  a  drug  can  be  manufactured  and 
marketed  under  its  "approved"  (generic)  name.  Generic  prescribing,  which  can  potentially 
reduce  treatment  cost,  has  led  to  an  increase  in  the  number  of  generic  manufacturers  and 
the  marketing  of  generic  drug  products.  A  method  to  ensure  that  efficacy  and  safety  is 
maintained  across  formulations  is  therefore  required. 
The  concept  of  bioavailability/  bioequivalence  became  a  major  public  issue  in  the  late 
1960's,  when  the  therapeutic  responses  between  proprietary  and  generic  products  for 
several  drugs  were  shown  to  be  different.  By  1970,  the  FDA  required  evidence  of 
"biological  availability"  in  applications  for  the  approval  of  certain  drugs.  Subsequently, 
this  requirement  has  developed  into  the  regulations  currently  used  in  bioavailability  and 
bioequivalence  studies.  (FDA,  1992)  The  statistical  methodology  employed  for 
bioavailability  /  bioequivalence  studies  has  evolved  over  the  years  to  cope  with  alterations 
to  the  regulatory  requirements.  Recently,  the  difference  between  population 
bioequivalence  (where  the  safety  of  prescribing  a  drug  for  the  first  time  is  ensured)  and 
individual  bioequivalence  (where  the  safety  of  switching  from  one  product  to  another  is 
ensured)  has  been  identified  (Anderson  &  Hauck,  1990;  Schall  &  Luus,  1993;  Hauck  & 
87 Anderson,  1994;  Schall  &  William,  1996).  Draft  guidelines  have  been  prepared  which 
identify  separate  criteria  for  each  of  these  issues  (FDA,  1997). 
5.1.4  Development  of  the  statistical  concepts  in  bioequivalence  testing 
In  bioequivalence  testing,  the  rate  and  extent  of  absorption  from  a  test  formulation  (T)  is 
compared  to  a  reference  formulation  (R).  If  the  average  population  values  for  the  test 
formulation(IIT)  and  the  reference  formulation(gR)  are  equal,  then  the  formulations  are 
concluded  to  be  bioequivalent.  However,  ýtTand  ýtRmay  differ  statistically  without  the 
difference  being  clinically  important. 
Following  the  inaugural  meeting  of  the  bioavallability  committee  in  1971,  the  proposed 
statistical  hypothesis  for  the  assessment  of  bioequivalence  was  the  subject  of  much  debate. 
During  the  following  decade  there  were  many  important  contributions  to  the  statistical 
methodology  used  in  bioequivalence  testing.  Amongst  the  most  prominent  were  the  power 
approach,  (Schunmann,  1981),  the  confidence  interval  approach  (Westlake,  1972,1976, 
1979;  Metzler,  1974),  the  reformulated  hypothesis  approach  (Schurimann,  1981;  Anderson 
&  Hauck,  1983)  and  the  Bayesian  approach  (Rodda  &  Davis,  1980;  Mandallaz  &  Mau, 
1981).  The  methods  were  initially  compared  and  contrasted  by  Metzler  and  Huang  (1983). 
More  recently  the  new  approaches  of  population  and  individual  bioequivalence  have  been 
discussed  (FDA,  1997).  However,  the  two  one  sided  test  approach  (Schurimann,  1987, 
1989)  which  is  operationally  identical  to  the  confidence  interval  approach  (Pidgen,  1992) 
used  in  this  chapter,  is  the  current  regulatory  standard. 
5.1.5  Confidence  interval  approach 
If  the  population  mean  parameter  estimates  for  the  test  and  reference  fon-nulations  are 
given  by  ýtTand  ýtR,  a  hypothesis  test  based  on  the  confidence  interval  of  the  mean 
difference  can  be  postulated.  The  concept  is  to  show  bioequivalence  by  rejecting  the  Null 
Hypothesis  of  bi  Oinequi  valence.  The  Null  Hypothesis  is  given  by 
88 Ho: 
ýtT 
- 
ýtR 
:! ý  a,  or 
ýtT 
- 
ýtR  ý!  a2 
where  a,  and  a2are  the  linlIts  for  the  region  of  acceptance,  where  a,  <  a2.  The  alternative 
hypothesis  of  bioequivalence  is  therefore  given  by 
Hl:  a,  "ý' 
ýtT 
- 
ýIR 
<a2 
The  (1-cc)  x  100%  confidence  interval  for  the  sample  mean  difference  is  given  by 
1)  92 
ß-P 
R-+ 
(tl-«/2, 
n-1). 
s 
T  n2 
FS 
where: 
5 
is  the  sample  mean  for  the  reference  formulation 
ýt,  is  the  sample  mean  for  the  test  formulation 
S2  is  the  mean  square  error  from  the  analysis  of  variance  between  formulations,  subjects 
and  periods. 
n  is  the  number  of  subjects 
t1-a12,  n-1's  the  appropriate  two  tailed  t-value  with  (x  usually  set  at  0.1  or  0.05  for  90%  or 
95%  confidence,  respectively. 
The  intervals  in  their  absolute  forin  are  difficult  to  interpret,  so  confidence  intervals  for  the 
relative  difference  are  nonnally  calculated 
99 
ýtT 
- 
ýtR 
Eq  5.1  (LD 
-9 
ýtR 
The  FDA  have  adopted  a  policy  of  accepting  bioequivalence  when  the  90%  confidence 
intervals  are  within  20%  (i.  e.  -al=a2=0.2)  of  the  reference  formulation.  (Westlake,  1972, 
1981;  Pidgen,  1992;  Chow  &  Liu,  1992a). 
89 5.1.6  Normality  vs  In-normality  (additive  vs  multiplicative  model) 
The  individual  Cmax  or  AUCO-.  parameters  (Y),  for  a  comparison  of  two  formulations 
using  a  standard  randomised  2x2  cross-over  study,  can  be  described  by  the  effects  model- 
Y=ýt+I+P+F+E 
where  g  is  the  overall  mean;  I  is  the  random  intersubject  effect;  P  is  the  period  effect;  F  is 
the  formulation  effect  and  E  is  the  random  intrasubject  error  in  observing  Y.  Both  I  and  E 
are  independent  and  normally  distributed  with  a  mean  of  zero.  Since  the  parameters  Cmax 
and  AUCO-.,  are  also  considered  to  be  normally  distributed,  the  bioequivalence  model  is 
additive  in  both  fixed  and  random  effects. 
However,  assumptions  of  normality  for  Cmax  and  AUCO-.  are  often  invalid,  since  the 
underlying  distributions  can  be  positively  skewed  or  truncated  at  zero.  In  addition,  it  has 
been  shown  that  intrasubject  and  intersubject  variances  often  lack  homogeneity  (Chow  & 
Liu,  1992b).  Ln-  transformation  can  correct  for  this  skew.  In  using  this  model  it  is 
assumed  that  the  effects  model  is  described  by  the  following  multiplicative  relationship 
Y=ýt  xIxPxFxE 
Upon  In-transformation  the  effects  can  again  be  deschbed  by  an  additive  model 
ln(Y)=In(ýt)  +  In(l)  +  In(P)  +  In(F)  +  In(E) 
This  concept  has  direct  application  to  the  pharmacokinetic  relationships  which  underly  the 
estimation  of  the  parameters  used  in  the  bioequivalence  test  i.  e. 
AUCO--  = 
F.  DOSE  Eq  5.3 
CL 
Upon  In-transformation  this  is  converted  to  the  additive  model 
ln(AUC,, 
-. 
)  =  In  F-  In  CL  +  In  DOSE  Eq  5.4 
such  that  In  AUCO-.  is  expressed  as  a  function  of  the  sum  of  formulation  effect  (InF)  and 
subject  effect  (InCL).  Therefore,  the  In-transformation  could  reduce  skew,  normalise 
variance  and  ensure  that  effects  are  addltive  (Steinijans  &  Hauschke,  1990). 
90 An  additional  advantage  is  that  the  In-transformed  (multiplicative)  model  provides  a 
confidence  interval  for  the  ratio  of  two  means  (OInRD)wlthout  the  need  for  further 
manipulation  (Mandallaz  &  Mau,  1981)- 
In 
ýUT 
In  RD=  In  4UT  -In 
JUR  I 
Eq  5.5 
ý  JU  R,  1 
The  Null  Hypothesis  of  bioinequivalence  for  the  ratio  of  the  two  formulation  means 
becomes- 
du  T 
ßT 
Ho:  In  -, 
<In  al  or  11)  --r-  >In  a2 
(  JUR,  7  (  JUR) 
while  the  corresponding  alternative  hypothesis  of  bioequivalence  becomes- 
1 
HI:  In  a  <In 
JUT 
<  Ina 
17 
ý,  JUR) 
Following  the  20%  rule  the  limits  for  a,  and  a2would  be  0.8  &  1.2,  respectively.  However 
on  the  logarithmic  scale  these  are  not  symmetrical  around  unity.  A  symmetrical  decision 
scheme  using  the  linUts  0.8  &  1.25  has  been  proposed  (Pabst  &  Jaegar,  1990)  and  is  now 
considered  to  be  a  regulatory  standard  (Chow  &  Liu,  1994). 
Usually,  both  normal  and  log-normal  models  are  applied  and  the  assumptions  of  normality 
and  In-normality  are  checked  in  each  case. 
91 5.1.7  Application  of  the  population  approach  to  bioequivalence  data 
Previously,  compartmental  approaches  have  been  used  to  directly  compare  the  absorption 
rates,  as  an  addition  to  standard  noncompartmental.  hypothesis  testing  (Graves  &  Chang, 
1989;  Piotrovskij  et  al.,  1995).  It  has  also  been  shown  to  be  useful  in  the  companson  of 
immediate  and  controlled  release  formulations  when  the  difference  in  dosing  frequencies 
would  not  allow  bioequivalence  to  be  established  noncompartmentally  (Miller  &  Ludden, 
1993).  The  utilisation  of  mixed  effect  modelling  in  the  general  context  of  bioequivalence 
testing  was  first  proposed  by  Kaniwa  et  al.  (1990),  and  more  recently  by  Li  et  al.  (1994) 
and  Pentikis  et  al.  (1996).  Kaniwa  et.  al.  directly  compared  compartmental  and 
noncompartmental  methods  for  estimating  bioequivalence  in  terms  of  AUCO-.  and  Cmax. 
For  six  different  drugs,  the  point  and  95%  Cl  for  ORDin  AUCO-..  and  Cmax  were  sin-fflarly 
estimated,  by  the  two  approaches.  The  same  number  of  Null  Hypotheses,  was  rejected  by 
both  approaches  (6  in  total).  They  also  showed  that  five  out  of  six  Null  Hypothesis  were 
still  rejected  when  data  was  reduced  by  80%. 
92 5.2  Aims 
The  aim  in  this  chapter  was  to  confirm  and  extend  the  work  of  Kanlwa  et  al.  (1990),  and 
discuss  where  the  population  pharmacokinetic  approach  to  bioequivalence  testing  would  be 
useful  in  drug  development  and  the  control  of  generic  equivalents. 
1)  Comparison  of  noncompartmental  and  compartmental  approaches  to 
bioequivalence  testing. 
The  previous  comparisons  of  the  compartmental  and  the  noncompartmental  approaches  to 
bioequivalence  testing  utilised  datasets  which  were  either  obviously  bioequivalent  or 
bioinequivalent  in  both  AUCO-.  and  Cmax.  In  this  analysis,  a  dataset  which  is 
bioequivalent  in  AUCO-oo  but  bioinequivalent  in  Cmax  is  investigated.  The  effect  of  mis- 
specifying  the  compartmental  model  and  the  NONMEEM  estimation  method  used  in  the 
computation  of  the  model  parameters  are  also  assessed. 
2)  The  Pharmacokinetic  model  and  Cmax  derivation 
The  regulatory  bodies  require  that  Cmax  is used  to  assess  the  rate  of  absorption.  Kaniwa  et 
al.  (1990)  showed  that  the  Op, 
_D 
in  Cmax  can  be  estimated  using  the  mean  population 
parameters.  However,  the  confidence  intervals  for  the  ORDwere  approximated  using  the  SE 
estimates  for  the  absorption  rate  of  the  test  formulation.  A  compartmental  method  for 
determining  the  point  and  Cl  estimate  for  the  ORDin  Cmax  is  therefore  required.  In  this 
analysis,  an  approach  for  estimating  the  point  and  CI  estimates  for  the  ORDin  Cmax, 
directly  from  a  one  compartment  model,  is  proposed.  A  surrogate  metric  for  the  direct 
estimation  of  Cmax  from  a  two  compartment  model  is  also  proposed. 
3)  Additive  and  Multiplicative  bioequivalence  models 
The  regulatory  agencies  require  that  both  additive  and  multiplicative  bioequivalence 
models  be  tested.  The  compartmental  methods  for  implementing  a  multiplicative 
bioequivalence  model  are  described  and  used  to  estimate  the  point  and  CI  estimates  for  the 
OlnRDin  AUCO-.  and  Cmax. 
93 4)  Power  of  the  population  approach  in  assessing  bioequivalence  from  reduced 
datasets 
Kaniwa  et  al  (1990)  previously  demonstrated  that  the  results  of  the  hypothesis  tests  were 
maintained  even  when  the  data  sets  were  reduced  by  80%.  In  this  analysis,  the  dataset  was 
reduced  by  assuming  three  different  sampling  schemes,  representing  three  different 
methods  for  the  collection  of  sparse  bioequivalence  data. 
5.3  Bloequivalence  Data 
Data  from  two  bioequivalence  studies,  comparing  the  reference  Natrilix  formulation  and  a 
test  indapamide  formulation  (Harris  Pharmaceuticals),  were  available  and  used  in  the 
assessment  of  the  population  compartmental  approach  to  bioequivalence  testing  . 
Both  had 
a  two  period  randomised  cross-over  design.  In  the  first  sudy,  16  young  male  healthy 
volunteers  received  one  2.5mg  tablet  of  each  fonnulation,  and  in  the  second  study  14 
young  male  healthy  volunteers  received  two  2.5  mg  tablets  of  each  formulation.  Plasma 
concentrations  were  measured  at  12  time  points:  0,0.5,1,1.5,2,2.5,3,4,6,8,12,24,48 
hours  after  each  dose. 
The  individual  plasma  concentration  versus  time  profiles  for  the  2.5mg  and  5.  Omg  studies 
are  shown,  split  by  formulation,  in  Figures  5.1  and  5.2,  respectively.  In  each  case  the  peak 
concentrations  were  highest  for  the  test  formulation. 
94 Figure  5.1  Individual  concentration  and  log  concentration  time  profiles  for  a)  The 
reference  and  b)  The  test  formulations  after  a  2.5mg  dose 
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96 5.4  Methods 
5.4.1  Noncom  partmental  approach  to  bioequivalence  testing 
AUCO-.  was  calculated  for  each  concentration  time  profile  using  the  linear  trapezoidal 
rule.  Cmax  was  taken  to  be  the  highest  observed  concentration  after  each  dose. 
A  two  way  ANOVA  was  performed  separately  for  each  study  and  then  again  for  the  total 
dataset  after  correcting  for  dose.  The  ANOVA  analysis  was  repeated  for  both  raw  and  In- 
transformed  AUCO-.  and  Cmax  parameters.  The  point  estimates  and  90%  confidence 
intervals  for  the  absolute  differences  and  ORDwere  calculated  using  the  mean  squared  error 
(S)  from  the  ANOVA  and  equation  5.1.  The  point  estimates  and  90%  confidence  intervals 
O]nRDwere  calculated  using  the  mean  squared  error  (S)  from  the  ANOVA  of  the  In- 
transformed  parameters  and  equation  5.5. 
5.4.2  Population  model  dependent  approach:  Full  model  development 
Using  both  FO  and  FOCE  (with  interaction)  methods,  one  and  two  compartment  models 
were  compared.  The  absorption  phase  was  charactensed  by  either  a  first  order  (Ka)  or a 
zero  order  (Ko)  absorption  model.  The  requirement  for  an  absorption  lag  (Tlag)  was  tested 
in  each  case.  Normal  fitting  criteria  were  used  to  compare  the  models  (Chapter  3). 
5.4.3  A  population  compartmental  approach  to  bioequivalence  testing 
The  following  outlines  how  estimates  of 
ORD  and 
01,1RD 
, 
for  AUCO-,,, 
, 
ka  and  Cmax 
,  were 
obtained  for  a  one  and  two  compartment  model. 
Estimation  of 
ORDin  AUCO-oo  for  a  one  and  two  compartment  model 
The  population  approach  to  estimatingORD  in  the  AUCO-.  o  utillses  the  following 
relationship- 
AUCo--  = 
F.  DOSE  Eq  5.6 
v,.  Ke 
97 where  formulation  specific  population  mean  estimates  of 
F 
and  Ke  were  used  to  provide  V, 
the  population  average  estimates  or  for  AUCO-,,  o,  shown  In  Eq  5.1. 
of  ý1 
Since  dose  and  Ke  are  independent  of  formulation,  the  ORDfrom  Eq  5.1  on  substituting  in 
Eq  5.6,  for  each  formulation,  simplifies  to- 
RD 
FF 
Vl 
T 
Vl 
R 
F 
Vl 
R 
Rearranging  for 
F 
gives  VI 
T 
FF 
Vl 
T 
VI 
R. 
(ORD  + 
Eq  5.7 
Eq  5.8 
This  relationship  can  be  utilised  in  NONMEM  to  obtain  parameter  estimates  of  ORDby 
using 
FFF 
-=-  . 
ýl-Formý  + 
.ýI+  ORDý.  ý  Formý 
VI  VI 
R 
Vl 
R 
Eq  5.9 
where  the  indicator  variable  Form,  takes  a  value  of  0  for  all  concentration  associated  with 
the  reference  formulation  and  I  for  all  concentrations  associated  with  the  test  formulation. 
F 
is  the  reciprocal  of  the  population  parameter  for  volume  of  distribution  divided  by  the 
V, 
bi  oavail  ability,  and  provides  NONMEM  with  estimates  of  scale  factor  for  the  conversion 
of  compartment  amounts  into  observed  concentrations.  The  following  can  be  estimated- 
V, 
-I 
FF  Form)  +F  VI 
R 
VI 
R 
. 
(I  +  ORD).  (Fonn) 
Eq  5.10 
98 Estimation  of  0"  in  Ka  for  a  one  and  two  compartment  model 
Bioequivalence  in  the  rate  of  absorption  can  be  obtained  by  comparing  the  absorption  rate 
constants  for  each  formulation.  Coding  the 
ORDas 
previously  shown  in  Eq  5.9,  gives- 
Ka  = 
KaR'ý  I-  Fonný  + 
KaR'ý  1+  ORDý.  ý  Fonný  Eq  5.11 
where  KaR  is  the  first  order  absorption  rate  for  the  reference  fonnulation 
Estimation  of 
ORDin  Cmax  for  a  one  compartment  model 
The  estimated  population  parameters  can  be  used  to  obtain  estimates  of  Cmax  for  a  one 
compartment  model.  A  one  compartment  model  with  first  order  absorption  can  be 
described  by  the  equation- 
F.  Dose.  Ka-  -Ke.  t 
_ 
-Ka.  t  Eq  5.12 
Vl.  (Ka  -  Ke)  *ýe 
and  may  be  written  in  the  form  - 
C(t)  :::::::::  A.  e 
-Ke.  t 
-A.  e 
-Ka.  t 
where  A- 
F.  Dose.  Ka 
Eq  5.13 
Vj.  (Ka  -  Ke) 
The  maximum  concentration  occurs  when  the  derivative  of  Eq  5.13  with  respect  to  t  is 
equal  to  zero  - 
dC(t) 
Ke.  A.  e 
-Ke.  Tpk 
+Ka.  A.  e 
-Ka.  Tpk 
=0  Eq  5.14 
dt 
Solving  for  the  peak  time  Tpk  gives  the  followng  equation  - 
In(K 
Tpk  =- 
ý/Ke 
Eq  5.15 
(Ka  -  Ke) 
So  Cmax  can  be  estimated  from  the  model  parameters  using  the  relationship- 
CmaXD  = 
F.  Dose.  Ka 
* (e 
-Ke.  Tpk 
-e 
-Ya.  Tpk 
V,.  (Ka  -  Ke) 
Eq  5.16 
99 where  Cmax  D  is  the  estimate  of  Cmax  derived  from  the  modelled  parameters.  TheORD 
between  CmaXR  D  and  CmaXT  D  can  be  calculated  using  the  formulation  specific  estimates  of 
F 
Ka,  Tpk,  -  and  the  population  mean  estimate  of  Ke.  V, 
However,  it  is  also  possible  to  estimate  Cmax  explicitly,  by  rearranging  Eq  5.16  and 
substituting  it  into  Eq  5.12,  to  give  the  following  relationship  - 
C(t)  -- 
Cmax 
E 
.( 
-K.  t  -Ka. 
) 
e- 
Ke.  Tpk 
e- 
Ka.  Tpk  e  -e 
Eq  5.17 
In  this  case  Cmax  E  is  an  estimated  model  parameter,  and  the  ORDbetween  CmaXR  E  and 
CmaXT  E  can  be  estimated  from  the  relationship  - 
EEE 
C  max  =C  maxý,.  (1  -  Form)  +C  maxR  -(I 
+  ORD).  (Form)  Eq  5.18 
Estimation  of  ORD  in  Cmax  for  a  two  compartment  model 
A  two  compartment  model  with  first  order  absorption  is  described  by  - 
F.  Dose.  Ka  ( 
K21 
-a)  -a.  t 
C(t)  =  V,  .[  (Ka  -  a)(,  8 
-a) 
e+ 
which  may  be  abbreviated  to- 
(K21 
+  (K21  -  ka)  -  Ka.  t 
(Ka  -  (a  -  Ka)(,  6  -  Ka)  e 
Eq  5.19 
C(t)  = 
F.  Dose.  Ka 
. 
[A 
*.  e-(x't+ 
B*  e-ß't  -(A  * 
V, 
Where  A  and  B  are  constants. 
(K21  -a)  B 
(Ka  -  a)(,  8  -  a) 
(K21-9) 
(Ka  -,  fl)(a  -  fi) 
dC(t) 
The  maximum  concentration  occurs  when  -=0i.  e. 
dt 
Eq  5.20 
A*+B  *= 
(K21  -  ka) 
(a  -  Ka)(,  8  -  Ka) 
dC(t) 
- 
F.  Dose.  Ka 
. 
[-(x.  A* 
.  e-'"t  -ß.  B*e  -ß't  +  Ka.  (A  *  +B*).  e 
-  Ka.  t1=0 
Eq  5.21 
dt  V, 
100 However,  this  cannot  be  solved  analytically  forTpk,  so  the  value  of  Tpk  has  to  be 
estimated  numerically.  The  ORD  for  the  derived  Cmax  (CmaXD)  can  then  be  estimated 
F 
using  the  formulation  specific  estimates  of  Tpk,  Ka  and  -  and  population  estimates  of  a  V, 
and  P. 
Since  Eq  5.21  cannot  be  solved,  it  is  not  possible  to  estimate  Cmax  directly.  However,  by 
adopting  the  methods  proposed  by  Wagner  and  Nelson  (Wagner,  1975)  it  is  possible  to 
obtain  an  approximation  of  Tpk.  The  Wagner  Nelson  method  can  be  used  to  characterise 
the  absorption  profile  of  a  drug  product.  If  absorption  is  governed  by  a  first  order  process, 
then  the  absorption  profiles  for  drugs  with  mono  and  bi-exponential  distributions  can  be 
predicted.  With  a  two  compartment  model  it  can  be  shown  that  - 
Ay  F.  D.  FK12  1  -Ka.  Tll 
V=--+. 
tKa.  ((x 
-  K21).  e  a(Ka  - 
K21  ).  e 
Eq  5.22 
VI  v, 
L 
cc  a(Ka  -  cc) 
where  AT  ISthe  total  amount  of  drug  in  the  central  compartment  at  time  T,  assuming  that 
V  no  elimination  has  occurred  i.  e.  0=0. 
Ay 
is  this  amount  as  a  concentration.  As  T  -->  00  V1 
F.  D 
K12  d(A 
T/V  1) 
ATapproaches  the  asymptotic  value,  VU 
Also  when  dT 
0  i.  e.  at  time 
AX 
V  TApk,  V  reaches  a  maximum.  Differentiating  Eq  5.22  with  respect  to  T  and  solving  for 
TApk  gives- 
1  (oc 
- 
K21) 
1 
TApk  =  (Ka  -  (x)  .1  (Ka 
- 
K2J1 
Where- 
K 
(A.,  8  +  B.  a) 
21  (A  +  B) 
B',  8 
(/ 
+1  ýB) 
Eq  5.23 
(AX  *.,  L  8+a  B  Eq  5.24 
(AX 
L B*+') 
101 TApk  is  an  approximation  of  Tpk  and  is  the  time  at  which  the  accumulative  amount 
absorbed  into  the  central  compartment  divided  by  VI  reaches  a  maximum.  The 
concentration  at  this  time  (CAmax  )  is  an  approximation  of  Cmax  and  is  given  by 
CA  max  = 
F.  Dose.  Ka  [A*. 
e  -cc.  TApk  +B*.  e-ý. 
TApk_ 
(A*+B*).  e  -Ka.  TApk 
V, 
Eq  5.25 
By  rearranging  Eq  5.25  and  substituting  in  to  Eq  5.19  CAmax  E  can  be  explicitly  estimated, 
using  the  relationship- 
CA  max 
I 
A*.  e  -CU  +B* 
.  e-P-t-(A*+B*).  e 
-Ka.  t] 
C(t) 
--L 
Ka.  TApk 
Eq  5.26  [A*. 
e-(x. 
TApk  +  B*.  e- 
P.  TApk 
_  (A  *+B*).  e- 
These  relationships  hold  providing  Ka  >  oc  >  P.  Also,  CAmaXE  approaches  Cmax  E  when 
the  fraction  of  drug  eliMMated  by  TApk  is  small  i.  e.  when  the  elimination  rate  is  very  small 
in  comparison  to  Ka  and  (x. 
Obtaining  population  estimates  of 
01. 
RD 
F 
From  Eq  5.5,  the  relationship  betweenOInRDand  -  becomes- 
V, 
In  RD  =  in 
F- 
In 
VI 
T 
VI 
R  Eq  5.27 
As  before,  to  provide  a  scale  for  the  conversion  of  compartmental  amounts,  in  NONMEM, 
the  relationship  can  be  expressed  as  - 
V 
1YF 
I 
In( 
F 
")+(qnRD*Form)  el  vi 
Eq  5.28 
Similarly,  the  relationship  between  Cmax  E  and0l,,  RDbecomes- 
E=  In(C  maXE 
)+(qnRD*ForM) 
C  max  el 
RI  Eq  5.29 
102 Obtaining  confidence  interval  for  the  population  estimates  of 
ORAandOInRD 
The  CI  for  theORD  or  OInRDin  F 
or  Ka  can  be  estimated  directly  using  the  SE  for  theORD  V, 
or  OlnRDparameter  estimates.  The  Cl  for  theORD  or  OlnRDin  CmaXD  cannot  be  obtained 
directly.  However,  the  limits  of  CmaXT  D  can  be  calculated  using  the  upper  and  lower  linuts 
of  the  KaT.  The  approximate  confidence  intervals  for  the 
ORDin  Cmax 
D 
can  be  estimated 
by  dividing  the  linuts  by  CmaXR  D  (Kan1wa  et  al.,  1990).  In  comparison,  the  95%CI  for  the 
ORD  or  OInRD1n  CmaXE  or  CAmaXE  can  be  directly  obtained  using  the  SE  for  theORD  or  OInRD 
parameter  estimates. 
The  95%  CI  derived  from  extended  least  squares  asymptotic  SE  estimates  calculated  using 
NONMEM  have  been  shown  to  contain  the  true  value  of  the  parameter  estimate  on  less 
than  95%  of  occasions  (Sheiner  &  Beal,  1987).  In  fact  90%  was  the  best  performance. 
Thus,  in  this  study  the  95%  confidence  intervals  from  NONMEM  are  taken  to  be 
equivalent  to  the  nominal  90%  confidence  intervals  used  to  perform  the  hypothesis  tests. 
5.5  Results 
5.5.1  Bloequivalence  assessment  using  noncom  partmental  estimates 
Figures  5.3  and  5.4  show  the  untransformed  and  In-transformed  individual  dose  corrected 
AUCo-oo  and  Cmax  estimates.  The  In-transfornation  reversed  the  skew  on  the  distribution 
of  AUCo-oo  and  normalised  the  distribution  of  Cmax.  The  bioequivalence  of  the  test  and 
reference  formulations  (AUCo-_  and  Cmax)  was  assessed  using  the  data  for  each  study 
separately  and  also  the  combined  dataset.  Both  the  untransformed  (additive  bloequivalence 
model  ),  and  the  In-transformed  (multiplicative  bioequivalence  model)  data  were  used.  The 
point  estimates  and  90%  CI  for  the  relative  differences  are  presented  in  Tables  5.1  to  5.4, 
103 along  with  the  ANOVA  which  was  used  to  provide  the  Error  MS  (S  2)  for  the  calculation 
of  the  confidence  intervals. 
Point  and  confidence  interval  estimates  for  the  relative  difference  in  AUC  0-. 
Using  an  additive  model 
The  point  and  90%  Cl  estimates  for  the  ORDin  AUC  o-oo  were  similar  for  the  two  studies 
and  none  of  the  confidence  intervals  overlapped  the  ±20%  lirmts  (Table  5.1).  The  Null 
Hypothesis  of  bioinequivalence  could  be  rejected,  so  the  formulations  were  considered  to 
be  bioequivalent  in  AUC  o-oo. 
104 Figure  5.3  a)  Untransformed  and  b)  Ln-transformed  distributions  of  dose  corrected 
AUCo-oo  (corrected  to  5mg) 
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105 Figure  5.4  a)  Untransformed  and  b)  Ln-transformed  distributions  of  dose  corrected  Cmax 
(corrected  to  5mg) 
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106 Table  5.1  ANOVA  of  AUCO-.,  absolute  and  relative  mean  differences  (ORD)  In  AUC0-. 
'  between  test  and  reference  formulations  for  the  2.5  mg  study,  the  5mg  study  and  for  both 
studies  combined 
2.5mg  Study 
Source  of  Variation  SS  df  MS  F  P-value 
Between  patients  2004580  15  133639  9.18  0.0001 
Between  fonnulations  2860  1  2860  0.20  0.6600 
Error  218285  15  14552 
otal  2225724  31 
Mean  difference  (ng.  ml-  I  hr)  18.9 
Relative  mean  difference  2.2% 
:!!  ý  -20%  or  ý!  +20% 
90%  Cl  -56.2  94.0 
90%  Cl  -6.4%  10.7% 
No 
5.  Omg  Study 
Source  of  Variation  SS  df  MS  F  P-value 
Between  patients  2344107  13  180316  9.09  0.0002 
Between  formulations  8198  1  8198  0.41  0.5300 
Error  257739  13  19826 
Total  2610043  27 
Mean  difference  (ng.  ml-l.  hr) 
Relative  mean  difference 
:! ý  -20%  or  ýý+20% 
34.2  90%  Cl  -60.6  129.1 
2.6%  90%  Cl  -4.6%  9.8% 
No 
F  Both  2.5  &  5.  Omg  Studies  Dose  corrected  (2.5mg  AUCO-.  x  2) 
Source7of  Variation  SS  df  MS  F  P-value 
Between  patients  13116118  29452279.9  11.60  0.00000 
Between  formulations  19588  1  19587.9  0.50  0.48400 
]Prrnr  1130926  29  38997.5 
1 
Total  14266632  59 
Mean  dl*fference  (ng.  ml-l.  hr) 
Relative  mean  difference 
-20%  or  ý!  +20% 
36.1  90%  Cl  -50.6  122.9 
2.3%  90%  Cl  -3.3%  7.9% 
No 
107 Table  5.2  ANOVA  of  Ln(AUC  O-oo),  absolute  and  relative  mean  differences  (01.  RD)  in 
Ln(AUC  0-.  ),  between  test  and  reference  formulations  for  the  2.5  mg  study,  the  5mg  study 
and  for  both  studies  combined 
Dose  2.5mg 
Source  of  Variation 
I 
SS  f  d  ms  F  P-value 
1 
Between  patients  2.5  20  15  0.170  8.60  0.000  1 
Between  fonnulations  0.002  1  0.002  0.11  0.7400 
Error  0.290  15  0.020 
Total  2.820  31 
Relative  Mean  difference  1.7%  90%  CI  -7.1%  10.4% 
:! ý  -20%  or  ý:  +25%  No 
Dose  5.  Omg 
Source  of  Variation  SS  df  MS  F  P-value 
Between  patients  1.370  13  0.110  8.93  0.0002 
Between  formulations  0.006  1  0.006  0.51  0.4900 
Error  0.150  13  0.010 
Total  1.53  27 
Relative  Mean  difference  2.9%  90%  CI  -4.3%  10.2% 
:5  -20%  or  ý!  +25%  No 
Dose  2.5mg  &  5.  Omg  2)  Dose  corrected  (2.5mg  AUCO-.  x 
Source  of  Variation 
1 
SS  qf 
] 
ue  ms  F  P-value 
Between  patients  4.912  29  , Do  0  0.169  11.00  0.000 
Between  fonnulations  0.008  1  0.008  0.50  0.4891 
IP-rrnr  0.448  29  0.015 
otal  5.367639  59 
Relative  Mean  difference 
:! ý  -20%  or  ý!  +25% 
2.2%  90%  Cl  -3.2%  7.7% 
No 
108 Table  5.3  ANOVA  of  Cmax 
,  absolute  and  relative  mean  differences  (ORD)  in  Cmax, 
between  test  and  reference  formulations  for  the  2.5  mg  study,  the  5mg  study  and  for  both 
studies  combined 
2.5mg  Study 
Source  of  Variation  SS  df  Ms  F  P-value 
Between  patients  3847  15  256  2.08  0.08 
Between  fon-nulations  939  1  939  7.62  0.01 
Error  1847  15  123 
Total  6632  31 
Mean  difference  (ng.  ml-1)  10.8  90%CI  3.9  17.7 
Relative  Mean  difference  26.8%  90%Cl  9.7%  44.0% 
:!!  ý  -20%  or  ý!  +20%  Yes 
5.  Omg  Study 
Source  of  Variation  SS  df  MS  F  P-value 
Between  patients  9520  13  732  6.08  0.0013 
Between  formulations  3035  1  3035  25.21  0.0002 
Error  1565  13  120 
Total  14120  27 
Mean  difference  (ng.  ml-1)  20.8  90%Cl  13.4  28.2 
Relative  Mean  difference  25.0%  90%Cl  16.2%  33.9% 
:! ý  -20%  or  ý!  +20%  Yes 
2.5  &  5.  Omg  Study  Dose  corrected  (2.5mg  Cmax  x  2) 
Source  of  Variation  SS  df  MS  F  P-value 
Between  patients  24965  29  861  2.79  0.00367 
Between  formulations  6786  1  6786  21.98  0.00006 
Error  8955  29  309 
, 
Total  40706  59 
Mean  difference  (ng-ml-  I)  21.3  90%Cl  13.6  29.0 
Relative  Mean  difference  26.0%  90%Cl  16.6%  3  5.4  % 
:! ý  -20%  or  ý!  +20% 
Yes 
109 Table  5.4  ANOVA  of  Ln(Cmax),  absolute  and  relative  mean  differences  (01nRD)  in 
Ln(Cmax),  between  test  and  reference  formulations  for  the  2.5  mg  study,  the  5mg  study 
and  for  both  studies  combined 
Dose  =  2.5mg 
Source  of  Variation  SS  df  Ms  F  P-value 
Between  patients  1.57  15  0.10  2.08  0.08 
Between  formulations  I  0.36  1  0.36  7.23  0.02 
Error  0.75  15  0.05 
ITotal  2.68  31 
Relative  Mean  difference  21.3%  90%CI  7.3%  35.2% 
<  -20%  or  >+25%  yes 
Dose  =  5.  Omg 
Source  of  Variation  SS  df  Ms  F  P-value 
Between  patients  0.97  13  0.07  4.52  0.0053 
Between  formulations  0.37  1  0.37  22.59  0.0004 
Error  0.21  13  0.02 
ITotal  1.55  27 
Relative  Mean  difference 
<  -20%  or  >+25% 
23.1%  90%cl  14.5%  31.6% 
yes 
Dose  =2.5  &  5.  Omg  Dose  corrected  (2.5mg  Cmax  x  2)1  1 
Source  of  Variation  SS  df  Ms  F  P-value 
Between  patients  2.55  29  0.09  2.64  0.00550 
Between  formulations  0.73  1  0.73  21.98  0.00006 
]P.  rrr,.  -r  0.98  29  0.03 
otal 
Relative  Mean  difference 
<  -20%  or  >+25% 
4.26  59 
22.1%  90%cl  13.8%  30.4% 
yes 
110 Point  and  confidence  interval  estimates  for  the  relative  difference  in  AUC  0, 
Using  the  multiplicative  model 
The  analysis  was  repeated  using  the  logarithms  of  AUC  o-oo  and  Cmax,  respectively 
(Table  5.2).  Subtraction  of  the  sample  means  provided  estimates  of  the  relative  difference 
(OInRA).  To  maintain  a  symmetrical  interval  on  the  logarithmic  scale,  the  upper 
bioequivalence  limit  was  set  to  +25%.  The  point  and  90%  CI  estimates  for  AUCo-oo  were 
relatively  unchanged  from  theORDestimates  discussed  above.  Therefore  bioequivalence  in 
AUCo-oo  could  again  be  concluded. 
The  point  and  confidence  interval  estimates  for  absolute  and  relative  difference  in 
Cmax 
Using  an  additive  model 
Although  the  point  estimates  for  the  ORDin  Cmax  were  similar  across  both  studies,  the 
90%C1  estimates  for  the 
ORDin  Cmax  were  wider  for  the  2.5mg  study  (Table  5.3).  The 
point  estimates  were  26.8  and  25.0  % for  the  2.5mg  and  the  5  mg  studies,  respectively. 
Both  were  greater  than  the  upper  lirrUt  (+20%).  Accordingly,  the  Null  Hypothesis  could 
not  be  rejected  and  bioinequivalence  in  Cmax  was  concluded. 
Using  a  multiPlicative  model 
Bioinequivalence  in  Cmax  was  concluded  when  the  multiplicative  model  was  used  (Table 
5.4).  However,  in  comparison  to  the  additive  model,  the  point  estimates  were  all  within  the 
upper  limit  (+  25  %).  The  confidence  intervals  were  also  smaller  with  the  multiplicative 
model.  In  particular,  the  +9.7  to  +44%  confidence  interval  for  the  2.5mg  study  using  the 
additive  model,  was  decreased  to  +7.3%  to  +35.2%  when  the  multiplicative  model  was 
used.  This  result  was  consistent  with  the  distribution  of  Cmax  being  characterised  as  In- 
normal. 
ill 5.5.2  Compartmental  analysis:  Development  of  the  structural  and  variability 
model 
The  development  of  the  population  pharmacokinetic  model,  for  the  combined  set  of  stud), 
data,  is  shown  in  Table  5.5.  The  structural  and  variability  model  was  determined  assuming 
that  there  was  no  difference  between  the  formulations.  Standard  one  and  two  compartment 
models,  parametensed  in  terms  of  cc,  P, 
V1 
and  A/B, 
F 
rates  (with  and  without  Tlag  )  were  tested. 
with  zero  and  first  order  absorption 
The  FO  method  was  used  in  runs  1  to  6.  In  run  1,  a  one  compartment  model  with  first 
order  absorption  using  an  exponential  model  for  interindividual  and  intraindividual 
variability  was  fitted.  In  run2,  a  two  compartment  model  was  fitted,  and  the  decrease  in 
objective  function  in  comparison  to  runI  was  statistically  significant  (P<0.001).  However, 
interindividual  variability  in  A/B  could  not  be  estimated.  In  run  3,  the  previous  model  was 
repeated  but  with  a  expression  combining  additive  and  proportional  error  to  estimate 
intraindividual  variability.  The  decrease  in  objective  function  was  not  statistically 
significant,  and  the  estimate  of  the  additive  component  of  intraindividual  vanability  was 
not  significantly  different  from  zero(ýYADD).  In  run  4,  an  absorption  lag  time  was  added  to 
the  model,  but  the  parameter  could  not  be  estimated.  Attempts  to  model  a  zero  order 
absorption  with  the  FO  method  resulted  in  rounding  errors,  and  therefore,  an  aborted 
covariance  step  (runs  5  and  6).  The  higher  objective  function  for  run  6  in  comparison  to  run 
5  (which  has  fewer  parameters)  was  mostly  likely  due  to  a  local  minimum,  which  could  not 
be  overcome  by  changing  the  starting  estimates. 
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00 Repeating  the  analysis  using  the  FOCE  with  interaction  method,  runs  7  to  11  (  Table  5.5), 
showed  similar  but  not  identical  results.  As  with  the  FO  method,  there  was  a  statistically 
significant  decrease  in  the  objective  function  when  a  two  compartment  model  was  fitted  ( 
run  8  vs  run  7),  p<0.001.  The  intersubject  vanablity  in  oc  and  A/B  could  not  be  estimated. 
In  run  9,  an  absorption  lag-time  of  0.37  hrs  was  estimated  and  there  was  a  further  decrease 
in  objective  function.  However,  the  estimates  of  Ka  and  Tlag  were  not  significantly 
different  from  zero.  Using  the  zero  order  absorption  model  with  the  FOCE  method  also 
resulted  in  rounding  errors  (runs  10  and  11,  Table  5.5).  The  differences  in  the  objective 
function  and  parameter  estimates  between  runs  10  and  11  was  again  most  likely  due  to  run 
II  terminating  at  a  local  minimum.  Both  the  FO  and  FOCE  methods  indicated  that  a  two 
compartment  model  with  first  order  absorption  best  described  the  pharmacokinetics. 
The  weighted  residual  versus  time  plot  for  the  two  estimation  methods  showed  that  there 
was  a  bias  in  the  fit  during  the  absorption  phase  when  the  FO  method  was  used  (Figure 
5.5a).  In  comparison,  the  weighted  residual  versus  time  plot  for  the  FOCE  method  does 
showed  no  obvious  bias.  (Figure  5.5b).  Splitting  the  weighted  residuals  versus  time  by 
forinulation  showed  that  during  the  absorption  phase  the  concentrations  for  the  test  and 
reference  products  were  under  and  over  estimated,  respectively.  (Figure  5.6). 
114 Figure  5.5  Weighted  residual  versus  time  after  dose  for  a  two  compartment  model  fitted 
using  a)  FO  method  (run  2)  b)  FOCE  with  interaction  method  (run8) 
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115 Figure  5.6  Weighted  residual  versus  time  for  a  two  compartment  model  with  first  order 
absorption  split  by  study  and  formulation 
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116 5.5.3  Estimation  of  the  relative  difference  in 
F 
Ka,  CmaXD  and  CAmaXE 
V, 
Equations  5.10  and  5.11  were  included  in  the  model  (Appendix  1.2)  to  allow  the  relative 
F 
differences  in  -  and  Ka  to  be  estimated.  Subsequently,  the  bias  in  the  weighted  residual  V, 
versus  time  plot  was  reduced  (Figure  5.7  vs  Figure  5.6)  and  there  was  a  further  significant 
decrease  in  objective  function  (P<0.001)  (run12  vs  run  8  Jable  5.6).  When  the  ORD 
parameters  were  estimated  the  estimateOf 
(J)Kawas  reduced  from  50%  to  27%(runl2  vs  run 
8).  Parameterising  the  model  in  terms  of  CAmax  (using  E.  q.  5.23,5.26,5.11  and  5.18- 
Appendix  1.2)  resulted  in  a  further  small  decrease  in  objective  function  (run  13  vs  run  12 
Table  5.6).  The  parameter  estimates  which  were  common  to  both  models  ((x,  p,  ka  and  A/B) 
were  very  similar.  The  point  estimates  forORDin  CAmax  E  and  Cmax  D  were  also  very 
similar  i.  e.  the  relative  difference  in  the  concentration  at  the  point  where  the  total  amount 
absorbed  reaches  a  maximum  is  very  similar  to  relative  difference  in  Cmax  for  this  dataset. 
Figure  5.8  shows  the  senstivity  of  the 
ORDin  CAmax 
E 
and  Cmax 
D 
to  individual  changes  in 
R 
(x  and  Ka 
,  while  other  parameter  estimates  were  fixed  to  those  for  run  12.  As 
approaches  (x,  the 
ORDin  CAmax 
E  becomes  much  greater  than  theORDin  Cmax.  In 
RR 
comparison,  the  divergence  when  cc  approaches  0  or  Ka 
,  or  Ka  approaches  cc  is  smaller. 
Therefore,  the  equivalence  of  the  ORDin  CAmax  and  Cmax  is  dependent  on  0  being  small. 
FE 
Runs  14  and  15  show  theOInRDestimates  for  -  and  Cmax  upon  utilising  E.  q's  5.28  and 
V, 
5.29  (Appendix  1.2),  respectively.  The  other  parameter  estimates  were  unchanged. 
117 Figure  5.7  Goodness  of  fit  for  two  compartment  model  with  first  order  absorption  split  by 
study  and  formulation  after  calculation  of  the  relative  difference  in  Ka  and  V,  ýF 
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Ka  R  hr-1 5.5.4  Comparison  of  compartmental  and  noncom  partmenta  I  approaches  to 
bioequivalence  assessment 
The  point  and  CI  estimates  for  theORDandOInRDin 
F, 
Ka,  Cmax  D,  and  CAmax  E  for  the 
V, 
two  compartment  model  with  first  order  absorption,  using  FOCE  method  (run  8&  12, 
Table  5.6),  are  compared  to  the  equivalent  non-compartment  estimates  in  Figures  5.9  to 
5.11.  The  point  and  Cl  estimates  for  theORDandOInRDfor  the  FO  fit  of  the  two 
compartment  model  and  both  FO  and  FOCE  fit  of  the  one  compartment  model,  are 
included  to  demonstrate  the  effect  of  estimation  method  and  model  mispecification  on  the 
bioequivalence  assessment. 
Comparison  of  the  point  and  confidence  interval  estimates  for  the  relative  difference 
in 
The  Null  Hypothesis  could  be  rejected  with  either  the  one  or  the  two  compartment  model, 
so  bioequivalence  was  concluded  in  each  case  (AUCO-oo/F/Vj)  (Figure  5.9).  The  point  and 
interval  estimates  were  practically  unchanged  by  using  the  multiplicative  instead  of  the 
additive  bioequivalence  model.  The  lack  of  difference  relates  to  there  being  no  obvious 
improvement  in  the  distribution  upon  assurnIng  In-normality  (section  5.5.1).  Point 
estimates  obtained  from  the  one  compartment  model  were  larger  than  those  obtained  using 
both  the  noncompartmental  and  two  compartment  methods.  The  CI  estimates  were  largest 
when  the  FO  method  was  used.  The  point  and  CI  estimates  were  very  similar  to  the 
noncompartmental  estimates  when  the  best  fit  two  compartment  model  was  fitted  using  the 
FOCE  estimation  method. 
121 Figure  5.9  Comparison  of  the  point  and  interval  estimates  for  the  a)  0  and  b)O  nRD  in  RD 
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122 Comparison  of  the  point  and  confidence  interval  estimates  for  the  relative  difference 
in  Ka,  Cmax  D  and  Cmax  E  (CAmax-Efor  two  compartment  model  ) 
Ka 
For  all  models,  the  point  estimate  for  the  relative  difference  in  Ka  was  significantly 
different  from  zero,  indicating  that  the  absorption  rate  for  the  test  formulation  was 
significantly  different  from  the  reference  formulation  (Figure  5.10a).  The  point  and  CI 
estimates  of  this  difference  varied  according  to  the  estimation  method  and  the  model.  For 
the  same  pharmacokinetic  model,  the  point  estimates  obtained  using  the  FOCE  method 
were  four  times  greater  than  those  obtained  using  the  FO  method.  Similarly,  for  the  same 
estimation  method,  the  CI  estimates  were  greatest  for  the  one  compartment  model. 
CmaxD 
Point  estimates  for  the  relative  difference  in  Cmax  D  were  derived  using  the  relative 
F 
difference  estimates  for  Ka  and  -(Figure  5.1  Ob).  Corresponding  asymmetrical 
V, 
confidence  intervals  were  obtained  using  the  bounds  of  the  CI  for  the  ORD  in  Ka  (the 
method  used  by  Kaniwa  et  al.  (1990):  the  upper  confidence  intervals  in  CmaXD  were  shorter 
than  the  lower  confidence  intervals. 
The  Null  Hypothesis  could  not  be  rejected  when  the  two  compartment  model  was  fitted 
with  the  FOCE  method.  The  Null  Hypothesis  of  bioinequivalence  could  be  rejected  in  all 
other  cases  where  a  compartment  model  was  utilised.  When  the  two  compartment  model 
was  fitted  using  the  FO  method  the  Cmax  D  point  estimate  for  theORDwas  very  small.  In 
comparison  to  all  other  runs,  Ka  in  this  run  was  estimated  to  be  smaller  than  cc.  Attempts 
were  made  to  constrain  Ka  >  (x  but  the  run  did  not  successfully  minimise. 
123 Figure  5.10  Comparison  of  the  point  and  interval  estimates  for  theORDin  a)  Ka  and  b) 
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124 CmaxE(CAmaxE) 
For  both  the  CmaXE  (one  compartment  model)  and  CAmax  E  (two  compartment  model) 
models,  the  Null  Hypothesis  of  bioinequivalence  could  not  be  rejected  when  the  additive 
bioequivalence  model  was  used  (Figure  5.11  a).  The  point  and  CI  estimates  for  the  relative 
difference  using  the  best  fit  two  compartment  model  and  FOCE  estimation  were  most 
similar  to  the  noncompartmental  estimate.  As  would  be  predicted  from  its  distribution 
(section  5.5.1)  all  point  and  CI  estimates  were  reduced  when  the  multiplicative 
bioequivalence  model  was  implemented  (Figure  5.11  b).  For  the  one  compartment  model, 
this  resulted  in  rejection  of  the  Null  Hypothesis  of  bioinequivalence. 
Overall,  the  results  were  found  to  be  independent  of  estimation  method.  However,  the 
point  and  confidence  interval  estimates  were  most  similar  to  the  non-compartmental 
estimates  when  the  FOCE  method  was  utilised.  In  this  dataset.,  fitting  a  one  compartment 
model  reduced  the  ability  of  the  compartmental  approach  to  detect  bloinequi  valence  in 
Cmax.  This  is  not  surprising,  since  it  would  be  expected  that  accurate  deternunation  of  the 
relative  difference  in  Cmax  would  requires  the  biphasic  distribution  model  to  be  well 
characterised  i.  e.  use  of  the  correct  model. 
125 Figure  5.11  Comparison  of  the  point  and  interval  estimates  for  the  a)  ORDand  b)OInRDin 
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TNAD  Qpnqý 
x4r-YiA 5.5.5  Bioequivalence  assessment  of  randomly  reduced  datasets  using  a 
compartmental  approach 
The  ability  of  the  population  compartmental  approach  to  conclude  the  correct  result  when 
the  data  was  reduced  by  80%  was  assessed  using  three  different  sampling  strategies: 
Full  randomisation  (FR):  20%  of  the  concentration  data  from  both  studies  was  randomly 
sampled 
Segmented  randomisation  (SR):  30%  of  concentrations  before  the  3hr  time  point  and 
10%  of  the  data  after  the  3hr  time  from  both  studies  was  randomly  sampled.  The  number 
of  concentrations  in  each  dataset  was  equivalent  to  20%  of  the  original  data. 
Matched  randomisation  (MR):  20%  of  concentrations  following  administration  of  the 
reference  formulation  were  randomly  sampled  from  both  studies  and  then  the  same  time 
points  after  the  test  formulation  were  extracted.  The  number  of  concentrations  in  each 
dataset  was  again  equivalent  to  20%  of  the  onginal  data. 
Number  of  sampled  datasets  analysed 
Ten  datasets  were  obtained  using  each  randomisation,  providing  30  sparse  datasets  in  total. 
The  small  number  of  randorrUsations  used  here  was  limited  by  time.  The  original  initial 
plan  was  to  use  this  investigation  as  a  pilot  for  a  larger  simulation  analysis. 
Comparison  of  one  and  two  compartment  model  fits  to  the  sparse  datasets  (using  the 
FOCE  method) 
A  comparison  between  the  fit  of  a  one  compartment  model  and  a  two  compartment  model 
with  first  order  absorption  to  each  of  the  30  sparse  datasets  is  shown  on  Table  5.7.  The 
AIC  criteria  (Chapter  3)  determined  that  90%  of  the  sparse  data  sets  fitted  a  two 
compartment  model  better  than  a  one  compartment  model. 
127 Table  5.7  Comparison  of  the  objective  function  and  parameter  precision  from  fitting  one 
and  two  compartment  models  to  the  sparse  datasets 
I  Full  RandoMisation 
Objective  Function  Parameter  Precision 
OBJ.  Diff  A  AIC 
1/2  CC  ka 
R 
#  1/2 
1  19.01  15.01  2  ns  s  S  1 
2  6.656  2.656  2  s  S  s  2 
3  19.666  15.666  2  s  s  S  2 
4  12.508  8.508  2  S  S  s  2 
5  17.621  13.621  2  S  s  S  2 
6  14.496  10.496  2  ns  ns  S  1 
7  25.906  21.906  2  S  s  s  2 
8  17.049  13.049  2  s  S  S  2 
9  17.268  13.268  2  S  s  s  2 
101  3.803  -0.197  11  ns  S  S  I 
Match  RandorMsation 
Objective  Function  Parameter  Precision 
OBJ.  Diff  A  AIC  *1/2  kaK  #1 
/2 
1  3.184  -0.816  1  s  ns  ns  1 
2  14.623  10.623  2  s  ns  s  1 
3  7.109  3.109  2  ns  s  s  1 
4  11.136  7.136  2  s  s  s  2 
5  13.681  9.681  2  s  ns  s  1 
6  19.408  15.408  2  s  s  s  2 
7  16.749  12.749  2  ns  s  s  1 
8  23.752  19.752  2  s  s  s  2 
9  19.005  15.005  2  s  s  s  2 
10  10.166  6.166  2  s  ns  s  I 
I  Seamental  Randomisation  I 
Objective  Function  Parameter  Precision 
OBJ.  Diff  A  AIC 
*  1/2  kaK  #1 
/2 
1  14.645  10.645  2  s  ns  s  1 
2  3.183  -0.817  1  s  s  s  1 
3  7.832  3.832  2  s  ns  s  1 
4  11.144  7.144  2  s  s  s  2 
5  6.877  2.877  2  s  s  s  2 
6  10.142  6.142  2  s  ns  s  1 
7  7.757  3.757  2  s  s  s  2 
8  11.194  7.194  2  s  s  s  2 
9  11.334  7.334  2  ns  s  s  I 
10  6.663  2.663  11  ns  s  s  1 
A  AIC=change  in  the  AIC  between  aI  and  2  compartment  model.  s=  Parameter  estimate 
statistically  different  from  zero  ns=  Parameter  estimate  not  statistically  different  from  zero. 
*  1/2  No  of  compartments  for  best  fit  model  based  on  AAIC 
#1/2  No  of  compartments  for  best  fit  model  based  on  AAIC  and  parameter  precision 
128 However,  if  precision  of  the  cc  P  and  KaRest1mates  (the  parameters  required  to  correctly 
characterise  a  two  compartment  model)  were  additionally  considered  in  deciding  which 
model  was  most  appropriate,  parameter  estimates  were  only  significantly  different  from 
zero  in  50%  of  cases.  Imprecise  two  compartment  parameter  estimates  were  obtained  for  3 
of  the  10  FR  datasets,  6  of  the  10  MR  and  6  of  the  10  SR  datasets. 
Assessment  of  bioequivalence  in  the  sparse  datasets  assuming  a  two  compartment 
model 
F  Figures  5.12  and  5.13  show  the  point  and  Cl  estimates  for  the 
ORD 
and 
theOlnRD  in 
V,  and 
CmaXE 
,  respectively,  for  the  sparse  datasets,  using  a  two  compartment  model  with  first 
order  input  and  the  FOCE  estimation  method. 
FNI 
The  averageORDpoint  estimates  across  the  FR,  SR  and  MR  datasets  were  +5.7%  ,  +6.0% 
and  +7.6%,  respectively.  The  average  for  all  30  datsets  was  +6.4%  which  was  100%  larger 
than  the  point  estimate  estimated  using  the  full  clataset  (FD).  The  width  of  the  average  CI 
across  all  the  sparse  datasets  was  also  almost  twice  that  estimated  for  the  full  dataset  (20  vs 
11  %,  respectively). 
The  averageOl.  RDpoint  estimates  across  the  FR,  SR  and  MR  datasets,  were  +4.4%  ,  +4.3% 
and  +  5.4%,  respectively.  The  average  for  all  30  datsets  in  this  case  was  +4.7  %,  which  was 
40%  larger  than  the  point  estimate  for  the  full  dataset  (+3.2 
The  average  width  of  the  CI  across  all  the  sparse  datasets  was  smaller  when  the 
multiplicative  bioequivalence  model  was  fitted  (16%  vs  20%)  and  therefore  closer  to  that 
for  the  full  data  set  (I  I%). 
129 Figure  5.12  The  point  and  interval  estimates  for  a) 
ORtDand  b)  OInRDin  FNI  for  the  sparse 
datasets.  COM  is  the  full  dataset  (FD)  analysed  using  the  compartmental  approach  and  NC 
the  full  dataset  (FD)  analysed  using  noncompartmental  approach 
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The  averageORDpoint  estimates  across  the  FR,  SR  and  MR  datasets  were  +37.1%  9 
+29.3%  and  +33.2%,  respectively.  The  average  for  all  30  datsets  was  +33%,  which  was 
40%  larger  than  the  point  estimate  obtained  using  the  full  dataset  (FD).  The  average  width 
of  the  CI  across  all  the  sparse  datasets  was  also  almost  300%  larger  than  that  for  the  FD 
(59.5  %  vs  20.7%,  respectively). 
The  averageOInRDpoint  estimates  across  the  FR,  SR  and  MR  datasets,  were  +20.8%  , 
+19.4%  and  +  18.4%,  respectively.  The  average  for  all  30  datsets  was  +19.5%,  which  was 
very  similar  to  the  point  estimate  for  the  full  dataset  (+20.8).  The  average  width  of  the  CI 
was  narrower  and  hence  closer  to  the  FD  estimate  when  the  muliplicative  bioequivalence 
model  was  used  (26.6%  vs  16.8,  respectively). 
131 Figure  5.13  The  point  and  interval  estimates  for  a)ORDand  b)O, 
nRDin  CmaxE\CAmaXE  for 
the  sparse  datasets.  COM  is  the  full  dataset  (FD)  analysed  using  the  compartmental 
approach  and  NC  the  full  dataset  (FD)  analysed  using  noncompartmental  approach 
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132 Hypothesis  testing:  Comparison  with  noncompartment  estimates  of  bioequivalence 
Table  5.8  shows  the  number  of  datasets  where  the  Null  Hypothesis  of  bioinequi  valence 
was  not  rejected,  split  by  sampling  scheme  and  repeated  for  additive  (ORD)  and 
multiplicative(OiriRD)  bioequivalence  models.  The  effect  of  choosing  the  most  appropriatte 
model  determined  in  Table  5.8  on  the  hypothesis  test  was  also  investigated. 
Table  5.8  The  number  of  Null  Hypothesis  of  Bi  oinequi  valence  which  were  rejected,  split 
by  sparse  sample  scheme,  compartmental  model  and  bioequivalence  model 
2  Compartment  1/2  model  Total 
F/Vj  CmwCE  F/Vj  CmaXE  F/Vj  CmaXE 
ORD  0  ORD  0  ORD  0  ORD  0  n/40  n/40 
InRD  InRD  InRD  InR 
FR  9  10  02  9  10  02  38  4 
NM  6  10  02  6  10  07  32  9 
SR  69  03  69  13  30  6 
Total  for  all  21  29  07  21  29  1  12 
I 
sparse  datasets 
1/2  model  Relative  difference  when  using  the  most  appropriate  model,  as  determined  in 
Table  5.7 
Effect  of  sampling  scheme 
FE 
When  a  two  compartment  model  was  used  to  estimate 
theOInRDin  -and  CmaX  the 
V, 
number  of  Null  Hypotheses  which  were  re  ected  was  similar  across  the  three  sampling  i 
schemes.  However,  the  total  number  of  times  the  Null  Hypothesis  of  bi  oinequi  valence  in 
F 
-was  rejected  was  greatest  for  the  FR  sampling  scheme.  Similarly,  the  number  of  times 
V, 
the  Null  Hypothesis  of  bioinequivalence  in  CmaXEwas  rejected  was  also  smallest  when  the 
FR  sampling  scheme  was  used. 
133 Effect  of  bioequivalence  model 
More  Null  Hypotheses  of  bioinequivalence  in 
F 
were  rejected  when  the  multiplicative  V, 
model  was  used.  In  contrast,  more  null  hypotheses  of  bioinequivalence  in  CmaXEwere  not 
rejected  when  the  additive  bioequivalence  model  was  used. 
Effect  of  choosing  best  fit  model  rather  than  the  two  compartment  model 
Using  the  best  fit  model  did  not  affect  the  number  of  Null  Hypothesis  of  bloinequi  valence 
in  F/VI  which  were  rejected.  However,  the  number  of  times the  Null  Hypothesis  of 
bioinequivalence  in  CmaXEwas  rejected  increased  from  0  to  1  for  the  additive 
bioequivalence  model  and  from  7  to  12  for  the  multiplicative  bioequivalence  model. 
134 5.6  Discussion 
The  results  show  that  a  population  compartmental  approach  to  bioequivalence  can  provide 
point  and  C1  estimates  for  the  relative  difference  in  absorption  rate  and  In  the  extent  of 
nlý 
absorption,  similar  to  those  estimated  using  the  standard  noncompartmental  approach.  The 
population  approach  may  therefore  have  application  in  bioequivalence  testing. 
5.6.1  Data  set  and  noncom  partmental  bioequivalence  assessment 
Both  the  additive  and  multiplicative  bioequivalence  models  determined  that  the 
formulations  were  bioequivalent  in  AUCO-.  and  bioinequivalent  in  Cmax.  The  affect  of 
the  bioequivalence  model  on  the  point  and  CI  estimates  was  investigated.  The  90%  CI  for 
the  relative  difference  in  Cmax  was  narrower  using  the  multiplicative  bioequivalence 
model.  Conversely,  since  In-transformation  did  not  normalise  the  distribution  of  AUCO-., 
the  point  and  90%  CI  estimates  for  the  relative  difference  in  AUQ)-.  were  not  affected  by 
using  the  multiplicative  bioequivalence  model.  The  wider  acceptance  interval  (-20%  to 
+25%)  used  with  the  multiplicative  bioequivalence  model  provided  a  greater  chance  of 
concluding  bioequivalence  (Chow  &  Liu,  1994).  The  point  estimate 
forOlnRDin  Cmax 
E 
was  less  than  the  upper  linut  of  bioequivalence  due  to  the  wider  acceptance  intervals  and 
the  increased  homogeneity  of  the  variance  upon  In-transformation.  The  similarity  of  the 
point  and  90%  CI,  across  the  two  studies,  was  expected,  given  that  2.5  mg  tablets  were 
used  in  both  studies.  The  90%  Cl  for  theORDin  Cmax  was  wider  in  2.5mg  study,  but  this 
was  reduced  on  using  the  multiplicative  model. 
The  single  concentration  measurements  used  for  Cmax  are  generally  considered  to  be  more 
variable  than  the  integrated  AUCO  .,  so  wider  acceptance  lirrUts  for  Cmax  have  been 
advocated  and  -30%  to  +  43  %  have  previously  been  accepted  by  the  European  regulators 
(Steinijans  et  al.,  1992).  However,  Cmax  often  relates  to  adverse  events,  so  the  acceptance 
limits  should  probably  be  considered  on  a  case  by  case  basis,  with  variability  and  PK  /PD 
135 relationship  being  taken  into  account  (Benet  &  Goyan,  1995).  In  this  analysis  the  ±  20% 
acceptance  intervals  were  used  for  Cmax  to  impose  the  strictest  criteria  and  therefore  the 
opportunity  of  showing  a  difference  between  the  compartmental  and  noncompartmental 
assessments  of  bloequivalence. 
5.6.2  Compartmental  assessment  of  bioequivalence  using  the  full  clataset 
The  isolated  bioinequivalence  in  Cmax  coupled  with  the  need  for  a  bi-exponential  equation 
to  describe  the  drug  distribution,  represented  a  problem  which  was  more  complex  than  that 
previously  investigated  using  a  compartmental  approach. 
While  a  two  compartment  model  was  shown  to  be  more  appropriate  than  a  one 
compartment  model,  the  optimal  model  to  describe  the  absorption  was  not  as  clearly 
determined.  The  FOCE  method  showed  that  there  was  little  difference  between  the 
objective  functions  for  the  first  and  zero  order  absorption  models.  However,  the  rounding 
errors  with  the  zero  order  model  resulted  in  the  failure  to  converge,  so  the  first  order 
absorption  model  was  used  to  ensure  that  CI  for  the  relative  difference  could  be  calculated. 
The  small  absorption  lag  time  of  0.37  hr  was  less  than  the  first  sampled  time  point  (0.5  hr  ) 
and  not  significantly  different  from  zero.  More  intensive  sampling  to  increase  the 
precision  in  this  estimate  would  probably  not  be  practical.  It  is  possible  that  the  structure 
of  the  absorption  model  may  differ  between  subjects.  However,  the  lack  of  bias  in  the 
weighted  residual  versus  time  plots  would  indicate  that  the  single  first  order  rate  model  was 
the  most  appropriate  model  for  the  average  subject. 
The  bias  in  the  weighted  residual  versus  time  plot  using  the  FO  method  was  removed  when 
the  fit  was  repeated  using  the  FOCE  method.  Therefore  the  advantage  of  the  FOCE  over 
the  FO  method  was  again  demonstrated. 
136 Mis-specifying  the  model,  by  using  a  one  compartment  model,  resulted  in  under-estimation 
of  Cmax,  so  it  is  not  surprising  that  the  point  estimates  for  the  relative  differences,  were 
found  to  be  lower  than  those  estimated  using  the  two  compartment  model. 
The  model  based  approach  provided  estimates  of  the  relative  difference  in  the  rate  of 
absorption  (Ka).  Previous  investigation  of  bioequivalence  data  using  compartmental 
modelling  has  centred  on  making  these  comparisons  (Graves  &  Chang,  1989;  Piotrovskij  et 
al.,  1995).  However,  while  identifying  a  difference  in  the  rate  of  absorption  can  be  useful 
for  comparing  the  release  profiles  the  clincal  relevance  of  any  difference  is  difficult  to 
assess.  On  the  other  hand,  due  to  its  correlation  with  the  extent  of  absorption,  Cmax  is  not 
a  good  estimate  of  rate  of  absorption,  but  it  has  greater  clinical  relevance. 
In  this  analysis,  the  work  by  Kaniwa  et.  al.  (1990)  has  been  extended  to  include  the 
estimation  of  a  more  appropriate  symmetrical  confidence  interval  for  the  relative  difference 
in  Cmax.  These  were  found  to  be  very  similar  to  those  estimated  using  the 
noncompartmental  method.  The  concentration  at  the  time  when  the  total  amount  absorbed 
per  unit  volume  reaches  a  maximum  (CAmax)  was  used  as  an  approximation  for  Cmax. 
For  this  dataset,  the  point  estimates  for  the  relative  difference  in  CAmax  and  Cmax  were 
very  similar.  However,  this  approximation  was  shown  to  be  highly  dependent  on  the 
assumptions  of  Ka  >  (x  >>  P.  In  particular,  P  had  to  be  small  so  that  the  amount  eliminated 
up  to  Tpk  was  negligible.  In  this  case  the  assumption  was  valid  as  the  terminal  half-life 
was  17  hours  in  comparison  to  the  initial  distribution  and  absorption  half-lifes  of  2  and  0.5 
hours,  respectively.  The  potential  bias  in  the  point  estimate  for  relative  difference  was 
shown  to  increase  dramatically  as  the  half-lifes  approach  one  another.  On  fixing  all  other 
parameters,  a  bias  of  20%  and  50%  was  demonstrated  when  TI/20was  set  to  7  hours  and 
3.5  hours,  respectively. 
137 5.6.3  Bioequivalence  assessment  of  randomly  reduced  datasets  using  a 
compartmental  approach 
The  application  of  the  population  compartmental  approach  to  bioequivalence  testing  was 
further  investigated  with  the  data  randomly  reduced  by  80%.  The  robustness  of  the 
estimates  under  this  reduction  was  investigated  by  repeating  the  reducti  I  ion  ten  times  for 
each  of  three  sampling  schemes.  The  bioequivalence  in  AUCO-oo  and  bioinequivalence  in 
Cmax  was  shown  to  be  relatively  robust  to  the  sampling  designs. 
The  noncompartmental  and  compartmental  point  and  CI  estimates  of  the  relative 
difference  in  both  rate  and  extent  of  absorption  were  similar  using  the  multiplicative 
bioequivalence  models.  In  comparison,  the  additiveORDpoint  and  CI  estimates  were 
inflated.  The  multiplicative  model,  may  suggest  that  the  modelling  approach  is  more 
dependent  on  the  In-normality  assumption  when  the  data  is  reduced,  however,  this  can  only 
be  confirmed  by  further  investigation. 
The  increase  in  the  number  of  Null  Hypotheses  of  bioinequi  valence  in  CAmax  which  were 
rejected  when  the  multiplicative  model  was  implemented,  may  be  due  to  the  wider 
acceptance  limits  and  greater  homogeneity  in  the  variance  estimate. 
There  was  little  difference  between  the  sampling  schemes  in  terms  of  the  average  point 
estimates  for  the  relative  difference.  However,  more  datasets  provided  by  the  completely 
random  sample  scheme  (FR)  were  appropriately  described  by  the  two  compartment  model. 
In  addition,  bioequivalence  in  extent  of  absorption  and  bioinequivalence  in  rate  of 
absorption  was  more  often  demonstrated  with  the  FR  sampling  scheme. 
The  most  appropriate  model  for  each  of  the  datasets  resulted  in  the  Null  Hypothesis  of 
bi  oinequi  valence  in  CAmax  being  rejected  on  more  occasions  than  when  the  two 
compartment  model  was  used.  Based  on  this  result,  it  would  appear  that  prior  knowledge 
of  the  distribution  model  is  required,  and  should  be  used  even  when  the  sparse  data  seem  to 
be  appropriately  described  by  a  simpler  model. 
138 5.6.4  Application  of  population  approach  to  bioequivalence  testing 
Standard  bioequivalence  data 
While  standard  2x2  cross-over  studies,  may  not  benefit  from  using  a  model  dependent 
population  approach,  there  may  be  some  circumstances  where  modelling  the  data  may 
offer  additional  information.  Meta-analysis  may  be  performed  to  investigate  potential 
reasons  for  differences  in  Cmax,  such  as  dose  dumping  (Graves  &  Chang,  1989). 
Population  pharmacokinetic  bioequivalence  investigation 
The  design  of  bioequivalence  studies  to  utilise  the  population  approach  is  more 
controversial.  In  particular,  the  transition  from  constrained  experimental  data  to  the 
"observational  type"  data  used  in  population  analysis  may  be  too  radical  for  the  regulatory 
authorities  and  the  pharmaceutical  industry.  However,  a  population  pharmacokinetic 
approach  may  have  application  to  situations  where  the  standard  2x2  cross-over  study  is  not 
appropriate. 
Complex  designs 
The  2x2  cross-over  design  is  most  often  considered  as  it  removes  interindividual 
variability  from  the  comparison.  However,  when  the  intnnsic  intrasubject  variability  is 
large,  the  power  of  the  analysis  is  greatly  decreased  (Ekbomn  &  Melander,  1989).  Since 
intrinsic  intraindividual  variability  cannot  be  calculated  from  2x2  cross-over  studies, 
higher-order  cross-over  designs  are  required  to  estimate  this  variability  (Kershner  & 
Federer,  1981;  Laska  &  Meisner,  1985;  Jones  &  Kenward,  1989).  If  more  than  two 
formulations  are  to  be  compared,  then  the  number  of  study  days  in  each  sequence  can 
become  very  large.  fEgher  order  cross-overs  can  be  time  consuming  and  costly.  In 
particular,  they  may  require  an  unethical  amount  of  plasma  sampling  and  have  an  increased 
tendency  for  study  dropouts  (Westlake,  1973).  By  removing  the  need  for  full  plasma 
concentration  time  profiles,  the  approach  may  make  some  of  the  higher  cross-over  designs 
easier  to  implement. 
139 Patients  vs  Volunteers 
Where  bioequivalence  testing  is  required  for  drugs  which  can  only  be  ethically  tested  in 
patients,  such  as  cytotoxics,  high  dose  opiates,  tarnoxifen  and  flutamide  etc.,  sparse 
sampling  would  allow  the  test  to  be  conducted  during  the  course  of  routine  treatment. 
Application  of  the  population  approach  may  also  allow  testing  of  the  assumption  that 
pharmacokinetic  equivalence  is  a  substitute  for  therapeutic  equivalence 
(Benet  &  Goyan,  1995;  British  Pharmaceutical  Conference,  1995;  Levy,  1995;  Marzo, 
1995).  However,  very  few  cases  of  clinical  inequivalence  have  been  identified.  In  one 
example,  the  concentration  of  cyclosporin  after  administration  of  its  n-ncro-emulsion 
formulation  (Neoral)  is  reduced  in  liver  transplant  patients,  the  bile  required  for  absorption 
is  reduced  as  a  result  of  choleostasis  (Friman  &  Backman,  1996).  Nevertheless,  the  limited 
number  of  identified  clinical  inequivalences  may  be  due  to  the  lack  of  prospective 
pharmacokinetic  studies  in  this  area.  Even  when  a  measurable  and  comparable  response 
can  be  recorded,  the  large  number  of  formulations  available  makes  adhoc  detection  of 
defective  formulations  extremely  difficult. 
The  population  approach  could  be  used  to  test  for  bioequivalence  differences  in 
formulations  which  are  thought  to  show  clinical  inequivalence. 
With  the  potential  advent  of  new  guidelines  which  separate  population  and  individual 
bioequivalence,  the  importance  of  characterising  the  interind1vIdual  and  jntraindividual 
variabilities  has  become  more  important  (FDA,  1997).  As  suggested  by  Sheiner  (1992), 
the  application  of  the  population  pharmacokinetic  approach  in  this  area  requires  further 
investigation. 
140 5.7  Conclusions 
In  this  chapter,  a  population  compartmental  approach  to  standard  "full  dataset" 
bioequivalence  studies  has  been  implemented.  The  most  appropriate  two  compartment 
model  provided  point  and  CI  estimates  for  the 
ORDandObaRAin 
the  "rate"  and  "extent"  of 
absorption,  which  were  almost  identical  to  the  noncompartmental  estimates.  The  FOCE 
method  should  be  utilised  in  preference  to  the  FO  approach,  since  it  improved  the  model  fit 
and  provided  theORDandOInRApoint  and  Cl  estimates  which  were  most  similar  to  the 
noncompartmental  estimates. 
Symmetrical  confidence  intervals  were  successfully  estimated  by  parameterising  for  Cmax 
within  the  compartment  model.  The  compartmental  bioequivalence  models  were  extended 
to  allow  the  present  requirements  for  In-transformation  of  parameters  to  be  met.  The 
application  of  the  population  approach  to  bioequivalence  testing  was  robust  even  when  the 
data  was  reduced  by  80%.  A  complete  randomised  (FR)  sample  scheme  performed  best, 
but  further  investigation  is  required. 
The  application  of  the  population  approach  may  be  useful  in  helping  to  reduce  the  amount 
of  plasma  sampling  when  complex  designs  are  required.  Furthermore,  when  patients  have 
to  be  used  for  bioequivalence  testing,  the  population  approach  may  allow  this  to  be 
implemented  as  part  of  routine  clinical  practice. 
5.8  Future  work 
Confidence  intervals 
Exact  95  %  Cls  for  the  hypothesis  test  have  previously  been  based  on  NONMEM's 
maximum  likelihood  estimate  (Combrink  et  al.,  1997).  The  shift  in  parameter  estimate 
which  causes  an  objective  function  change  of  +3.68  corresponds  to  the  95%  CI  limit.  A 
full  simulation  or  bootstrapping  technique  has  also  been  used  to  estimate  the  CI  for  the 
141 relative  difference  in  F/Vj  and  Cmax  (Pentikis  et  al.,  1996).  Further  work  using  these 
approaches  to  calculate  the  confidence  intervals  is  required. 
Sample  Size 
A  sample  size  of  20%  of  the  original  data  was  used  in  this  study  to  represent  the  4  to  5 
samples  per  patient  (at  least  two  per  formulation  per  patient  in  the  majority  of  patients), 
and  is  consistent  with  that  used  by  Kaniwa  at  al.  (1990).  It  was  proposed  here  as  an 
arbitrary  defined  minimum  that  a  prospective  population  bioequivalence  investigation 
would  require.  Large  simulation  studies  are  required  to  explore  the  pharmacokinetic, 
variability  and  sampling  issues  identified  in  this  analysis.  The  different  randomisations 
represent  potential  study  designs  for  the  collection  of  sparse  bioequivalence  data,  so  the 
requirement  for  further  work  on  optimal  designs  for  a  sparse  data  approach  to 
bioequivalence  testing  is  also  highlighted. 
142 CHAPTER  6 
THE  DOSE  RESPONSE  RELATIONSHIP  FOR 
THE  HMG  COA  REDUCTASE  INHIBITOR 
SIMVASTATIN 
143 In  this  chapter,  mixed  effect  modelling  is  utilised  in  the  assessment  of  the  dose  response 
relationship  for  the  HMG-CoA  reductase  inhibitor  simvastatin.  The  change  in  total 
cholesterol  and  each  of  its  various  subfractions  is  investigated  using  a  set  of  hierarchical 
models.  A  covariate  analysis  is  undertaken  to  determine  which  factors  most  influence  the 
lipid  response.  The  consequence  of  the  apparent  inappropriateness  of  the  current 
recommended  dosage  regimen  is  discussed  and  alternative  dosing  strategies  are  compared 
through  simulation. 
6.1  Introduction 
6.1.1  Dose  ranging  studies 
The  primary  aim  of  phase  II  studies  is  to  confirm  the  efficacy  and  tolerability  of  a  new  drug 
in  the  larger  patient  population  and  provide  the  PK/PD  information  for  development  of  a 
dosing  regimen  for  the  Phase  HI  programme.  Three  basic  study  designs  which  are 
generally  utilised  to  provide  this  infonnation  are  discussed  below. 
Dose  escalation  design 
This  design  has  been  considered  to  most  closely  resemble  clinical  practice  since  the  dose  is 
increased  until  a  desired  response  is  obtained.  However,  it  has  been  associated  with  an 
overestimation  of  the  minimum  dose  required  to  produce  this  response  (Temple,  1982; 
Freston,  1986)  and  has  been  linked  to  the  introduction  of  atenolol,  captopril  (Temple, 
1982;  Reid  &  Meredith,  1990)  chlorothaliclone  (Tweeddale  et  al.,  1977;  Materson  et  al., 
1978)  and  chlorthiazide  (Berglund  &  Andersson,  1976)  at  doses  which  were  ultimately 
found  to  be  higher  than  those  required  to  treat  the  majority  of  patients.  As  suggested  by 
Sarnbol  et  al.,  (1991),  the  expectation  of  unrealistic  therapeutic  responses  may  have 
exacerbated  the  underlying  design  problem.  Sheiner  et  al.,  (1989,1991)  have  suggested 
that  more  appropriate  interpretation  of  the  data  may  have  prevented  this  overestimation. 
144 They  highlighted,  that  since  sensitive  subjects  achieve  an  acceptable  response  at  lower 
doses,  the  mean  response  at  the  higher  doses  only  reflects  the  response  for  the  insensitive 
subjects.  They  proposed  that  the  inherent  bias  in  the  escalation  design  could  be  largely 
avoided  by  utilising  a  mixed  effects  modelling  approach.  While  this  approach  does  not 
fully  account  for  the  observations  missing  from  the  sensitive  patients  at  higher  doses,  they 
suggested  that  maintaining  these  subjects  on  their  final  dose  throughout  study  period  would 
further  help  to  reduce  the  bias  in  estimation  of  the  "typical"  dose  response  relationship. 
Unfortunately,  the  sequential  nature  of  the  design  makes  it  prone  to  bias  when  there  are 
carry-over  effects  or  time  dependent  changes  in  the  disease  state  (Girard  et  al.,  1995). 
Parallel  group  design 
In  this  case,  subjects  are  randomised  to  receive  either  placebo  or  one  of  several  selected 
doses.  The  advantage  of  this  design  is  that  it  only  lasts  for  one  or  two  (if  the  study  utilises 
an  additional  placebo  run  in  phase)  treatment  periods.  Therefore,  the  study  is  easy  to 
manage,  and  patients  are  not  lost  on  follow-up.  While  it  was  proposed  that  this  design 
avoided  the  bias  inherent  in  the  escalation  studies  (Temple,  1982),  Sheiner  et  al.  (1989, 
1991)  and  Sambol  et  al.  (1991)  disputed  its  appropriateness  for  dose  ranging  studies  in 
general.  Interpolation  between  the  pre-selected  doses  may  be  prone  to  bias  since  the  dose 
response  relationship  is  only  based  on  one  dose  response  measurement  per  subject.  Thus, 
the  selection  of  the  minimum  effective  starting  dose  for  future  studies  is  most  often  taken 
to  be  the  lowest  effective  dose  in  comparison  to  placebo  and  therefore  pre-selected  in  the 
study  design.  The  single  administration  also  prevents  the  estimation  of  intraindividual 
variability,  so  there  is  limited  infO'Mat'on  on  which  to  build  a  model  for  the 
individualisation  of  dose  after  observation  of  initial  response. 
Cross-over  design 
This  design  although  potentially  more  complicated  and  problematic  from  an  ethical  stand 
point  has  been  shown  to  be  very  robust  in  the  estimation  of  dose  response  relationships 
145 (Girard  et  al.,  1995).  In  this  design  every  subject  receives  every  dose,  so  the  ratio  of 
sensitive  to  insensitive  patients  is  the  same  at  each  dose  level.  Furthennore,  the  study 
design  allows  information  to  be  gained  by  utilising  both  analysis  of  variance  (ANOVA) 
and  population  dose  response  modelling.  This  chapter  utillses  both  approaches  in  the 
establishment  of  a  dose  response  relationship  for  simvastatin. 
6.1.2  Hypercholesterolaemia:  Clinical  consequence  and  treatment 
It  is  well  established  that  hypercholesterolaernia  is  a  major  risk  factor  for  the  development 
and  progression  of  atherosclerotic  cardiovascular  disease  and  it  is  also  generally  accepted 
that  lipid  lowering  strategies  are  indicated  for  its  prevention.  In  most  instances,  dietary 
intervention  remains  the  recommended  first  step  towards  cholesterol  reduction.  When  drug 
treatment  is  indicated,  the  3  -hydroxy-3  -methyl  glutaryl  -Coenzyme  A  (HMGCoA)  reductase 
inhibitors,  including  simvastatin,  have  become  established  as  effective  and  well  tolerated 
treatments.  The  main  goal  in  the  treatment  of  hypercholesterolaemia  is  to  reduce  the  risk  of 
the  premature  development  (primary  intervention)  or  the  recurrence  (secondary  prevention) 
of  vascular  events,  and  the  HN4G  CoA  inhibitors  have  now  been  shown  to  be  beneficial  in 
reducing  the  incidence  of  both  (MAAS  Investigators,  1994;  Pederson,  1994;  Shepherd  et 
al.,  1995). 
Common  or  "polygenic"  hypercholesterolaemia  arises  from  a  combination  of  genetic, 
dietary  and  environmental  factors,  and  is  usually  mild  to  moderate  in  degree.  The  more 
serious  genetic  or  "familial"  hypercholesterolaemia  affects  about  I  in  500  people  and  is 
associated  with  a  greater  CHD  risk.  The  treatment  strategy  is  similar  for  both  forms,  with  a 
more  aggressive  approach  being  adopted  when  a  genetic  predisposition  is  known.  Patients 
with  a  cholesterol  greater  than  5.2  mmol.  1-1  are  initiated  on  a  lipid  lowering  diet  and, 
depending  on  the  response  and  presence  of  other  risk  factors,  drug  treatment  may  be 
considered.  At  present  the  accepted  target  range  in  control  of  hypercholesterolaernia  is  a 
146 total  cholesterol  <  5.6  mmol.  l-'  where  it  is  an  isolated  risk  factor  and  <5.2  mmol-1-1  where 
there  are  multiple  nsk  factors  present. 
6.1.3  Lipoproteins  and  cholesterol:  Classification 
Plasma  lipoproteins  are  water-soluble  complexes  composed  of  lipids  (triglycerides, 
cholesterol  and  phospholipids)  and  one  or  more  specific  proteins,  called  apolipoproteins. 
They  are  broadly  classified  as  high  density  lipoproteins  (HDL),  low  density  lipoproteins 
(LDL),  very  low  density  lipoproteins  (VLDL)  andchylornicrons.  Each  has  a  particular  role 
in  the  transportation  and  utilisation  of  lipids. 
The  chylomicrons,  pass  dietary  cholesteryl  esters  from  the  gastro-intestinal  tract  to  the 
liver,  where  the  cholesterol  is  stored  or  oxidised  to  form  bile  acids.  Cholesterol  can  also  be 
synthesised  from  acetyl  CoA  in  the  liver.  The  rate  determining  step  for  this  process  is  the 
conversion  of  HMG-CoA  to  mevalonate  and  this  is  controlled  by  the  HMG-CoA  reductase 
enzyme.  Sixty  to  seventy  percent  of  the  total  plasma  cholesterol  is  contained  within 
circulating  LDL  particles.  Cells  requiring  cholesterol  synthesise  receptors  and  take  up  LDL 
by  receptor-mediated  endocytosis.  Free  cholesterol  from  dead  cell  membranes  is  adsorbed 
onto  HDL  particles  and  esterified  with  long  chain  fatty  acids.  The  resulting  cholesteryl 
esters  are  subsequently  transferred  to  LDL  or  VLDL  (when  triglycerides  are  present) 
particles  and  redistributed. 
6.1.4  Simvastatin 
Simvastatin  is  a  semisynthetic  prodrug,  which  is  a  structural  analogue  of  lovastatin,  a 
fermentation  product  of  Aspergillus  terrus  (Hoffmann  et  al.,  1986). 
Mechanism  of  action 
Several  of  its  metabolites,  most  notably  simvastatin  acid  are  active  and  capable  of 
competitively  and  reversibly  inhibiting  HMG  CoA  reductase,  (Mauro,  1993).  Inhibition  of 
hepatic  cholesterol  biosynthesis,  gives  rise  to  an  increased  expression  of  LDL  receptors. 
147 These  receptors  bind  LDL  particles  and  remove  them  from  circulation  thus  lowering  total 
circulating  cholesterol  (Plosker  &  McTavish,  1995). 
Pharmacokinetics 
Simvastatin  is  well  absorbed  (  approximately  60-80%)  but  undergoes  extensive  first  pass 
metabolism.  The  bioavailability  of  sirnvastatin  acid  has  been  shown  to  be  less  than  5% 
(Todd  &  Goa,  1990;  Mauro,  1993).  Several  studies  in  healthy  volunteers  (Todd  &  Goa, 
1990;  Pentikainen  et  al.,  1992;  Mauro,  1993)  and  in  patients  with  hypercholesterolaemia 
(Cheng  et  al.,  1992)  have  demonstrated  that  the  peak  concentrations  of  the  active 
metabolites  occur  after  I  to  3  hours.  Animal  enzyme  inhibition  and  radiolabelled  drug 
studies  have  demonstrated  that  simvastatin  and  its  metabolites  concentrate  in  the  liver 
(Todd  &  Goa,  1990;  Mauro,  1993).  Correspondingly,  the  circulating  levels  of  simvastatin 
are  lower  than  that  for  other  less  lipophilic  statins  (Pentikainen  et  al.,  1992).  At  least  five 
metabolites  including  the  simvastatin  acid  have  been  identified  by  animal  microsomal 
studies  (Plosker  &  McTavish,  1995).  The  hepatic  extraction  ratio  for  slinvastatin  is  large 
(93%)  and  the  majority  of  the  metabolites  are  found  in  the  bile  (Todd  &  Goa,  1990;  Mauro, 
1993).  The  total  body  clearance  for  sirnvastatin  is  approximately  31.8L.  hr-1  and  the 
elimination  half-life  for  simvastatin  acid  is  around  1.9  hours.  Less  than  10%  of  the  peak 
EIMG  CoA  reductase  activity  remains  after  12  hours  (Mauro,  1993). 
Similar  effects  of  gender  and  age  on  the  pharmacokinetics  of  the  HMG  CoA  reductase 
inhibitors  were  noted  following  a  single  dose  of  atorvastatin  (Gibson  et  al.,  1996)  and 
multiple  doses  of  sirnvastatin  and  lovastatin  (Cheng  et  al.,  1992).  After  17  days  of 
slmvastatin  (40mg  per  day),  the  mean  plasma  concentration  was  40-60%  higher  in  elderly 
patients  than  young  patients  and  20%-50%  higher  in  females  than  males  (Walker,  1989). 
Tolerability  and  adverse  effects 
Adverse  events  with  simvastatin  are  usually  mild  and  transient  with  treatment  related 
discontinuation  rates  being  between  2%  and  6%  (Todd  &  Goa,  1990;  Pederson,  1994; 
148 Pedersen  &  Tobert,  1996).  Creatinine  kinases  are  raised  in  about  5%  of  patients,  but  the 
incidence  of  myopathy  and  rhabdomyolysis  is  rare  (Thompson,  1993;  Plosker  &  McTavish, 
1995). 
Clinical  efficacy 
Decreases  of  20  to  40%  in  total  serum  cholesterol,  35  to  45%  in  LDL  cholesterol,  20  to 
40%in  LDL  :  HDL  cholesterol  and  10  to  20%  in  total  triglycerides,  as  well  as  increases  of 
5  to  15%  in  HDL  cholesterol  have  been  shown  (Plosker  &  McTavish,  1995).  The  dose 
escalation  studies  which  have  been  undertaken  were  not  placebo  controlled  i.  e.  (Molgaard 
et  al.,  1988;  Leclercq  &  Harvengt,  1989;  Sirtori  et  al.,  1989;  French  et  al.,  1990).  The 
placebo  controlled  dose  ranging  trials  are  summarised  in  Table  6.1.  Although  the  lipid 
lowering  efficacy  of  sirnvastatin  is  well  recognised,  it  appears  that  the  current  dose  range 
was  based  mainly  on  parallel  dose  studies.  Furthermore,  although  dose  ranging  studies 
have  been  performed,  there  do  not  appear  to  be  any  published  account  of  attempts  to  model 
the  dose  response  relationship. 
Factors  important  in  the  prediction  of  clinical  response 
It  has  been  shown  that  the  pre-treatment  level  may  be  correlated  with  the  percentage 
reduction  in  both  total  cholesterol  and  LDL  cholesterol  (N4olgaard  et  al,  1988;  Nfiserez  et 
al.,  1994).  However,  other  studies  have  suggested  that  the  percentage  change  is 
independent  of  baseline  level  (Farish  et  al.,  1990;  Todd  &  Goa,  1990;  Frohlich  et  al., 
1993). 
149 Table  6.1  Placebo  controlled  dose  ranging  studies  for  sirnvastatin 
Reference  Patient  Duration  Study  No  Dosage  Total-C  LDL-C  HDL-C  Tfi-  LDL  Type  (weeks)  design  Patients  Regimen  (%)A  (%)A  (%)A  gylcefides  /HDL-C 
(mg)  *  (%)A  (%)A 
Mol  Familia  4  Parallel  8  Placebo 
-5  -6  -1  +2  -5 
et  al.  Group  8  2.5  -16  -18  +2  -17  -19  (1986)  4  5  -22  -27  -2  +5  -8  8  10  -25  -28  +10  -26  -34  4  20  -25  -30  +11  -14  -36  7  40  -32  -37  +21  -34  -47  4  80  -36  -42  +8  -11  -47  Sim  ons  Familia 
1 
4  Parallel  5  Placebo  +5  +8  0  -20  +8 
et  al.  &  poly-  group  15  2.5-10  -20  -20  0  -24  -20  (1987)  gemc  10  20-80  -30  -37  +8  -44  -42 
Kuhn  Elderly  4  Parallel  4  Placebo  +1  +2  +11  -12  -9 
et  al.  group  5  2.5  -10  -19  16  +16  -23  (1989)  4  5  -14  -20  -2  +8  -18 
6  10  -21  -30  +9  -15  -35 
4  20  -35  -49  +4  -14  -51 
Nakaya  Not  4  Parallel  5  Placebo  +3  +2  +12  -13 
&  Goto  defined  group  5  1.25  -8  -8  +4  -13 
(1989)  5  2.5  -13  -20  +18  -25 
5  5  -20  -27  +4  -14 
5  10  -24  -33  +4  -16 
5  20  -26  -40  +12  -10 
Goto  Not  12  Parallel  72  placebo  -3  -6  -2  +9 
et  al.  defined  group  72  2.5  -15  -24  +6  -9 
(1989)  72  5  -21  -30  +6  -14 
Walker  Elderly  4  Parallel  31  placebo  -3  -3 
et  al.  group  32  2.5  -17  -23 
(1990)  32  5  -19  -27 
32  10  -23  -31  +11  -15 
32  20  -28  -37  +7  -20 
Keech  Poly-  8  Parallel  207  placebo 
et  al.  genic  Group  208  20  -27  -38  +5  -17 
(1994)  206  40  -29  -41  +6  -19 
Tuomilehto  Not  8  Parallel  28  placebo  -3  -5 
(1994)  defined  Group  28  2.5  -16  -21 
et  al.  28  5  -20  -25 
27  10  -22  -28 
26  20  -25  -33 
29  40  -30  -41 
*  Daily  dose  A  %change  from  baseline 
While  age  has  been  shown  to  affect  the  phannacokinetics  of  simvastatin  (6.1.4),  the 
influence  of  age  on  response  could  not  be  shown  (Antonicelli  et  al.,  1990;  Plosker  & 
McTavish,  1995).  In  one  prospective  cross-over  study  an  interaction  between  gender  and 
response  was  demonstrated  (Clifton  et  al.,  1994).  Similarly,  in  a  large  study  of  2083 
patients,  gender  was  identified  as  a  significant  predictor  of  the  reduction  in  LDL 
cholesterol  (Miserez  et  al.,  1994).  Therefore,  the  variability  in  response  to  sinivastatin  may 
be  partially  explained  by  patient  characteristics,  and  the  potential  for  dose  adjustment  on 
this  basis  requires  further  investigation. 
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In  this  chapter,  data  from  a  phase  11  dose  ranging  study  was  used  to  establish  the  dose 
response  relationship  for  simvastatin.  The  primary  aims  were  as  follows- 
1)  Use  ANOVA  and  standard  statistical  tests  to  determine  which  doses  were  associated 
with  significant  changes  in  total  cholesterol  and  its  various  subfractions. 
2)  Establish  the  relationships  governing  the  changes  in  cholesterol  and  its  various 
subfractions  by  determining  the  most  appropriate  pharmacodynamic  model  for  each. 
3)  Investigate  for  relationships  between  demographic  covariates  and  the  parameters  of  the 
established  models. 
4)  Compare  the  results  and  extrapolations  from  the  models  with  other  dose  ranging  studies. 
5)  Use  the  models  to  propose  suitable  dosing  strategies  for  future  treatment 
6)  Discuss  the  limitations  of  the  study  design  and  the  potential  for  using  more  intuitive 
designs  for  dose  ranging  studies 
6.3  Study  data 
The  study  was  part  of  a  wider  investigation  into  the  tolerance,  safety  and  efficacy  of 
HMGCoA  inhibitors  in  a  West  of  Scotland  population.  Other  studies  from  the  programme 
investigating  the  management  of  patients  with  the  co-existence  of  hypercholesterolaernia 
and  hypertension  have  previously  been  reported  (Farish  et  al.,  1990;  Macdonald  et  al., 
1990,1991).  The  aim  of  this  particular  study  was  to  investigate  the  lipid  response  to  a 
range  of  sirnvastatin  doses.  All  patients  had  co-existing  hypertension  and  had  previously 
completed  the  initial  12  week  tolerance  and  efficacy  study  (Macdonald  et  al.,  1991).  The 
standard  lipid  lowering  diet,  recommended  by  the  European  Artherosclerosis  Society 
(Study  Group,  1988)  and  blood  pressure  control  were  maintained  throughout  the  study.  In 
a  randomised.  single  blind  Latin  square  crossover  design,  patients  received  either  placebo, 
151 10mg,  20mg  or  40mg  as  a  single  daily  dose  for  12  weeks.  The  treatment  sequences  were  as 
follows. 
Period  time  (weeks) 
0-12  12-24  24-36  36-48 
Group  A  Placebo  10mg  40mg  20mg 
Group  B  10mg  40mg  20mg  Placebo 
Group  C  40mg  20mg  Placebo  10mg 
Group  D  20mg  Placebo  10mg  40mg 
The  demographics  for  the  41  patients  who  completed  the  study  are  shown  in  Table  6.2.  The 
demographics  were  similar  across  the  four  treatment  groups.  The  population  comprised 
30  females  (mean  age  58  years  and  mean  body  weight  70  kg)  and  11  males  (mean  age  56 
years  and  mean  body  weight  82  kg).  All  doses  of  slmvastatin  were  well  tolerated  and  no 
significant  abnormalities  were  detected  on  routine  laboratory  testing. 
6.4  Assay  procedures 
The  total  triglycerides  and  total  cholesterol  were  measured  by  recognised  enzymatic 
methods  (Bucolo  &  David,  1973;  Allan  et  al.,  1974).  The  various  lipoprotein  subfractIons 
were  first  separated  by  preparative  ultracentrifuge  and  precipitation  techniques  (Farish  et 
al.,  1983).  Inter  assay  coefficients  of  variation  were  2.0%  for  the  measurement  of  total 
cholesterol,  2.5%  for  the  total  triglycerides  and  between  2.5  -  9.0%  for  the  measurement  of 
the  total  cholesterol  subfractions.  Total  cholesterol  and  total  triglyceride  concentrations 
were  determined  every  six  weeks,  and  the  concentrations  of  the  lipid  subfractions:  LDL 
cholesterol,  HDL  cholesterol  and  VLDL  cholesterol  were  determined  every  12  weeks. 
152 Table  6.2  Summary  of  patient  demographics 
Group 
Data  A  B  c  D  All  Groups- 
FEMALES 
No 
I 
9  7  7  7  30 
AGE  years 
Mean  57.2  59.1  60.1  55.1  57.9 
SD  6.4  1.9  5.1  8.7  6.3 
MAX  69  62  67  67  69 
MIN  48  56  52  41  41 
Weight  Kg 
Mean  66.5  72.1  65.1  78.2  70.2 
SD  12.1  9.3  9.1  13.5  12.3 
MAX  91.0  85.4  84.4  107.2  107.2 
MIN  52.8  50.8  51.6  60.8  50.8 
MALES 
No  3  3  3  2  11 
AGE  years 
Mean  54.7  55.0  58.3  53.5  55.5 
SD  7.7  5.1  3.8  4.6  5.8 
MAX  60.0  62.0  63.0  58.0  63.0 
MIN  44.0  51.0  54.0  49.0  44.0 
Weight  Kg 
Mean  83.9  86.4  81.1  71.5  81.6 
SD  10.2  13.5  8.6  16.5  13.0 
MAX  99.5  104.4  93.8  90.7  104.4 
MIN  72.0  69.6  72.6  55.0  55.0 
ALL 
AGE  years 
Mean  56.6  57.9  59.6  54.8  57.2 
SD  6.8  3.7  4.8  7.9  6.2 
MAX  69.0  62.0  67.0  67.0  69.0 
MIN  44.0  51.0  52.0  41.0  41.0 
Weight  Kg 
Mean  70.9  76.4  69.9  76.7  73.3 
SD  13.9  12.5  11.6  14.4  13.4 
MAX  99.5  104.4  93.8  107.2  107.2 
MIN 
lmmý 
1  52.8  50.8  51.6 
- 
55.0  50.8 
153 6.5  Methods 
6.5.1  ANOVA  and  statistical  tests 
The  influence  of  dose,  period  and  group  on  each  of  the  lipid  measurements  was  initially 
investigated  using  ANOVA.  Since  there  were  unequal  numbers  in  each  group,  this  was 
accomplished  using  general  linear  modelling  (GLM).  For  the  total  cholesterol  and  total 
triglycerides  measurements,  an  additional  factor  was  included  to  investigate  for  differences 
between  week  6  and  week  12  samples.  When  the  F  ratio  test  demonstrated  that  there  was 
a  significant  difference  (P<0.05),  between  the  levels  of  a  factor,  Tukey's  tests  with  error 
rates  of  0.05,0.01,0.001  (to  adjust  for  multiple  comparisons)  were  used  to  determine 
which  levels  were  significantly  different. 
6.5.2  Population  dose  response  models 
Population  dose  response  relationships  were  determined  using  the  FO  and  FOCE 
estimation  methods  (Chapter  3).  Each  lipid  subfraction  and  subfraction  ratio  was  modelled 
as  a  separate  lipid  response  variable  (LR).  In  each  case,  a  hierarchy  of  models,  similar  to 
those  of  Sambol  and  Sheiner  (1991)  were  fitted  to  determine  the  most  appropriate 
relationship. 
The  placebo  measurements  (PM)  were  modelled  as: 
LRii  = 
(01 
- 
(1  +  17ii»  - 
(1  +  cij)  Eq  6.1 
where  01  is  the  average  PM,  PM.  For  active  drug,  the  response  was  modelled  using  one  of 
the  following  expressions: 
LRij  --:: 
[(01 
' 
(1 
+  77i 
J) 
- 
(02 
* 
(1 
+  17i2 
),  If  (Dose  >  0))]  - 
(I 
+  cij)  Step  model  Eq  6.2 
LRij::  --: 
[(01'(1 
+  77ii))  - 
(02 
+  03*  Dose)  - 
(1 
+  '7i2)  If  (Dose  >  0) 
(1 
+  cij)  Steplinear 
model  Eq  6.3 
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(02 
1 
LRij  I 
)) 
-( 
(I 
-ij 
Emax  model  Eq  6.4  1 
(01 
"( 
03  +  Dose)  *+  1IJ  A.  +E) 
Where  LRij  is  the  lipid  subfraction  response  for  the  ith  individual  at  the  jth  observation,  01 
is  the  typical  patient's  estimated  placebo  measurement,  02  is  Emax,  03  is  D50  and  Ilik  Is  the 
random  interindividual  error.  Interindividual  variability  estimates  were  initially  obtained 
for  both  the  placebo  response  (k=1)  and  the  reduction  component  of  the  model  (k=2).  The 
variance  of  the  intraindividual.  errors  (Fij)  was  also  estimated.  A  proportional  error  model 
was  initially  used  for  all  random  effects.  The  NMTRAN  user  supplied  PRED  subroutines 
used  to  implement  these  models  are  shown  in  Appendix  1.3. 
A  graphical  representation  of  the  three  models  is  shown  in  Figure  6.1.  The  step  model, 
which  describes  an  all  or  nothing  response  (Eq  6.2),  was  compared  to  the  step-linear  model 
which  models  the  step  response  but  has  an  additional  term  to  describe  a  subsequent  change 
in  response  with  increasing  dose  (Eq  6.3).  Therefore,  the  step-linear  model  (full  model) 
has  one  more  parameter  than  the  step-model  (reduced  model).  The  full-reduced  pair  can  be 
tested  using  a  likelihood  ratio  test  (Chapter  3). 
If  a  graded  response  could  be  established,  then  the  more  physiological  Emax  model  was 
fitted.  In  this  case,  structural  parameters  for  Emax  and  D50  were  estimated  (Eq  6.4).  As 
the  step-linear  model  and  the  Emax  model  are  different  models  with  the  same  number  of 
parameters,  they  do  not  form  a  full/reduced  pair.  The  AIC  (Chapter  3)  was  therefore  used 
to  compare  the  step-linear  and  Emax  models.  Since  the  number  of  parameters  is  the  same 
for  each  model  the  AIC  is  simply  equal  to  difference  between  the  objective  functions. 
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6.5.3  Covariate  analysis  and  further  model  development 
Individual  placebo  estimates  were  obtained  (Chapter  3)  and  associations  with  patient 
covariates  were  investigated  graphically.  ForEq  6.3  and  6.4  interindividual  variability  was 
estimated  on  the  whole  "reduction  portion"  of  the  model,  so  individual  parameter  estimates 
Of  02andO3were  not  available.  Instead,  individual  specific  responses  at  each  dose  level 
were  plotted  against  the  patient  covariates  to  investigate  for  possible  relationships. 
Potential  covariates  were  formally  tested  using  the  likelihood  ratio  test  (Chapter  3). 
The  appropriateness  of  the  interindividual  and  intraindividual  variability  models  was  also 
tested.  In  particular,  an  additive  and  additive  plus  proportional  model  for  intraindividual 
variability  was  also  tested.  Since  relationships  between  the  drug  response  and  the 
measurement  on  placebo  were  detected,  covariance  between  the  two  TI's  was  also  tested. 
Lipid  response  in  terms  of  reduction  in  total  cholesterol  or  LDL  cholesterol  is  most  often 
communicated  in  terms  of  a  percent  reduction  from  the  pre-treatment  baseline  level  i.  e. 
156 Table  6.1.  While  these  percentages  can  be  calculated  from  the  model  parameters  of  Eq  6.2 
to  6.4,  the  percentage  reductions  at  each  dose  level  can  themselves  be  modelled.  The 
percentage  reduction  model  equivalent  to  Eq  6.4  is  as  follows 
LRY.  ---:  100% 
01.  Dose  (1 
+  171)  Percentage  reduction  model  Eq  6.5 
- 
02+  Dose 
Where  %LRij  is  the  lipid  subfraction  response  for  the  ith  individual  at  the  jth  observation 
as  a  percent  change  from  the  placebo  measurement.  This  model  reduces  the  number  of 
structural  parameters  by  one,  thus  simplifying  the  model  and  variance  structure.  This 
model  was  also  used  in  the  investigation  of  covariate  relationships.  The  NMTRAN  user 
supplied  PRED  subroutine  used  to  implement  this  models  is  shown  in  Appendix  1.3. 
6.5.4  Predictions  and  simulations 
Predictions  and  simulations  were  undertaken  using  the  parameter  estimates  (structural  and 
variance)  from  the  final  model.  Since  no  pre-treatment  data  was  available  the  placebo 
response  could  not  be  estimated.  To  allow  extrapolation  to  the  wider  population  initial 
(baseline)  and  placebo  measurements  were  considered  to  be  equivalent  i.  e.  the  placebo 
effect  was  assumed  to  be  negligible  in  comparison  to  the  drug  effect. 
6.6  Results 
Forty  one  patients  completed  the  study  and  provided  328  total  cholesterol  and  triglyceride 
concentrations,  and  164  measurements  of  the  other  subfractions. 
6.6.1  Mean  reductions  and  analysis  of  variance  (ANOVA) 
The  mean  absolute  values  and  percent  changes  are  summarised  in  Table  6.3.  The  mean 
(SD)  total  cholesterol  and  total  triglycerides  concentrations  after  12  weeks  at  each  dose 
level  were  very  similar  to  those  after  6  weeks.  The  mean  concentration  of  total  cholesterol 
and  its  constituent  subfractions,  with  the  exception  of  HDL  cholesterol,  decreased  with 
157 increasing  dose.  The  concentration  of  HDL  cholesterol  was  shown  to  increase  with 
increasing  dose.  The  maximum  percentage  changes  from  the  placebo  measurement  (PM) 
for  total,  LDL  and  HDL  cholesterol  were  -31(11.7)  %,  -41(12)%  and  +14(14)% 
respectively.  The  maximum  reductions  in  the  ratios  of  total  to  HDL  cholesterol  and  LDL 
to  HDL  cholesterol  were  -39  and  -47  %,  respectively.  The  maximum  fall  in  ratios  were 
therefore  greater  than  that  for  total  and  LDL  cholesterol  alone. 
The  ANOVA  results  for  total  cholesterol  and  each  of  the  subfractions  are  shown  in  Table 
6.4.  With  the  exception  of  HDL  cholesterol,  a  significant  difference  between  the  dose 
levels  was  detected  for  all  measurement  (P<0.05).  There  was  no  evidence  for  a  period 
effect  with  any  measurements.  The  similarity  between  the  mean  at  6  and  12  weeks  for  the 
total  cholesterol  and  total  triglycerides  measurements  was  confirmed  by  the  lack  of  week 
effect.  The  week  6  and  12  measurements  were  therefore  considered  as  multiple 
observations  for  purposes  of  population  dose  response  modelling.  There  was  evidence  of  a 
group  effect  for  the  total  cholesterol,  total  triglycerides  and  VLDL  cholesterol  responses. 
The  results  of  the  multiple  comparisons  between  the  response  at  each  dose  level  are  shown 
in  Table  6.3  (see  foot  note  for  details).  There  was  a  significant  reduction  from  the  placebo 
concentrations  at  all  dose  levels  for  total,  LDL,  VLDL,  LDL:  HDL  and  total:  HDL 
cholesterol.  In  comparison,  a  significant  reduction  from  placebo  in  total  triglycerides  was 
only  shown  at  the  40mg  dose  level.  A  significant  reduction  between  the  10mg  and  the 
40mg  was  shown  for  total  (wk6  &  wk12),  LDL,  and  LDL:  HDL  cholesterol.  The 
differences  in  concentrations  between  the  20  and  40mg  doses  was  not  significant  for  any 
measurements.  Multiple  comparisons  showed  that  Group  A  was  significantly  different 
(P<0.05)  from  groups  B,  C  and  D  for  the  total  triglycerides  and  that  Group  A  was  also 
significantly  different  (P<0.05)  from  groups  C  and  D  for  VLDL  cholesterol.  Group 
differences  for  total  cholesterol  were  not  found  to  be  statistically  different  upon  multiple 
companson. 
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--4 Table  6.4  ANOVA  for  total  cholesterol  and  its  the  various  subfractions 
Analy  sis  of  Variance  for  Total  Cholesterol  :  Week  6  and  Week  12  Measurements 
Source  DF  Seq  SS  Adi  SS  Adj  MS  F  P 
Dose  3  297.4  298.1  99.4  135.45  0-000 
Group  3  16.8  16.8  5.6  7.64  0.000 
Period  3  1.4  1.4  0.5  0.65  0.5S-1 
Week  1  0.3  0.3  0.3  0.38  0.536 
Error  317  232.5  232.5  0.7 
Total  327  548.5 
Analysis  of  Variance  for  Total  Trip-lycerides:  Week  6  and  Week  12  Measurements 
Source  DF  Seq  SS  Adj  SS  Adj  NIS  F  P 
Dose  3  12.4  12.90  4.30  5.84  0.001 
Group  3  30.2  30.18  10.06  13.67  0.000 
Period  3  2.5  2.55  0.85  1.15  0.327 
Week  1  0.0  0.00  0.00  0.01  0.938 
Error  317  233.3  233.27  0.74 
Total  327  278.4 
Analvsis  of  Variance  for  HDL  cholesterol 
Source  DF  Seq  SS  Adj  SS  AdýMS 
Dose  3  0.63  0.64  0.21 
Group  3  0.21  0.21  0.07 
Period  3  0.02  0.02  0.01 
Error  154  13.87  13.87  0.09 
Total  163  14.73 
Analy  sis  of  Variance  for  LDL  cholesterol 
Source  DF  Seq  SS  Adj  SS  AdLMS 
Dose  3  123.4  122.6  40.9 
Group  3  1.1  1.1  0.4 
Period  3  0.6  0.6  0.2 
Error  154  84.4  84.4  0.5 
Total  163  209.5 
Analysis  of  V4riance  for  VLDL 
Source  DF  SPA  SS  Adj  SS  Adj  MS 
Dose  3  4.1  4.1  1.4 
Group  3  2.9  2.9  1.0 
Period  3  0.3  0.3  0.1 
Error  154  26.1  26.1  0.2 
Total  163  33.3 
F 
2.4 
0.8 
0.1 
F 
74.6 
0.7 
0.4 
F 
8.1 
5.7 
0.6 
p 
0.074 
0.511 
0.974 
p 
0.000 
0.580 
0.771 
p 
0.000 
0.001 
0.618 
160 6.6.2  Population  Dose  Response  Relationships 
The  objective  functions  and  likelihood  ratio  tests  for  the  model  fits  are  shown  in  Table  6.5. 
The  fit  of  the  step-linear  model  was  superior  over  the  step-model  in  all  cases  except  for  the 
total  triglycerides,  where  the  response  was  adequately  described  by  the  simpler  model  (p< 
0.15).  With  HDL  and  VLDL  cholesterol,  the  decrease  in  objective  function  was 
considerably  less  in  comparison  to  that  for  LDL  cholesterol  ,  total  cholesterol  and  the  ratio 
models.  Only  subfractions  showing  a  superior  fit  to  the  step-linear  model  were  considered 
further.  On  fitting  the  Emax  models,  only  total  (Run3)  and  LDL  cholesterol  (Run  6) 
showed  a  greater  decrease  in  objective  function  over  the  steplinear  model.  Individual 
profiles  for  the  total  and  LDL  cholesterol  responses  are  shown  in  Figures  6.2a  and  6.3a. 
The  estimated  population  Emax  response  relationships  for  these  data  with  ±1  SD  of  inter- 
subject  variability  and  ±1  SD  inter-subject  plus  intraindividual  variability  are  shown  in 
Figures  6.2b  and  6.3b.  Estimated  structural  and  variability  parameters  are  shown  with 
corresponding  standard  errors  in  Table  6.6.  Emax  values  for  total  and  LDL  cholesterol 
were  2.7mmol.  1-1  (95%  Cl  2.4  to  3.1mmol.  1-1)  and  2.6mmol.  1-1(95%  Cl  2.2  to  2.9mmol.  1-1) 
with  D50  of  5.  Omg  (95%  CI  3.3  to  6.8mg)  and  6.3mg  (95%  CI  3.5  to  9.  Omg),  respectively. 
There  was  little  change  in  the  variability  to  accompany  the  small  drop  in  objective  function 
between  the  Emax  and  step-linear  models  for  total  and  LDL  cholesterol  reduction.  For  the 
HDL  cholesterol,  the  objective  function  was  increased  slightly  on  fitting  the  Emax  model 
(Table  6.5).  The  population  average  percentage  reduction  for  competing  models  are  also 
shown  in  Table  6.6  and  there  was  little  difference  between  the  model  predictions. 
However,  the  Emax  model  would  be  favoured  for  extrapolation  outside  the  study  dose 
range.  The  estimated  population  Emax  profiles  for  total,  LDL  and  HDL  cholesterol  are 
shown  in  Figure  6.4.  The  tested  dose  range  was  predicted  to  only  cover  20%  (70  to  90%  of 
Emax)  of  the  upper  portion  of  total  and  LDL  cholesterol  response  curves,  and  the  middle 
30%  (40  to  70%)  of  the  HDL  response  curve. 
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9-» 6.6.2  Covariate  analysis 
Figure  6.5  shows  boxplots  of  both  the  modelled  individual  placebo  estimates  and  the 
individual  estimates  of  response  by  gender  for  the  total  cholesterol  Emax  model  (Run  3). 
Similarly,  the  corresponding  plots  for  the  LDL  cholesterol  Emax  model  (Run  6)  are  shown 
in  Figure  6.6.  In  both  cases,  males  had  a  slightly  lower  median  placebo  estimate  and 
slightly  higher  median  response  estimate.  The  differences  were  more  obvious  for  LDL 
cholesterol  Emax  model  (Figure  6.6). 
Relationships  between  individual  estimates  of  response  and  both  the  observed  placebo 
measurements  (PM)  and  body  weight  are  shown  in  Figures  6.7  and  6.8.  Patients  with  a 
high  PM  were  shown  to  have  a  larger  absolute  response  (Figure  6.7  a  and  Figure  6.8  a).  In 
this  case,  the  relationship  for  LDL  cholesterol  Emax  model  (Figure  6.7  a)  was  less  apparent 
than  that  for  total  cholesterol  Emax  model  (Figure  6.8  a).  There  was  also  some  evidence  of 
a  linear  relationship  between  body  weight  and  response  for  both  the  total  and  LDL 
cholesterol  Emax  models  (Figure  6.7b  and  6.8b,  respectively). 
166 Figure  6.5  Covariate  relationships  for  total  cholesterol  model:  a)  Modelled  individual 
placebo  estimates  by  gender  and  b)  Modelled  individual  estimates  of  response  by  gender. 
Horizontal  line  and  boxes  indicate  median  and  interquartile  range  (Ql-Q3),  respectively. 
The  whiskers  extend  to  the  lowest  and  highest  values  that  are  still  inside  the  region  defined 
by  Q1  -  1.5.  (Q3  -  QI)  to  Q3  +  1.5.  (Q3  -  Q1),  showing  the  range  of  the  data.  The  other 
lines  indicate  values  which  lie  outside  this  interval. 
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167 Figure  6.6  Covariate  relationships  for  LDL  cholesterol  model:  a)  Modelled  individual 
placebo  estimates  by  gender  and  b)  Modelled  individual  estimates  of  response  by  gender. 
Horizontal  line  and  boxes  indicate  median  and  interquartile  range  (Ql-Q3),  respectively. 
The  whiskers  extend  to  the  lowest  and  highest  values  that  are  still  inside  the  region  defined 
by  Q1  -  1.5.  (Q3  -  Q1)  to  Q3  +  1.5.  (Q3  -  QI),  showing  the  range  of  the  data.  The  other 
lines  indicate  values  which  lie  outside  this  interval. 
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168 Figure  6.7  Covariate  relationships  for  total  cholesterol  model:  The  modelled  individual 
estimates  of  response  at  40  mg  versus  a)  The  observed  placebo  measurement  and  b)  Body 
weight 
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Placebo  Nleasuremett  nAIA/I;  ' Figure  6.8  Covariate  relationships  for  LDL  cholesterol  model:  The  modelled  individual 
estimates  of  response  at  40  mg  versus  a)  The  observed  placebo  measurement  and  b)  Body 
weight 
Placebo  Nkasurement  nAAM:  ' 
a)  -1.0 
w 
1.4 
-1.6 
5-2.0 
-2.2 
P;  00.  -2.4 
0-4 
-2.6 
-2.8 
Body  Kg 
b) 
-1.0  to 
-1.2 
44 
-1.6 
E-2.0 
-2.2 
OMW 
-2.4 
-2.6 
-2.8 
170 Model  development  and  covariate  effects  for  the  total  cholesterol  response 
Absolute  reduction  model 
The  development  and  covariate  investigation  for  the  total  cholesterol  using  the  absolute 
reduction  model  is shown  in  Table  6.7.  The  best  structural  model  from  the  initial  model 
development  i.  e.  Run  3  Table  6.5,  is  included  for  comparison.  The  additive  component, 
using  a  combined  additive  and  proportional  intraindividual  variability  model,  was 
estimated  to  be  zero.  Re-running  with  an  additive  instead  of  a  proportional  model 
increased  the  objective  function  (Run  3b),  so  the  proportional  model  was  used  for  the 
covariate  investigation. 
In  Run  22,  the  FOCE  with  interaction  method  was  used  instead  of  the  FO  method;  the 
estimates  of  variability  and  precision  were  less  and  run  times  were  reasonable,  so  further 
model  development  utilised  this  estimation  method. 
Estimating  covariance  between  the  modelled  placebo  measurement  PM  and  the  response, 
significantly  reduced  the  objective  function,  P<0.01  (Run  23  vs  Run  22).  However,  a 
further  significant  reduction  was  achieved  when  the  observed  PM  was  used  as  a  covariate 
of  Emax,  P<0.025  (Run  24  vs  Run  23)  and  the  covariance  term  could  be  subsequently 
removed  without  significantly  increasing  the  objective  function  (Run  25  vs  Run  24). 
Including  PM  with  D50  (Run  26),  or  gender  with  either  Emax  (Run27)  or  D50  (Run  28)  also 
significantly  decreased  the  objective  function.  However,  the  parameter  estimates  for  the 
gender  effects  were  not  significantly  different  from  zero.  Including  gender  with  the 
modelled  PM  (Run  28b)  did  not  significantly  decrease  the  objective  function.  Adding 
body  weight  with  a  linear  or  non-linear  relationship  did  not  improve  the  fit,  but  the  use  of 
weight-corrected  dose  did  reduce  the  objective  function  (Run  29). 
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N Including  PM  with  Emax  provided  the  lowest  objective  function,  and  none  of  the  possible 
two  factor  models  (runs  30  to  32)  resulted  in  a  further  statistically  significant  decrease  in 
objective  function.  The  weight  correction  of  dose  still  decreased  the  objective  function  and 
was  included  in  the  final  model  (Run  33). 
Percentage  reduction  model 
The  development  and  covariate  investigation  for  the  total  cholesterol  model  using  the 
percentage  reduction  model  is  shown  in  Table  6.8.  For  the  basic  model  (Run  34),  the 
population  parameter  estimates  (SE)  for  Emax  and  D50  were  31.7  % (±7.6%)  and  5.03mg  ( 
±17%),  respectively.  In  this  case,  the  additive  model  was  shown  to  be  more  appropriate 
than  the  proportional  model  (Run  34b  vs  Run  34).  The  lower  variability  estimates  and 
improved  precision  for  the  parameter  estimates  was  again  shown  when  the  FOCE  method 
was  utilised.  (Run  35).  Estimating  interindividual  variability  on  both  Emax  and  D50  did  not 
significantly  decrease  the  objective  function  (Run  36).  As  expected,  similar  covariate 
relationships  to  those  for  the  absolute  reduction  model  were  detected.  Including  PM  with 
Emax  (Run  37)  or  D50  (Run  38)  significantly  decreased  the  objective  function.  Similarly, 
including  gender  with  D50  (Run  40)  significantly  reduced  the  objective  function. 
However,  the  reduction  in  objective  function  when  gender  was  included  with  Emax  (Run 
39)  did  not  reach  statistical  significance,  and  neither  of  the  estimates  for  the  gender  effects 
were  significantly  different  from  zero  (  Run  39  and  Run  40).  The  addition  of  weight- 
corrected  dose  again  reduced  the  objective  function  without  increasing  model  complexity 
(Run  4  1). 
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N As  with  the  absolute  reduction  model,  none  of  the  two  covariate  models  significantly 
reduced  the  objective  function  further.  However,  the  best  single  covariate  model  was 
less  easy  to  determine,  since  the  objective  functions  for  PM  with  D50  and  PM  with 
Ernax  were  very  similar  (Run  37  vs  Run  38),  even  after  correcting  dose  for  body 
weight  (Run  45  vs  Run  46).  There  was  no  difference  in  the  weighted  residual  versus 
dose  plots  for  the  two  models  (Figure  6.9).  The  lack  of  distinction  between  the  two 
models  is  due  to  the  high  degree  of  correlation  between  Emax  and  D50.  Absolute 
reductions  in  (oF 
.  Fsp  of  4%  (Run  45)  or  5%  (Run  46)  corresponding  to  a  decrease  of 
ýF  _SP 
24%  and  30%  in  the  interindividual  variability  (O)p  2) 
were  achieved  with  the  final 
models. 
Using  the  parameters  from  Run  45,  the  predicted  D50,  for  a  75  kg  person,  with  initial 
measurements  of  6,7.8,1  OmMol.  1-  I  was  9.00,6.26,2.91  mg,  respectfully.  Similarly, 
using  the  parameters  from  Run  46,  the  predicted  maximum  reduction  would  be  25.8, 
34.8  45.6%,  respectfully.  These  correspond  to  absolute  maximum  reductions  of  1.6, 
2.7.4.6mMol.  L-1  and  lowest  possible  values  of  4.4,5.1,5.4mMol.  1-1,  respectfully. 
Figure  6.10  shows  the  predicted  percentage  reductions  for  the  three  different  initial 
measurements  using  the  population  typical  parameter  estimates  from  Run  45  (Figure 
6.10  a)  and  Run  46  (Figure  6.10  b).  The  lines  are  the  predicted  responses  for  a  75kg 
person,  and  the  upper  and  lower  limits  around  each  line  correspond  to  the  predictions 
for  a  100kg  and  a  50kg  person,  respectfully.  The  predictions  for  average  weight 
(75kg)  and  average  initial  measurement  (7.8mMol.  L-1  )  were  very  similar  for  the  two 
models,  due  to  the  high  degree  of  correlation  between  Emax  and  D50.  However,  as 
expected,  the  predictions  for  higher  or  lower  initial  values  were  very  different.  When 
the  covariate  effect  was  on  Emax  (Run  46)  the  maximum  percentage  reduction  was 
predicted  to  increase  as  the  initial  measurement  increased. 
175 Figure  6.9  Weighted  residuals  versus  dose  for  the  percentage  reduction  model  for 
total  cholesterol  a)  Run  45  (PM  as  covariate  of  D50)  and  b)  Run  46  (PM  as  covanate 
of  Emax) 
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176 Figure  6.10  The  predicted  reduction  in  total  cholesterol  for  a  typical  70kg  subject 
with  a  placebo  measurement  of  6  (dotted  line),  7.8  (solid  line)  and  10  (dot_dashed 
line)  mMol-L-1  in  accordance  with  a)Run  45  Table  6.8  and  b)  Run  46  Table  6.8.  The 
intervals  around  each  line  show  the  effect  of  body  weight  over  the  range  of  50  (lower 
limit)  to  100  (upper  limit)  kg  on  the  predicted  response 
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177 In  contrast,  the  initial  measurement  did  not  affect  the  maximum  possible  percentage 
reduction  when  the  covariate  effect  was  related  to  D50  (Run  45).  Body  weight  had 
the  greatest  influence  on  the  predicted  percentage  reduction  at  doses  around  D50. 
The  effect  decreased  as  the  predicted  percentage  response  approachedEmax. 
Model  development  and  covariate  effects  for  the  LDL  cholesterol  response 
absolute  reduction  model 
The  development  and  covariate  investigation  for  the  LDL  cholesterol  using  the 
absolute  reduction  model  is  shown  in  Table  6.9.  The  best  structural  model  from  the 
initial  model  development,  Run  6  Table  6.4,  is  included  for  comparison.  The 
additive  component  when  a  combined  additive  and  proportional  intraindividual 
variability  model  was  tested,  was  estimated  to  be  zero.  Re-running  with  an  additive 
instead  of  a  proportional  model  increased  the  objective  function  (Run  6b),  so  the 
proportional  model  was  used  for  the  covariate  investigation.  Although  using  the 
FOCE  method  did  not  greatly  alter  the  variability  or  precision  in  parameter  estimates 
(Run  47),  it  was  utilised  in  the  covariate  model  development  for  consistency  with  the 
total  cholesterol  modelling.  Testing  covariance  between  the  placebo  measurement 
and  the  response  (Run  48)  or  interindividual  variability  on  both  Emax  and  D50  (Run 
49)  did  not  significantly  decrease  the  objective  function.  The  addition  of  weight- 
corrected  dose  again  reduced  the  objective  function  without  increasing  model 
complexity  (Run  50).  Including  PM  with  Emax  (Run  5  1)  or  D50  (Run  52)  did  not 
significantly  decrease  the  objective  function.  Although  including  gender  with  either 
parameter  did  significantly  decrease  the  objective  function  (Run  53  and  54),  the 
parameter  estimates  for  the  difference  were  not  significantly  different  from  zero. 
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N Including  gender  with  the  modelled  PM  (Run  54b)  did  not  significantly  decrease  the 
objective  function.  Including  gender  on  both  Emax  and  D50  (Run  55)  was  not  significantly 
different  from  the  best  one  covariate  model  (Run  54),  and  correcting  dose  for  body  weight 
did  not  improve  the  parameter  precision  of  the  gender  effect  (Run  55). 
Percentage  reduction  model 
The  development  and  covariate  investigation  for  the  LDL  cholesterol  model  using  the 
percentage  reduction  model  is  shown  in  Table  6.10.  For  the  basic  model,  the  population 
parameter  estimates  (SE)  for  Emax  and  D50  were  43.9%  (±7%)  and  6.02mg  (±22%), 
respectively  (Run  57  Table  6.9).  The  percentage  reduction  data  was  again  shown  to  be 
most  appropriately  modelled  using  an  additive  intraindividual  error  model  (Run  57b  vs 
Run  57).  There  was  no  change  in  the  parameter  estimates  upon  using  the  FOCE  method 
(Run  58)  but  it  was  again  used  for  consistency.  Estimating  interindividual  variability  on 
both  Emax  and  D50  significantly  decreased  the  objective  function  (Run  59),  so  this  variance 
structure  was  used  for  the  covariate  investigation.  Estimating  covariance  between  the 
parameters  did  not  further  decrease  the  objective  function  (Run  60).  Using  weight 
corrected  dose  was  again  shown  to  decrease  the  objective  function  (Run  61).  In 
comparison  to  the  covariate  analysis  using  the  absolute  reduction  model,  including  gender 
with  Emax  (Run  64)  did  not  significantly  decrease  the  objective  function,  yet  including 
PM  with  Emax  (Run  62)  or  D50  (Run  63)  did  significantly  decrease  the  objective  function. 
The  parameter  estimate  for  the  gender  effect  on  D50  was  not  significantly  different  from 
zero  (Run  65).  Out  of  the  possible  two  factor  covariate  models  (Run  66  to  Run  69)  only 
the  model  including  gender  and  PM  with  D50  significantly  further  reduced  the  objective 
function,  but,  the  confidence  interval  for  the  gender  effect  still  included  zero. 
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00 Therefore,  although  lower  objective  functions  were  obtained  by  including  a  gender  effect, 
the  only  covariate  model  with  sufficiently  precise  parameter  estimates  was  PM  related  to 
D50  (Run  63).  Again,  the  use  of  weight  corrected  dose  further  decreased  the  objective 
function  and  was  included  in  the  final  model  (Run  70).  Run  71  shows  the  effect  of  PM  on 
Emax  with  weight  corrected  dose  for  completeness. 
The  absolute  reductions 
in(OD50  and(OEMAX,  between  the  basic  (Run  59)  and  final  model 
(Run  70),  were  3%  and  10%,  respectfully.  The  absolute  reductions  correspond  to 
percentage  decreases  in  the  interindividual  variabilities 
(O)D50  2 
and(OEMAX 
2 
)of  18%  and 
30%,  respectively. 
Using  the  parameters  from  Run  70,  the  predicted  D50  for  a  75kg  person,  with  initial 
measurements  of  4,5.4  and  8mMol.  1-1  was  10.9,7.5  and  1.2mg,  respectively.  Similarly, 
using  the  parameters  from  Run  7  1,  the  predicted  maximum  possible  reduction  would  be 
36.7,46.3  and  64.1  %,  respectfully.  These  correspond  to  absolute  maximum  reductions  of 
1.5,2.5  and  5.1mMol.  L-1,  and  lowest  possible  values  of  2.5,2.9,  and  2.9mMol.  1-1 
respectfully.  Figure  6.11  shows  the  predicted  percentage  change  for  three  different  initial 
measurements  for  Run  70  (Figure  6.1  1a)  and  Run  71  (Figure  6.1  1b).  As  before,  the  lines 
show  the  predicted  response  for  a  75kg  person,  and  the  upper  and  lower  limits  around  each 
line  correspond  to  the  predictions  for  a  100  and  50kg  person,  respectfully.  As  with  the 
total  cholesterol  predictions,  the  predictions  for  average  weight  (75kg)  and  average  initial 
measurement  (7.8mMol.  L-1  )  were  very  similar  for  the  two  models.  Similarly,  the 
differences  in  the  predictions  upon  changing  the  initial  measurements  was  again 
demonstrated. 
182 Figure  6.11  The  predicted  reduction  in  LDL  cholesterol  for  a  typical  70kg  subject  with 
placebo  measurements  of  4  (dotted  line),  5.4  (solid  line)  and  8  (dot-dashed  line)  mMol.  1:  1 
in  accordance  with  a)Run  70  Table  6.9  and  b)  Run  71  Table  6.9.  The  intervals  around  each 
line  show  the  effect  of  body  weight  over  the  range  of  50  (lower  limit)  to  100  (upper  limit) 
kg  on  the  predicted  response 
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183 6.6.3  Simulation  of  responder  rate 
The  distribution  of  total  cholesterol  after  doses  of  0,2.5,5,7.5,10,20,30,40,80,  and  160 
mg  was  simulated  for  a  population  of  1000  patients  with  a  mean  (SD)  for  PM  and  body 
weight  of  8.0  (0.8)mMol.  L-I  and  75  (13)kg,  respectively.  The  simulation  used  the 
parameter  estimates  from  the  following  Runs: 
Run  45  -  PM  as  a  covariate  of  D50  and  dose  corrected  for  body  weight 
Run  46-  PM  as  a  covariate  of  Emax  and  dose  corrected  for  body  weight 
In  the  simulations,  the  "placebo"  response  was  assumed  to  be  zero,  and  the  pre-treatment 
baseline  measurements  were  considered  to  be  equivalent  to  the  PM  used  in  the  model 
development  (see  Section  6.5.4). 
Patients  achieving  a  total  cholesterol  <  5.6  mMol.  L-'  were  considered  to  be  completely 
controlled  and  defined  as  "responders".  The  responder  rate  was  defined  as  the  percentage 
of  responders  at  each  dose  level. 
The  range  in  the  simulated  total  cholesterol  concentrations  achieved  at  each  dose  level  is 
shown  on  Figure  6.12.  There  was  no  obvious  difference  between  the  two  models.  The 
simulated  percentage  of  responders  by  pre-treatment  concentration  are  shown  on  Table 
6.11  and  Figure  6.13a.  Predicted  responder  rates  at  doses  of  10,20  and  40mg  were  22.6, 
40.9,54.5%,  and  24,41.9  and  56.2%  for  Run  45  and  Run  46,  respectively.  In  general,  the 
predicted  responder  rate  was  I  to  2%  different  over  the  whole  dose  range  (0  to  160mg). 
The  similarity  between  the  responder  rates  is  consistent  with  the  similarity  in  the  achieved 
concentrations  (Figure  6.12).  A  doubling  of  dose  from  10  to  20mg  was  predicted  to 
increase  the  responder  rate  by  -80%,  while  a  doubling  from  20  to  40mg  would  only 
increase  the  responder  rate  by  a  further  34%  (Figure  6.14  a). 
184 Figure  6.12  Distribution  of  predicted  total  cholesterol  concentrations  across  dose  for  a)  Baseline  on  D50  model  (Run  45)  and  b)  Baseline  on  Emax  model  (Run  46).  Horizontal  line 
and  boxes  indicate  median  and  interquartile  range  (Ql-Q3),  respectively.  The  whiskers 
extend  to  the  lowest  and  highest  values  that  are  still  inside  the  region  defined  by  QI- 
1.5.  (Q3  -  Q1)  to  Q3  +  1.5.  (Q3  -  QI),  showing  the  range  of  the  data.  The  other  lines 
indicate  values  which  lie  outside  this  interval. 
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L(9  OW)  (nv) A  larger  than  a  doubling  of  dose  would  be  required  to  double  the  number  of  responders 
with  doses  >20mg  (Table  6.11).  In  comparison  to  the  10mg  to  20mg  to  40mg  titration,  an 
alternative  titration  of  7.5mg  to  15mg  to  80mg  would  increase  the  responder  rate  by  at  least 
70%  at  each  step  (Figure  6.14b). 
As  expected,  the  responder  rates  were  predicted  to  be  markedly  different  between  patients 
with  high  and  low  pre-treatment  concentrations.  For  example,  the  responder  rate  in 
patients  with  a  low  pre-treatment  concentration  (<7.2  mMol/1:  1)  taking  5mg  daily  was 
predicted  to  be  similar  to  that  in  patients  with  a  high  pre-treatment  (>8.8  mMol/I:  I) 
concentration  taking  160mg  daily  (Table  6.11).  In  addition,  when  considering  the  tails  of 
the  pre-treatment  concentration  distribution  (  <7.22  or  >8.8  mMol.  l:  '),  the  predicted 
responder  rate  was  different  for  the  two  models  (Figure  6.13  b&  c).  For  these  individuals, 
the  model  from  Run  46  (baseline  as  a  covariate  of  Emax)  predicted  a  significantly  higher 
responder  rates  than  the  model  from  Run  45  (baseline  as  a  covanate  of  D50).  This 
difference  increased  to  a  maximum  over  the  dose  range  of  10  to  30mg.  The  maximum 
differences  (14.5%  and  18.3%  for  pre-treatment  cholesterol  of  <7.2  mMol.  1:  1  and  >  8.8 
mMol.  L-1,  respectively)  decreased  slightly  as  dose  was  further  increased. 
The  potential  dosage  regimens  for  patients  with  high  (>8.8  mMol.  l;  ')  and  low  (<7.2 
mMol.  L_1)  pre-treatment  total  cholesterol  concentrations  are  compared  in  Figures  6.15  and 
6.16,  respectively. 
189 Figure  6.15  Predicted  percentage  responding  in  a  simulated  population  of  152  patients 
with  pre-treatment  cholesterol  >8.8  m.  Mol.  L_1,  using  the  baseline  on  D50  model  (Run  45)- 
(dashed  line)  and  the  baseline  on  Emax  model  (Run  46)-(solid  line).  a)  Response  at  10,20 
&  40mg  b)  Response  at  7.5,15  &  80mg 
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6.7.1  Mean  reductions  and  analysis  of  variance 
The  mean  total  cholesterol  pre-treatment  (i.  e.  PM)  was  7.8  ±I-ImMol.  L_1  and  therefore  the 
average  patient  had  at  least  a  three  fold  increased  risk  of  fatal  CHD  compared  to  subjects 
with  a  normal  cholesterol  i.  e.  <  5.2  mMol.  L-'  (Study  group,  1998).  In  comparison,  the 
mean  total  triglycerides  pre-treatment(  2.4  mMol.  L_')  were  only  marginally  raised  in 
comparison  to  the  range  of  2.3  to  5.6  mMol.  L-'  for  mild  to  moderate  hypertriglyceridaemia. 
Treatment  was  therefore  mainly  required  to  lower  the  total  cholesterol  in  general,  and  LDL 
cholesterol  in  particular. 
The  mean  percentage  reduction  in  total  cholesterol  after  the  40mg  dose  i.  e.  31%,  was  the 
same  as  that  estimated  in  a  previous  investigation  of  subjects  sampled  from  the  same 
hypertensive,  hypercholesterolaemic  population  (Macdonald  et  aL,  1991).  Changes  in  the 
lipid  sub-fractions  across  the  dose  range  were  also  consistent  with  previous  dose  ranging 
studies  which  utilised  different  patient  populations  (Table  6.3  vs  Table  6.1).  The  average 
response  to  sirnvastatin  would  therefore  appear  to  be  consistent  across  various  sub-groups 
of  the  potential  target  population.  The  equivalence  of  total  cholesterol  and  total 
triglyceride  responses  after  6  and  12  weeks  of  dosing  corresponds  to  the  maximum 
response  occurring  with  the  first  6  weeks  of  treatment  with  a  particular  dose  (Todd  &  Goa, 
1990).  Although  the  ANOVA  and  subsequent  multiple  comparisons  indicate  the 
significant  treatment  effects  across  the  tested  doses,  extrapolation  and  prediction  of 
responses  to  other  doses  and  differences  between  potential  future  dosing  strategies  requires 
the  utilisation  of  modelling  techniques. 
6.7.2  Population  dose  response  relationships 
Since  there  were  no  period  effects,  the  lipid  responses  were  modelled  ignoring  the  dose 
administration  sequence.  The  total  triglycerides  were  only  mildly  raised,  so  it  is  not 
192 surprising  that  the  simplest  step  model  was  the  most  appropriate  in  this  case.  The  effects 
on  VLDL  and  HDL  cholesterol  were  best  described  by  the  step-linear  model  which  predicts 
that  the  change  in  HDL  and  LDL  would  increase  linearly  within  the  observed  dose  range. 
The  mean  parameter  estimates  for  Emax  and  D50were  precisely  estimated  for  the  reduction 
in  both  total  and  LDL  cholesterol.  The  parallel  nature  of  the  projected  dose  response 
curves  (Figure  6.4),  and  the  similarities  in  the  estimated  Emax  and  D50  values  highlight 
that  the  principle  effect  of  simvastatin  is  to  reduce  total  cholesterol  by  removing  circulating 
LDL  cholesterol.  The  association  between  decreasing  LDL  cholesterol  and  increasing 
HUILDUL  cholesterol  during  treatment  with  simvastatin  is  consistent  with  previous  studies 
(Tuornilehto  et  al.,  1994).  Although,  the  changes  in  the  total:  HDL  cholesterol  and 
LDL:  HDL  cholesterol  ratios  may  be  important  to  the  assessment  of  the  total  benefit  from 
treatment,  reduction  in  CHD  mortality  has  been  more  clearly  related  to  changes  in  total  or 
LDL  cholesterol  alone. 
The  LDL  and  total  cholesterol  responses  over  the  10  to  40  mg  dose  ranges  were  predicted 
to  fall  into  the  upper  70-90%  of  the  projected  dose  response  curve  (Figure  6.4).  However, 
the  total  and  LDL  cholesterol  model  extrapolations  may  be  biased  by  the  small  portion  of 
the  dose  response  relationship  covered  by  the  study  dose  range.  Although,  formal  model 
validation  would  require  prospective  evaluation  over  a  wider  dose  range,  the  predicted 
responses  were  consistent  with  the  results  from  the  primary  placebo  controlled  dose 
ranging  studies  detailed  in  Table  6.1  and  shown  in  Figures  6.17  &  6.18.  Nevertheless,  the 
models  did  not  extrapolate  as  well  to  the  recent  high  dose  studies  (also  shown  in  Figures 
6.17  and  6.18),  i.  e.  the  predicted  median  responses  for  160mg  was  less  than  that  measured 
(Davidson  et  al.,  1997).  Whilst  this  is  not  surprisIng  given  that  the  observation  was  well 
outside  the  dose  range  used  to  develop  the  model,  the  lack  of  a  placebo  in  the  high  dose 
study  could  also  account  for  the  difference. 
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a However,  other  emerging  work  appears  to  support  the  notion  that  the  ffMG-CoA  reductase 
inhibitors  have  a  response  curve  which  is  still  log-linear  at  doses  3  to  4  times  the  current 
maximum  dose  (Bradford  et  al.,  1991;  Pedersen  &  Tobert,  1996),  and  data  in  this  range  is 
needed  to  support  the  models  derived  in  this  analysis  . 
6.7.3  Covariate  analysis 
Previously,  pre-treatment  concentration  and  gender  have  been  shown  to  be  predictors  of  the 
total  and  LDL  response  to  simvastatin  (Miserez  et  al.,  1994).  In  this  analysis,  attempts 
were  made  to  determine  which  aspect  of  the  dose  response  relationship  each  covariate  most 
influenced.  Initially,  an  absolute  reduction  model  was  used,  however,  percentage  reduction 
from  baseline  is  most  often  reported  when  comparing  response  of  lipid  lowering  therapies. 
Utilising  the  percentage  reduction  models  reduced  the  number  of  interindividual  vanablity 
terms  required  in  the  basic  model.  The  transformation  of  the  data  led  to  an  additive 
intraindividual  variability  model  being  more  appropriate  than  the  proportional  error  model 
used  with  the  absolute  reduction  model.  This  change  highlights  the  importance  of 
rechecking  the  modelling  assumptions. 
In  contrast  to  the  absolute  reduction  model  for  total  cholesterol,  which  determined  that  PM 
was  best  included  as  a  covariate  of  Emax,  changing  to  the  percentage  reduction  model 
indicated  that  PM  could  equally  be  a  covariate  of  D50-  While  the  high  degree  of  correlation 
between  Emax  and  D50  will  always  be  a  confounding  factor,  larger  numbers  and  a  wider 
coverage  of  the  dose  response  relationship  may  allow  the  effect  of  PM  on  each  or  both 
parameters  to  be  more  accurately  determined.  For  the  LDL  cholesterol,  utilising  the 
percentage  reduction  model  allowed  estimation  of  interindividual  varibility  on  both  Emax 
and  D50,  and  determination  of  a  statistically  significant  effect  of  PM  on  Emax  and  D50- 
Therefore,  although  the  percentage  reduction  model  helped  uncover  more  potential 
covariate  relationships  it  did  not  help  to  clarify  their  relative  importance. 
196 Gender  was  a  potential  covariate  for  both  the  total  and  LDL  cholesterol  responses,  and 
gender  differences  in  both  the  pharmacokinetics  (Cheng  et  al.,  1992)  and 
pharmacodymanics  of  simvastatin  have  been  previously  demonstrated  (Clifton  et  al.,  1994; 
Nhserez  et  al.,  1994).  However,  estimates  of  the  relevant  parameter  were  not  significantly 
different  from  zero.  Confounding  with  PM  and  the  female  preponderance  in  the  study 
population  possibly  prevented  precise  estimation  of  gender  differences. 
The  relationship  between  PM  and  response  is  consistent  with  the  action  of  simvastatin  on 
the  number  of  liver  LDL  receptors.  A  shift  in  the  equilibrium  between  production  and 
removal  of  LDL  particles  towards  a  higher  rate  of  removal  should  theoretically  produce  a 
more  profound  reduction  when  the  circulating  levels  are  high.  However,  in  this  analysis  it 
was  not  possible  to  determine  whether  the  effect  would  result  in  a  steeper  decline,  a  greater 
overall  reduction  or  both. 
Nevertheless,  the  importance  of  the  pre-treatment  level  in  comparison  of  responses  was 
highlighted.  On  this  basis,  a  difference  between  baseline  levels  could  also  account  for  the 
disparity  between  the  predicted  and  observed  response  to  the  160mg  dose  (Figure  6.17  and 
6.18). 
The  association  between  body  weight  and  the  response  to  simvastatin  is  more  difficult  to 
justify  since  the  use  of  an  additional  parameter  to  account  for  the  effect  did  not  have  a  large 
affect  on  the  fit.  Furthermore,  although  weight  reduction  in  association  with  a  lipid 
lowering  diet  is  reported  to  decrease  plasma  cholesterol  by  up  to  25%  (Study  Group,  1988), 
the  average  weight  did  not  change  over  the  study  duration,  and  subjects  from  this  study 
population  have  previously  failed  to  respond  to  dietary  measures  (Farish  et  al.,  1990). 
Nevertheless,  a  weight  corrected  dose  may  be  justified  pharmacokinetically.  Liver  size  is 
related  to  body  weight,  so  the  efficiency  with  which  the  active  metabolites  are  cleared  from 
the  liver,  via  biliary  excretion,  may  increase  with  increasing  weight.  This  explanation  may 
also  theoretically  account  for  gender  effects  found  in  previous  studies. 
197 While  the  detected  covariate  relationships  are  consistent  with  previously  postulated 
covariate  effects,  the  large  majority  of  the  interindividual  variability  remained  unexplained. 
Further  work,  in  a  larger  population,  may  allow  the  covariate  relationships  so  far  identified 
to  be  fully  characterised  and  other  covariates,  which  may  help  to  explain  more  of  the 
interindividual  variability,  to  be  determined. 
6.7.4  Simulation  of  responder  rate 
For  hypercholesterolaernia  as  an  isolated  nsk  factor,  it  is  recommended  that  total 
cholesterol  should  be  maintained  below  5.6  mMol.  L-1.  For  simplicity,  the  responder  rate 
was  predicted  using  this  concentration.  However,  if  the  incidence  of  multiple  risk  factors 
within  the  population  was  known,  a  range  of  target  concentrations  could  be  used  to  more 
accurately  predict  the  overall  responder  rate. 
The  accuracy  of  simulations  are  conditional  on  the  adequacy  of  the  models,  so  the 
simulations  used  parameters  from  both  Run  45  and  Run  46  to  test  for  differences.  A 
larger  responder  rate  was  predicted  for  the  model  with  PM  related  to  Emax  (Run  46),  and 
the  magnitude  of  this  difference  was  predicted  to  increase  with  both  increasing  dose  and 
the  increasing  value  for  PM. 
The  change  in  responder  rate  with  increasing  dose  is  consistent  with  the  Emax  model  used 
in  the  simulations  i.  e.  on  approach  to  the  asymptotic  part  of  the  Emax  curve  a  larger  and 
larger  dose  is  required  to  produce  the  same  increase  in  response  and,  therefore  responder 
rate. 
Although,  it  would  be  possible  to  individualise  dose  based  on  the  pre-treatment  cholesterol 
measurements,  the  range  of  commercially  available  tablet  strengths  limit  the  dose  selection. 
The  current  available  strengths  in  the  UK  (10  and  20mg)  allow  for  titration  from  10mg  in 
steps  of  10  mg.  However,  this  would  seem  to  only  allow  for  titration  in  the  "flatest" 
198 portion  of  the  dose  response  curve.  A  smaller  tablet  strength  of  5  to  7.5  mg  would  allow 
smaller  titrations  starting  from  the  D50  and  therefore  the  steeper  portion  of  the  dose 
response  curve.  However,  rationalisation  of  treatment,  based  on  achievement  of  a 
particular  "target"  cholesterol  level,  could  lead  to  a  completely  different  set  of  dose 
strengths.  Importantly,  the  choice  of  doses  has  to  take  into  account  the  relationship 
between  dose  and  adverse  effects.  Fortunately,  the  toleration  to  all  doses  including  80mg, 
was  good  in  the  primary  dose  ranging  studies,  and  any  side-effects  have  usually  been  mild 
(Section  6.1.4).  However,  for  a  prophylactic  treatment  even  mild  side-effects  may  be 
sufficient  to  reduce  compliance,  so  it  is  prudent  to  dose  patients  with  the  lowest  possible 
dose  required  to  achieve  the  desired  effect.  With  this  in  mind,  the  choice  of  7.5,15  and  80 
mg  doses  may  for  several  reasons  be  more  advantageous.  Firstly,  an  average  responder  rate 
similar  to  that  for  the  20mg  dose  could  be  achieved  with  an  initial  dose  of  15  mg  (Table 
6.11),  and  the  lower  dose  may  lead  to  a  reduced  incidence  of  side-effects.  A  subsequent 
titration  to  80mg  would  provide  a  pronounced  increase  in  responder  rate  for  resistant 
patients.  Secondly,  for  patients  with  a  low  pre-treatment  measurement  (i.  e.  <7.2  mMol.  L_1) 
7.5mg  may  be  a  more  prudent  starting  dose,  since  the  responder  rate  is predicted  to  be  very 
similar  to  that  for  the  10  mg  (53  to  55.  %  vs  54.2  to  57.7%,  Table  6.11),  and  yet  the  smaller 
dose  may  again  be  sufficient  to  decrease  the  incidence  of  adverse  effects.  Furthermore,  a 
subsequent  titration  to  l5mg  would  provide  a  responder  rate  of  between  73  to  80%,  which 
is  substantial  given  that  another  three  fold  increase  in  dose  would  be  required  to  increase 
responder  rate  by  another  10%.  Lastly,  since  the  responder  rate  is  much  lower  in  patients 
with  a  high  pre-treatment  measurement  (i.  e.  >8.8  mMol-L-1)  a  starting  dose  of  80mg  may 
be  appropriate  since  the  risk  of  developing  CHD  could  outweigh  the  risks  of  any  potential 
adverse  events. 
Patients  not  adequately  responding  to  this  dose,  may  only  achieve  a  greater  reduction  with 
the  addition  of  a  second  agent  such  as  a  bile  acid  sequestrant  (Da  Col  et  al.,  1990,1993; 
199 Desager  et  al.,  1991)  or  a  fibrate  (Deslypere,  1992;  Feussner  et  al.,  1992).  However,  the 
increased  potential  for  more  serious  adverse  effects  i.  e.  myopathy  and  rhabdomyolysis 
must  be  considered  if  a  combination  with  a  fibrate  is  to  be  advocated  (Plosker  & 
McTavish,  1995). 
6.7.5  Study  design 
The  dearth  of  published  knowledge  on  the  dose  response  relationship  for  sirnvastatin, 
appears,  despite  the  number  of  dose  ranging  studies,  to  be  due  to  the  acceptance  of  the  poor 
information  provided  by  cuffent  practices  in  the  design  and  analysis  of  dose  ranging 
studies.  Specifically,  use  of  the  parallel  design  has  not  provided  individual  dose  response 
information  and,  therefore,  only  a  conservative  exploration  of  the  dose  response 
relationship. 
The  present  study  design  has  only  explored  doses  over  a  narrow  range  at  the  upper  end  of 
dose  response  relationship,  and  the  identification  of  both  the  structural  and  covanate 
models  was  restricted  by  this  limitation.  In  particular,  it  was  not  possible  to  detennine 
whether  the  correlation  between  PM  and  response  was  most  appropriately  modelled  by 
including  it  with  D50  or  Emax.  Escalation  of  subjects  over  a  wider  range  of  doses  would 
have  allowed  better  characterisation  of  the  dose  response  relationship  and  the  covariate 
effects.  This  approach  would  seem  particularly  appropriate  for  simvastatin  given  the  low 
incidence  of  adverse  effects.  The  lag  time  of  six  weeks  until  the  maximal  effect  is 
achieved  could  restrict  the  number  of  doses  used  in  any  future  escalation  design.  However, 
the  number  of  subjects  achieving  the  desired  total  cholesterol  concentration  could  be 
increased  by  altering  the  starting  dose  and  titration  steps  based  on  the  pre-treatment  value. 
6.7.6  Future  clinical  practice 
The  potential  shortcomings  of  the  present  range  of  doses  must  be  balanced  against  the 
therapeutic  success  of  simvastatin.  However,  with  the  link  between  control  of 
200 hypercholesterolaernia  and  reduction  in  cardiovascular  morbidity  and  mortality  becoming 
established,  the  need  to  rationalise  treatment  may  now  be  more  important.  Effective 
clinical  management  of  an  individual  patient's  response  requires  that  Information  Is 
provided  to  help  rationalise  between  dose  escalation  and  the  addition  of  other  drug  therapy. 
Covariate  effects  (i.  e.  pre-treatment  level  and  gender)  may  alter  the  dose  response 
relationship  and  influence  this  decision. 
D-- 
I  i-eviously,  the  comparisons  of  HMG  CoA  inhibitor  potencies  has  been  based  on  mean 
dose  response  relationships  (Illingworth  et  al.,  1994).  The  results  of  this  investigation  have 
shown  how  these  may  lack  accuracy  and  would  benefit  from  the  estimation  and 
comparison  of  population  dose  response  relationships  (Marshall  et  al.,  1994)  as  developed 
by  Sambol  and  Sheiner  (1991). 
6.8  Conclusions 
The  analysis  has  identified  structural  models  for  each  of  the  lipid  responses  to  simvastatin. 
Despite  the  restrictions  of  the  study  design,  an  Emax  relationship  for  the  reduction  in  total 
and  LDL  cholesterol  was  established  as  the  most  appropriate  model.  Average  predictions 
for  responses  outwith  the  studied  dose  range  were  consistent  with  observations  made  in 
previous  dose  ranging  studies. 
In  the  covariate  analysis  it  was  not  possible  to  determine  whether  the  correlation  between 
PM  and  response  was  best  modelled  by  including  it  with  Emax  or  D50  or  both.  The 
estimation  of  the  effect  of  gender  on  the  reduction  in  LDL  cholesterol  was  confounded  by 
the  majority  of  females  having  a  high  PM.  Modelling  the  response  as  a  function  of  dose 
per  kg  body  weight  further  decreased  the  objective  function  without  increasing  the  model 
complexity. 
Simulations  predicted  that  the  percentage  of  responders  (patients  attaining  a  cholesterol 
<5.2  mMol.  L-1  would  increase  from  24%  on  10mg  to  56%  on  40mg.  However,  based  on 
201 this  analysis  a  more  rationale  set  of  doses  may  be  7.5,15  and  80  mg,  and  it  was  predicted 
that  these  would  offer  greater  flexibility  since  more  of  the  dose  response  range  could  be 
covered.  In  particular,  it  was  predicted  that  this  would  allow  patients  to  be  prudently 
titrated  in  accordance  with  pre-treatment  measurements. 
It  may  be  hypothesised  from  this  analysis  that  a  more  appropriate  design  and  interpretation 
of  the  primary  dose  ranging  studies  would  have  resulted  in  different  doses  of  simvastatin 
being  used  in  phase  III  trials.  Furthermore,  a  better  understanding  of  the  dose  response 
relationship  and  possible  importance  of  covariates  at  an  early  stage  in  the  clinical 
development  programme  may  have  helped  to  provide  a  definitive  recommended  dose  range 
before  the  drug  was  established  in  clinical  practice. 
202 CHAPTER  7 
DOSE/  CONCENTRATION/  RESPONSE 
RELATIONSHIP  FOR  A  NOVEL  CLASS  III 
ANTI-ARRHYTHMIC  DOFETILIDE: 
COMPARISON  BETWEEN  PATIENTS 
AND  HEALTHY  VOLUNTEERS 
203 In  this  chapter  mixed  effects  modelling  is  used  to  establish  the  dose  concentration 
response  relationship  for  a  novel  class  III  anti-arrhythmic  drug  under  development  for  the 
treatment  of  re-entrant  cardiac  arrhythmias.  Effect  compartment  methodology  is  used  to 
account  for  the  temporal  delay  between  peak  plasma  concentration  and  maximum  increase 
in  the  QTc  interval,  a  surrogate  marker  of  Class  III  anti-arrhythmic  activity.  A  comparison 
between  healthy  volunteers  and  patients  with  ischeamic  heart  disease  is  made  by  testing  for 
differences  in  the  parameters  of  resulting  PK/PD  models.  Covariates  which  could  help 
explain  the  variability  in  the  PK  and  PD  components  of  the  model  are  investigated.  To  aid 
in  the  design  of  future  studies,  fixed  dose  and  dose  per  kilogram  body  weight  short  term 
infusions  are  compared  using  simulation.  The  potential  safety  implications  for  each 
regimen  are  discussed.  Similarly,  the  steady  state  concentrations  which  give  rise  to  QTc 
prolongations  associated  with  an  increased  risk  of  Torsades  de  Pointes  (TdP)  were  also 
predicted. 
7.1  Introduction 
7.1.1  Re-enterant  cardiac  arrhythmias 
Abnormal  heart  rhythms  known  as  cardiac  arrhythrruas  can  be  characterised  by  electro- 
cardiographic  (ECG)  techniques.  The  effectiveness  of  drug  treatment  and  other  procedures 
in  the  correction  or  the  prevention  of  rhythm  abnon-nalities  can  be  detected  and  measured 
by  an  alysing  ECG  patterns.  The  PQRST  waveform  describes  one  cardiac  cycle. 
204 R  Various  alterations  in  the  time  and  shape 
of  this  waveform  correspond  to  known 
rhythm  disturbances  and  can  be  attributed 
to  abnormal  electrical  conduction  in 
particular  areas  of  the  myocardium. 
Both  increased  automaticity  of  pace  maker 
cells  which  initiate  the  electrical  wave 
fronts,  and  cyclical  re-activation  of  the 
myocardium  by  wavefronts  are  common  causes  of  cardiac  arrhythmias.  Re-activation 
results  from  temporal  and  spatial  inhomogeneities  in  conduction  and  refractoriness  within 
the  myocardium;  which  allow  advancing  wavefronts  to  fractionate  into  more  independently 
circulating  activation  wavelets.  Re-excitation  of  previously  refractory  myocardium 
produces  a  re-entrant  arrhythmia  which  can  result  in  symptomatic  tachycardias,  atnal 
fibrillation  and  life-threatening  episodes  of  ventricular  fibrillation  (VF). 
7.1.2  Class  III  antiarrhythmics 
Agents  which  lengthen  the  refractory  period  form  an  important  class  of  drugs  for  the 
treatment  and  prevention  of  re-entrant  arrhythmias  (Singh,  1993).  Arniodarone  and  sotalol 
are  effective  agents  in  the  control  of  various  types  of  arrhythrrua,  and  show  class  III  activity 
along  with  other  pharmacological  actions  (Beckers  &  Kulbertus,  1987;  Singh  & 
Nademanee,  1987;  Nora  &  Zipes,  1993).  Although  a  recent  study  has  shown  evidence  to 
the  contrary  (Kuck,  1996),  arniodarone  is  generally  considered  to  be  effective  in 
maintaining  sinus  rhythm  (Middlekauff  et  al.  1993)  and  Improving  the  survival  of  patients 
with  life  threatening  arrhythmias  (Herre  et  al.  1989;  Ceremuzynski,  1993;  Greene,  1993). 
However,  it  has  an  exceptionally  long  terminal  half-life  (20  to  60  days  ),  so  steady  state 
conditions  are  not  achieved  until  several  months  after  the  start  of  therapy  (Rodden,  1993). 
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PQST The  slow  peripheral  accumulation  is  highly  vanable  due  to  extensive  plasma  protein 
binding  (>98%  )  and  the  incidence  of  adverse  events  i.  e.  impairment  of  thyroid  function 
and  pulmonary  toxicity  have  not  been  found  to  correlate  with  plasma  concentrations  (Ulrik 
et  al.  1992;  Greene,  1993).  The  bradycardic  side-effects  of  sotalol  have  been  largely 
removed  by  resolving  the  racernic  mixture  and  administering  the  d-isomer  which  has  no 
beta-blocking  activity  (Johnston  et  al.  1985).  However,  control  of  ventricular  rate  through 
antagonism  of  the  beta-adrenoreceptor  may  be  important,  since  the  mortality  rate  with  the 
single  isomer  has  been  shown  to  be  greater  than  with  placebo  (Waldo  et  al.  1996). 
Nevertheless,  the  predictable  pharmacology  of  a  pure  class  IHantiarrhythlmc  may  offer  the 
advantage  of  predictable  efficacy  and  the  potential  of  a  safer  treatment  option  for  both  the 
termination  and  prevention  of  cardiac  arrhythmias. 
7.1.3  Dofetilide 
Dofetilide  (UK-68,798)  (N-(4-  (2-  (2-(4-  (methane  sulphonamido)  phenoxy)  N- 
methyethylamino)  ethyl)  phenyl)  methane  is  a  pure  class  III  anti  arrhythmic,  as  stratified  by 
the  Vaughan  Williams  classification  for  antiarrhythmics.  Accordingly,  it  selectively 
inhibits  the  rapid  component  of  the  delayed  rectifier  potassium  current  Mr,  prolongs  the 
period  that  the  cardiac  tissue  is  refractory  to  further  excitation,  but  does  not  affect  the 
velocity  of  myocardial  conduction  (Gwilt  et  al.  1991;  Carmellet,  1992).  The  prolongation 
of  the  effective  refractory  period  (ERP)  and,  therefore,  the  action  potential  duration  (APD), 
prevents  the  propagation  of  cycling  waves  of  reactivation  (Gwilt  et  al.  1991;  Knilans  et  al. 
1991).  Dofetilide  has  been  shown  to  be  effective  in  treatment  and  prevention  of 
arrhythmias  with  a  re-entrant  mechanism  i.  e.  atrial  fibrillation  (AF)  (Suttorp  et  al.  1992) 
, 
paroxysmal  supraventricular  tachyarrhythmias  (pSVT)  (Connelly  et  al.  1992;  Wong  et  al. 
1992)  and  ventricular  tachycardia  and  fibrillation  (VT/VF)  (Echt  et  al.  1991;  Fananapazir 
&  Cropp,  1992;  Thomsen  et  al.  1992). 
206 7.1.4  Pharmacokinetics  of  dofetilide 
Previous  studies  have  shown  a  linear  relationship  between  dose  and  both  AUC  and  Peak 
concentration  (Sedgwick  et  al.  1991;  Rasmussen  et  al.  1992).  Elimination  from  the  plasma 
following  intravenous  infusion  has  been  shown  to  be  biexponential  with  a  terminal  half-life 
of  7.5  to  9.0  hours  (Rasmussen  et  al.  1992;  Smith  et  al.  1992;  Funck-Brentano,  1993). 
Over  70%  of  the  parent  drug  appears  to  be  excreted  unchanged  in  the  urine  while  the 
remainder  is  inactivated  by  metabolism.  The  potential  for  metabolic  interactions  is 
therefore  limited  and  in  addition  dofetilide,  is  only  moderately  bound  to  plasma  proteins 
(64%). 
7.1.5  Pharmacodynamics  of  dofetilide 
The  QT  interval  is  the  time  between  the  depolarisation  and  repolarisation  of  the  ventricular 
myocardium,  and  corresponds  to  the  ventricular  refractory  period.  It  is  measured  by 
standard  ECG  methods  and  is  used  in  this  chapter  as  an  non-invasive  surrogate  marker  of 
class  HI  antiarrhythmic  activity  and  safety. 
Although  QT  prolongation  has  been  successfully  modelled  (Whiting  et  al.  1980;  Holford  et 
al.  198  1) 
,  the  reliability  of  QT  as  a  general  marker  for  antiarrhythmic  effect  has  previously 
been  questioned  (Vaughan-Williams,  1985).  However,  its  relevance  when  considering 
class  III  specific  agents  has  more  recently  been  highlighted  (Podrid,  1992). 
The  length  of  the  QT  interval  is  inversely  related  to  heart  rate,  so  antiarrhythmics  with  a 
negative  inotrophic  effect  can  prolong  the  QT  interval. 
Development  of  individual  regression  equations  has  been  shown  to  produce  the  least  biased 
heart  rate  corrected  QT  (QTc)  measurements  (Kelman  et  al.  1981).  However,  the 
population  regression  models  are  the  most  commonly  employed  i.  e.  (Bazett,  1920).  When 
heart  rate  ch  anges  are  small  within  individuals  the  two  approaches  are  comparable. 
207 Dofetilide  has  no  effect  on  heart  rate,  but  correction  is  still  required  to  allow  comparison  of 
the  QT  intervals  measured  within  and  between  study  days. 
7.1.6  Torsades  de  Pointes  (TdP) 
All  antiarrhythmic  drugs  have  a  relatively  narrow  therapeutic  window.  The  maximum 
therapeutic  concentrations  are  limited  by  the  risk  of  proaffhythmia.  A  major  concern  with 
the  class  III  antiaffhythmics  is  Torsade  de  Pointes  (TdP),  a  form  of  polymorphic  VT  which 
can  degenerate  into  ventricular  fibrillation.  The  incidence  of  UP  is  associated  with  many 
factors  and  a  wide  variety  of  clinical  settings  (Morganroth,  1987;  Keren  &  Tzivoni,  1991). 
However,  the  most  frequently  reported  cause  of  this  arrhythmia  is  exposure  to  drugs  known 
to  delay  repolarisation  (Stratmann  &  Kennedy,  1987).  The  overall  incidence  of  UP  is  low 
even  for  the  class  III  drugs  Mattioni  et  al.  1989),  though  prevention  is  important  Since 
episodes  can  be  life-threatening  (Sclarovsky  et  al.  1983;  Kuck  et  al.  1984;  Brown  et  al. 
1986;  Dancey  et  al.  1997).  High  plasma  drug  levels  lead  to  excessive  prolongation  of  QTc, 
so  overdose  is  a  common  cause  of  UP  (Neuvonen  et  al.  1979;  Belton  et  al.  1982;  Kuck  et 
al.  1984).  Prolongation  of  QTc  is  the  single  most  common  precursor  to  UP  (Zehender  et 
al.  1991).  Stratmann  and  Kennedy  reviewed  197  cases  of  UP  49  %  had  a  predose  QTc 
420  msecs,  in  comparison  the  normal  range  for  QTc  interval  in  healthy  volunteers  is  380  to 
400  msecs  (Stratmann  &  Kennedy,  1987).  In  89%  of  the  cases  investigated  the  pre-TdP 
QTc  was  >  560  msecs.  Similarly,  in  79%  of  the  cases  pre-TdP  QTc  had  been  prolonged 
by  >  25%.  While  the  degree  of  prolongation  has  not  as  yet  been  shown  to  correlate  with 
efficacy  (Surawicz  &  Knoebel,  1984),  it  may  be  possible  to  identify  what  is  sufficient  for 
efficacy  but  not  associated  with  an  increased  risk  of  TdP.  The  QTc  interval  may  therefore 
be  a  particularly  useful  surrogate  in  the  determination  of  therapeutic  regimens  for  class  III 
anti  arrhythmic  s- 
208 7.2  Background  to  analysis 
Early  pharmacodynamic  data  for  dofetilide  suggested  that  the  minimum  dose  to  cause  a 
measurable  change  in  QTc  was  5mcg.  kg-1  and  1.5mcg.  kg-1  in  healthy  volunteers  and 
patients  with  ischaemic  heart  disease  (IHD),  respectively.  This  difference  suggested  that 
the  dose  concentration  response  relationships  may  be  different  between  patients  and 
volunteers.  Since  it  is  known  that  disease  processes  can  alter  the  efficacy  of  many  drugs, 
the  presence  of  ischaernic  heart  disease  may  increase  the  sensitivity  of  the  myocardium  to 
dofetilide.  Alternatively,  the  attenuation  of  effect  could  simply  be  the  result  of  an  increase 
in  target  tissue  concentration  as  a  result  of  a  disease  related  reduction  in  clearance  or 
plasma  protein  binding.  Moreover,  a  combination  of  both  these  effects  could  play  a  role  in 
disease  related  modification  of  efficacy. 
In  drug  development,  comparative  studies  of  matched  groups  of  patients  and  volunteers 
are  used  to  determine  the  potential  for  disease  related  changes  to  influence  the  dose 
response  relationship.  The  data  from  such  a  study  is  used  in  this  chapter  to  develop  a 
PK/PD  model  for  dofetilide. 
209 7.3  Aims 
The  primary  aims  in  this  chapter  were  :- 
1)  To  develop  a  PK/PD  model  to  describe  the  effect  of  dofetilide  on  QTc  interval 
2)  To  compare  the  response  to  dofetilide  in  patients  with  ischaernic  heart  disease  with  that 
in  healthy  subjects. 
3)  To  estimate  the  variability  in  the  pharmacokinetic  and  pharmacodynamic  parameters  and 
to  identify  and  explore  any  covariate  relationships  which  help  explain  the  variability. 
4)  To  compare  the  variability  in  pharmacokinetics  and  pharmacodynamics  following  fixed 
dose  and  dose  per  kilogram  regimens 
5)  Use  the  PK/PD  relationship  to  predict  the  safety  of  various  dosage  regimens  with  regard 
to  the  incidence  of  Torsade  de  Pointes,  and  thus  to  help  in  rational  design  of  future  studies. 
7.4  Study  design 
Two  groups  of  patients  with  ischaemic  heart  disease  (IHD)  were  given  increasing  doses  of 
1,2,4  and  4,6,8mcg.  kg-1  of  dofetilide,  respectively.  (A  third  group  was  to  receive  6,8, 
10mcg.  kg-',  but  this  arm of  the  study  was  closed  due  to  lack  of  recruitment).  The  healthy 
volunteers  received  1,67  1OItg.  kg-1  of  dofetilide. 
Individuals  were  given  three  escalating  doses  and  a  randomly  inserted  placebo  dose,  on  a 
single  blind  basis.  Each  dose  was  administered  via  a  syringe  driver,  as  an  infusion  over  30 
minutes.  A  one  week  washout  period  was  allowed  between  each  study  day. 
7.5  Data 
Eight  patients  were  recruited  into  each  of  the  two  patient  groups  and  the  healthy  volunteer 
group.  Three  females  were  recruited  into  the  study  (  two  were  healthy  volunteers).  A  total 
of  1594  plasma  samples  and  1416  measures  of  QTc  were  available  for  analysis.  Patient  10 
only  received  one  dose  and  placebo,  being  lost  to  follow  up  after  the  after  4mcg/kg  dose. 
210 Measurements  for  Patient  no  II  at  the  highest  dose  of  8mcg/kg  were  unobtainable,  for  the 
same  reason  . 
Table  7.1  summarises  the  demographic,  biochemical  and  the  pre-dose  QT/QTc  data  for  the 
healthy  volunteers  and  IHD  patients.  While  the  two  subgroups  were  matched  for  height 
and  age,  the  IHD  patients  were  significantly  heavier  (mean  difference  14.4kg)  than  the 
healthy  volunteers  (Table  7.1).  In  terms  of  clinical  biochemistry  the  two  groups  were  also 
well  matched.  However  the  mean  creatinine  clearance  (CLcr)  for  the  healthy  volunteers 
(68ml.  min-1)  was  significantly  lower  (P<0.005)  than  that  estimated  for  the  IHD  patients 
(92ml.  min-1)  Table  7.1.  There  was  no  difference  between  the  mean  predose  baseline 
QT/QTc  values. 
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N 7.6  Methods 
Modelling  was  implemented  using  both  the  first  order  (FO)  and  first  order  conditional 
estimation  (FOCE)  methods  (Chapter  3) 
7.6.1  Pharmacokinetics 
Intravenous  infusion  models  with  up  to  three  compartments  were  compared.  Models  were 
parameterised  using  micro  rate  constants,  with  a  central  compartment  volume  of 
distribution  also  being  estimated  in  each  case. 
7.6.2  Pharmacodynamics 
The  pharmacodynamic  measure  QT  was  corrected  for  heart  rate  (BR)  to  give  QTc  (the 
corrected  QT  interval)  using  Bazett's  fonnula  (Bazett,  1920) 
QTC  - 
QT 
-A-R 
where  RR  is  the  RR  interval  from  the  eletrocardiogram. 
The  placebo  response  was  smoothed  using  a  three  point  moving  average,  and  the  QTc 
measurements  were  corrected  by  subtracting  the  smoothed  placebo  response.  NEssing 
placebo  values  were  replaced  by  the  average  of  the  values  on  either  side.  After  placebo 
correction  the  QTc,  measurement  of  dofetilide  pharmacodynamic  response  was  modelled 
using  two  approaches.  In  the  first  instance  the  post-dose  QTc  measurements  were 
r 
corrected  by  subtracting  the  predose  measurements.  Change  in  QTc  was  modelled  as 
function  of  concentration  (C). 
A  QTc  =f  (C) 
In  a  second  set  of  models  the  baseline  was  included  as  an  additional  parameter 
i.  e.  A  QTc  =f  (C)  +  Baseline 
A  linear  and  an  Emax  model  were  used  as  functional  forms  for  f(C) 
213 7.6.3  PK/PD  modelling 
A  direct  relationships  between  compartmental  concentrations  and  QTc  was  initially 
considered.  However,  a  temporal  discrepancy  between  concentration  and  effect  i.  e. 
:  31% 
By  considering  drug  transfer  between 
the  central  compartment  and  the  effect 
compartment  to  be  governed  by  first 
hysteresis  (shown  in  adjacent  diagram)  was 
evident  in  the  QTc  vs  plasma  concentration 
plots 
The  relationship  was  therefore  modelled  using 
the  standard  effect  compartment  methodology 
described  previously  in  Chapter  1.2.3  and 
outlined  in  more  detail  below. 
Kjo 
4*. 
-  k12 
'N'  Peripheral  Central  <-- 
[Compartment 
Compartment 
I  K21 
order  processes,  the  change  in  the 
amount  of  drug  in  the  effect 
compartment  (Ae)  can  be  related  to 
the  amount  in  the  central  compartment  (A,  ) 
dAe 
-=A,  *Kle- 
Ae.  Keo 
dt 
where  KI,  and  Keo  are  first  order  rate  constants. 
Eq  7.1 
Since  Ae  cannot  be  directly  measured,  it  is  more  useful  to  relate  drug  effect  to  the 
concentration  in  the  plasma  compartment.  The  compartmental  amounts  can  be  replaced  by 
the  corresponding  volume  and  concentration  terms 
Ve. 
dCe 
VI*Kle  *C  -  Ve.  Keo.  Ce 
dt 
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Ki,  W 
Effect 
Compartment 
Eq  7.2 
Concentration where  V,  and  Ve  are  the  volume  of  distribution  terms  for  the  central  and  effect 
compartments,  respectively.  The  corresponding  drug  concentrations  for  the  drug  in  each 
compartment  are  given  by  C  and  Ce,  respectively. 
At  steady  state  there  is  no  net  transfer  of  drug  between  the  plasma  and  the  effect 
compartment  so 
dCe 
=0  and  the  right  side  of  Eq  7.2  must  therefore  be  equal  to  zero.  If  we  dt 
arbitrarily  define  Cess  =  Css  (Eq  7.3)  then  to  satisfy  Eq  7.2 
Ve.  Keo.  Ce 
ss  =  VI.  Kj,.  Css  Eq  7.4 
The  volume  of  distribution  for  the  effect  compartment  under  this  assumption  of  equal 
steady  state  concentrations  can  therefore  be  derived 
Ve  =  Vj. 
Kle 
Eq  7.5 
Keo 
Thus  Eq  7.2  may  be  written  as 
dCe 
-=  Keo(C  -  Ce)  Eq  7.6 
dt 
The  rate  constant  Keo  represents  the  loss  from  the  effect  compartment  and  characterises  the 
dis-equilibrium  between  C  and  the  measured  effect.  The  half-life  for  the  equilibrium  is 
therefore  0.693/Keo. 
The  differential  equation  Eq  7.6  could  be  used  to  simultaneously  fit  the  pharmacokinetic 
and  phannacodynamic  data.  Differential  equation  solvers  are  available  within  NONMEM, 
but  runtimes  can  be  vastly  increased  and  the  modelling  can  become  cumbersome.  In  this 
chapter,  the  PK  data  was  modelled  in  a  separate  step  to  the  estimation  of  Keo  and  the  PD 
model.  The  need  for  differential  equations  was  avoided  by  fixing  KI,  to  be  very  small  in 
comparison  to  the  other  rate  constants  (i.  e.  0.01  *  K10)  and  treating  the  effect  compartment 
as  an  extra  pharmacokinetic  compartment.  The  assumption  Ce,,  =  C, 
s  was  preserved  by 
utilising  Eq  7.5  in  the  NMTRAN  code  (Appendix  1.4). 
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Potential  differences  between  healthy  volunteers  and  IHD  patients  were  investigated  by 
estimating  separate  parameters  for  each  sub  group.  Relationships  between  the  various 
biochemical  or  demographic  covariates  and  the  individual  PK/PD  parameter  estimates 
were  investigated  (Chapter  3).  Both  weight  and  ideal  body  weight  were  considered.  Ideal 
body  weight  (IBW)  was  calculated  as  follows- 
IBW(men)  (kg)=  50  +0.91.  (height(cm)  -  152) 
IBW(men)  (kg)=  45  +0.91.  (height(cm)  -  152)  (Synder  et  al.  1975) 
Renal  function  was  assessed  by  calculating  the  serum  creatinine  clearance  (CLcr)  using  the 
Cockcroft  Gault  equation  (Rowland  &  Tozer,  1989a). 
CLcr  = 
(140 
-  Age)  x  Weight 
x  [1.23(male); 
orl.  04(female)] 
serum  creatinine 
where  age  is  in  years,  weight  in  kg  and  serum  creatinine  in  ýtmolll 
7.7  Results 
7.7.1  Noncom  partmental  pharmacokinetic  estimates 
Both  AUCO-i,,  f  and  Cmax  increased  in  proportion  to  the  administered  dose  (Figure  7.1a  & 
b).  The  slopes  for  the  two  linear  relationships  were  mean  (SE)  0.064ng.  hr.  rnl-'.  mcg-1  (2%) 
and  0.023ng.  ml-l.  mcg-1  (7%),  respectively.  A  small  negative  relationship  between  both 
dose  corrected  AUCO-i,,  f  and  Cmax  and  increasing  body  weight  could  be  shown  (Figure  7.2 
a&  b).  The  slopes  for  these  relationships  were  -4  hr.  ml-l.  kg-lx  10-7  (SE  42%)  and  -3  ml- 
l.  kg-lx 
10-7  (SE  16%),  respectively. 
216 Figure  7.1  Relationships  between  dose  and  a)  AUCO-i,  f  and  b)  Cmax 
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Weight  kg 7.7.2  Pharmacokinetics 
In  accordance  with  previous  studies  (section  7.1.4),  the  post  infusion  distribution  was 
shown  to  be  at  least  biexponential  (Figure  7.3).  Development  of  a  two  compartment 
population  phan-nacokinetic  model  is  shown  in  Table  7.2.  In  run  1,  the  intraindividual 
variability  component  was  modelled  using  the  exponential  expression  (Chapter  3),  and  the 
parameters  were  estimated  using  the  FO  method.  In  run  2,  the  combined  expression  for 
intraindividual  variability  was  utilised,  but  the  parameters  were  still  estimated  using  the  FO 
method.  The  large  decrease  in  the  value  of  the  objective  function,  combined  with  the 
greater  degree  of  precision  in  the  parameter  estimates,  especially  the  interindividual 
variability,  indicated  that  the  second  error  structure  was  more  appropriate.  However,  using 
the  model  described  in  run  2,  there  was  a  significant  bias  in  the  weighted  residuals  as 
shown  in  Figure  7.4  a  and  b.  In  run  3,  this  bias  was  removed  by  using  the  FOCE  method 
to  estimate  the  population  parameters  as  shown  in  Figure  7.5  a  and  b.  A  decrease  in 
variability  and  increase  in  the  precision  of  the  parameter  estimates  was  associated  with  the 
improvement  in  fit.  There  was  no  indication  in  the  residuals  that  a  more  complex  model 
was  required  (Figure  7.5b).  As  expected,  using  a  three  compartment  model  did  not  further 
improve  fit,  so  the  two  compartment  model  was  deemed  to  be  the  most  appropriate  model. 
In  run  4,  the  FOCE  method  was  retained  but  the  additive  expression  from  the 
intraindividual  variability  component  was  removed.  The  large  increase  in  objective 
function  indicated  that  although  small  (0.05ng.  ml-1)  and  imprecisely  estimated,  the  additive 
component  was  important  to  the  model  fit.  In  run  5,  the  precision  of  the  interindividual 
variability  estimates  for  K10  and  V,  were  improved  by  removing  the  interindividual 
variability  term  from  the  estimation  of  K12.  However,  the  large  increase  in  objective 
function  indicated  that  the  reduced  model  complexity  resulted  in  a  compromised  fit. 
219 Figure  7.3  Mean  log  concentration  over  a)  50  hours  and  b)  5)  hours 
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223 7.7.3  Interaction  vs  no  interaction  with  FOCE  method 
The  population  parameters  estimated  using  the  "no  interaction"  option  were  different  to 
those  estimated  using  the  "interaction"  option  (Table  7.2  run  6  vs  run  3).  This  was  most 
easily  demonstrated  by  comparing  CL 
,  Q,  Vss,  TI/2cc 
and 
TI/20 
obtained  for  each  method 
(table  7.3).  The  derived  population  terminal  and  distributional  half-life  estimates  were 
very  similar.  However,  the  clearance  (CL),  inter  compartmental  clearance  (Q)  and  volume 
of  distribution  at  steady  state  (Vss)  estimates  were  different  for  the  two  methods 
(Table7.3). 
Table  7.3  Derived  CL,  Q,  Vss,  TI/2(X  and  TI/2p  for  the  FOCE  interaction  (run3)  and 
FOCE  nointeraction  (run  6)  methods 
Run  Method  CL  Q  VSS  T1/2  (X  T1/2  P  L.  hr-l  L.  hr-l  L  i  -'  h  -1  m  n  r 
3  FOCE  15.2  198  185  2.5  8.9 
interaction 
6  FOCE  19.0  186  217  2.2  9.0 
nointeraction  I 
As  previously  discussed,  the  objective  functions  are  estimated  differently,  so  method 
comparison  has  to  be  based  on  goodness  of  fit  plots  (Chapter  3).  Figure  7.6  shows  the 
residual  plots  for  each  method  grouped  by  sample  times.  The  "no  interaction"  method 
showed  a  slight  positive  bias  at  the  0.67,0.83,1.0,1.25  and  1.5  time  points  i.  e  during  the 
first  hour  post  infusion.  The  SE's  estimated  by  this  method  were  also  larger  than  those 
estimated  using  the  "interaction"  method  (Table  7.2).  So  both  model  fit  and  parameter 
precision  were  better  when  the  "interaction"  method  was  used. 
Therefore,  a  two  compartment  model,  incorporating  both  additive  and  exponential 
components  for  intraindividual  variability,  and  using  the  FOCE  with  "interaction" 
estimation  method  was  considered  to  best  describe  the  pharmacokinetics  (run  3  Table  7.2). 
224 Figure  7.6  Residuals  versus  time  for  the  a)  Interaction  (run  3)  and  b)  No  interaction  (run  6) 
FOCE  methods  used  for  the  two  compartment  pharmacokinetic  model. 
Horizontal  line  and  boxes  indicate  median  and  interquartile  range  (QI-Q3),  respectively. 
The  whiskers  extend  to  the  lowest  and  highest  values  that  are  still  inside  the  region  defined 
by  Q1  -  1.5.  (Q3  -  Q1)  to  Q3  +  1.5.  (Q3  -  Q1).  The  *'s  indicate  values  which  lie  outside  this 
interval. 
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While  the  pharmacostatistical  model  can  be  developed  using  any  parameterisation, 
prospective  application  of  covariate  relationships  is  more  intuitive  when  they  are  related  to 
parameters  that  have  a  physiological  basis  (Chapter  3).  Further  modelling  was  undertaken 
using  models  parameterised  in  terms  of  volume  of  distribution  and  clearance  using 
standard  relationships  within  NMTRAN.  The  individual  parameter  estimates  from  run  3 
Table  7.2  are  shown  by  subject  group  in  Table  7.4.  The  average  estimates  of  V,  and  Vss 
were  respectively  lower  and  higher  in  the  IHD  patients,  however,  these  differences  were 
not  found  to  be  statistically  significant  (run  7  to  10  Table  7.5). 
7.7.5  Covariate  analysis 
Graphical  analysis  identified  four  possible  covariate  relationships:  Vss  with  both  body 
weight  and  ideal  body  weight  (Figure  7.7  a  and  b)  and  CL  with  both  CLcr  and  body  weight 
(Figure  7.8  a  and  b).  The  importance  of  these  relationships  was  tested  using  the  series  of 
models  described  in  Table  7.6.  In  accordance  with  the  relationship  between  dose  corrected 
Cmax  and  body  weight  (section  7.7.1),  relating  Vss  to  body  weight  significantly  decreased 
the  objective  function  (run  II  Table  7.6).  The  comparison  between  run  12  and  run  13 
demonstrates  that  the  relationship  was  dependent  on  the  association  between  body  weight 
and  the  volume  of  distribution  of  the  peripheral  M)  rather  than  the  central  compartment 
(Vi).  The  difference  in  the  relationships  is  shown  graphically  in  Figure  7.9.  The  decrease 
in  the  %CV  (wvss)  of  3.5%  (run  11  v  run  3,  Table  7.6)  after  inclusion  of  body  weight  is 
equivalent  to  a  33%  reduction  in  the  variability  in  Vss  (O)VSS2) 
. 
The  variability  was  not 
further  reduced  by  modelling  Vss  as  a  function  of  ideal  body  weight  (run  14  Table  7.6). 
226 Table  7.4  Summary  of  the  individual  distribution  half-life,  terminal  half-life  and  volume 
parameters  (VI  and  Vss)  split  by  healthy  volunteers  and  IHD  patients 
IHD  Group  Volunteer  Group 
ID  TI/2  T1/2  Vss  Vi  ID  T1/2  T1/2  Vss  Vi 
cc  P  (L)  (L)  cc  P  (L)  (L) 
(mins  )  (hrs)  (mins)  (hrs) 
1  2.4  8.9  215  11.4  17  2.5  9.2  236  16.5 
2  2.4  10.5  204  11.6  18  3.2  8.8  151  13.3 
3  2.7  8.8  231  14.7  19  2.2  9.7  227  16.4 
4  3.0  8.0  160  14.6  20  3.1  10.9  137  12.2 
5  2.8  9.2  181  15.9  21  2.4  9.8  210  16.1 
6  2.5  8.3  222  18.9  22  2.6  9.3  163  13.7 
7  2.6  11.3  171  13.2  23  4.0  8.1  112  11.8 
8  1.9  9.2  194  11.9  24  3.0  8.2  196  16.5 
9  3.7  9.4  257  31.4 
10  2.9  6.8  169  17.0 
11  2.1  7.7  220  15.7 
12  2.3  8.7  139  10.5 
13  2.4  10.0  192  14.0 
14  0.5  9.8  188  2.2 
15  2.7  8.8  205  13.3 
16  2.6  8.8  179  18.4 
Median  2.5  8.9  194.0  14.0  2.6  9.2  179.2  16.1 
Mean  2.4  9.0  196.6  14.4  2.8  9.2  179.1  15.0 
SD  0.7  1.1  30.4  6.0  0.6  0.9  42.1  2.3___a 
227 Table  7.5  Comparison  between  the  population  phan-nacokinetic  parameters  for  healthy 
volunteers  and  IHD  patients  using  the  FOCE  with  interaction  estimation  method 
Run  I  Parameter 
Tested 
Run3 
Parameter 
Estimate 
Parameter 
Estimate  for 
the  IHD 
Group 
Parameter 
Estimate  for 
the  Volunteer 
Group 
Obj 
Fun 
A  Obj 
Fun 
2 
LRT3 
7  CL  (L.  hr-  15.2  16  13.9  -3002.58  -2.23  P<O.  15 
(SE%)  (4)  (5)  (8) 
8  V,  (L)  13.5  12.4  15.1  -3000.86  -0.51  P<0.5 
(SE%)  (14)  (20)  (4) 
9  Vss  (L)  185  193  174  -3001.90  -1.55  P<0.3 
(SE%)  (4)  (4)  (9) 
10  Q  (L.  hr-  198  200  195  -3000.41  -0.11  P<0.8 
(SE%)  (5)  (6)  (9) 
1)  Differences  in  the  parameter  estimates  between  the  groups  are  tested  individually  in 
runs  7-  10  by  comparing  them  to  run  3. 
2)  Comparison  with  objective  function  from.  run  3  Table7.2 
3)  LRT  =  Likelihood  Ratio  Test 
228 Figure  7.7  Covariate  relationships  between  Vss  and  a)  Body  weight  and  b)  Ideal  body 
weight.  The  closed  circles  represent  the  healthy  volunteers  and  the  open  circles  the  IHD 
patients. 
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232 While  modelling  CL  as  a  function  of  I/SCRT  did  not  decrease  the  objective  function  (run 
15  Table  7.6)  there  was  a  significant  reduction  when  CL  was  modelled  as  a  function  Of 
body  weight  (run  16  Table  7.6).  An  absolute  reduction  in  O)CL  of  3.4%  indicated  that  30% 
of  the  variability  in  CL((OCL  2) 
could  be  explained  by  body  weight.  Inclusion  of  CLcr  in  the 
CL  model  significantly  reduced  the  objective  function  (run17  Table  7.6)  but  the  slope  of 
the  resultant  model  was  not  significantly  different  from  zero  (SE  >50%CV).  The 
relationship  between  body  weight  and  CL  is  consistent  with  the  association  between 
AUCO-i,,  f  and  body  weight  (section  7.7.1). 
When  both  Vss  and  CL  were  related  to  body  weight,  a  further  significant  reduction  in  the 
objective  function  was  observed  (run  18  vs  run  II  Table  7.6),  and  the  valuesOf 
05 
1 
06 
,W 
CL  and  wvss  were  consistent  with  the  previous  estimates  (run  18  vs  run  11  &  run  17  Table 
7-6).  Allowing  for  a  covariance  between  CL  and  Vss  did  not  alter  the  selection  of  body 
weight  as  a  significant  covariate  of  each.  Run  18  was  therefore  the  final  covanate  model 
for  the  phannacokinetics  of  dofetilide.  The  relationships  between  Vss  and  CL,  and  body 
weight  are  equivalent  to  1.5L.  kg-l  +  68L  and  0.1  14L.  hr-1.  kg-1  +  6.4L.  hr-1,  respectively. 
7.7.6  Pharmacodynarnic  analysis 
The  mean  QTc  time  profile  shown  in  Figure  7.10  was  consistent  with  that  for  the 
individual  subjects.  The  maximum  measured  QTc  interval  increased  in  proportional  to  the 
administered  dose  (Figure  7.1  1a).  Although  the  variability  in  Tmax  for  the  QTc  interval 
decreased  with  increasing  dose,  there  was  no  indication  of  a  relationship  between  the  mean 
Tmax  and  dose  (figure  7.1  1b),  indicating  that  the  lag  between  concentration  and  QTc 
response  (Figure  7.12a)  is  likely  to  be  due  to  a  delay  in  the  distribution  of  dofetilide  to  the 
site  of  drug  effect.  Since  the  plot  of  QTc  versus  the  population  predicted  peripheral 
compartment  concentration  showed  a  proteresis,  distribution  into  the  peripheral 
pharmacokinetic  compartment  occurs  at  a  slower  rate  than  the  accumulation  at  the  site  of 
233 drug  effect  (Figure  7.12b).  Therefore,  the  small  temporal  delay  between  the  observed 
concentration  and  QTc  response  requires  an  effect  compartment  model  and  the  half-life  of 
the  delay  between  plasma  concentration  and  effect  should  be  between  the  distribution  and 
terminal  phase  half-lives  (2.5  minutes  to  8.9  hours). 
Figure  7.10  Mean  QTc  versus  Time.  Vertical  line  indicates  the  planned  time  for  the  end  of 
the  infusion. 
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1 
7.11  a)  Maximum  achieved  QTc  interval  versus  administered  dose  (slope  of  linear 
regression  was  0.12  msecs.  mcg-'  )  b)  Time  for  the  maximum  achieved  QTc  interval  versus 
administered  dose 
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235 Figure  7.12  Mean  placebo  corrected  QTc  versus  a)  The  mean  measured  concentration  b) 
The  population  predicted  peripheral  compartment  concentration.  The  arrows  show  the 
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236 7.7.7  PK/PD  analysis 
Development  of  the  population  pharmacodynamic  model  is  shown  in  Table  7.7.  In  Run  19, 
the  relationship  between  baseline  corrected  QTc  and  the  concentration  in  the  effect 
compartment  (Ce)  was  described  using  a  linear  relationship,  the  intraindividual  variability 
component  was  described  using  a  combined  error  model,  and  the  parameters  were 
estimated  using  the  FOCE  with  "interaction"  method  (Chapter  3).  The  estimates  of  42% 
and  22msecs  for  the  exponential  and  additive  variability,  respectively,  and  are  equivalent  to 
40msecs  at  predicted  QTc  prolongation  of  50msecs.  In  Run  20,  the  introduction  of  an 
additional  parameter  to  model  the  placebo  corrected  baseline  QTc  significantly  decreased 
the  intraindividual  variability  and  the  objective  function  (A-655).  The  estimates  for  the 
exponential  and  additive  components  were  12%  and  20msecs,  respectively,  are  equivalent 
to  26  msecs  at  predicted  QTc  prolongation  of  50  msecs.  While  the  parameter  estimate  for 
the  slope  of  the  concentration  response  relationship  was  unchanged,  the  Keo  estimate  was 
increased  from  1.29hr-1  to  3.85  hr-1  and  the  half-life  of  the  hysteresis  was  decreased  from 
0.5  to  0.2  hours.  Therefore,  the  variability  in  baseline  has  more  affect  on  the  temporal 
displacement  estimate  than  the  slope  estimate,  which  characterises  the  sensitivity  of  the 
myocardium  to  dofetilide. 
The  standard  error  for  the  exponential  component  was  large  (SE%  >  100%)  indicating  that 
the  estimate  was  not  significantly  different  from  zero.  Run  21  was  a  repeat  of  run  20  with 
intraindividual  variability  being  described  using  the  additive  expression  only.  Since  the 
increase  in  the  objective  function  was  not  significant,  the  simpler  form  was  retained  and  the 
specification  of  "interaction"  or  "no  interaction"  was  no  longer  required. 
In  run  22,  an  Emax  relationship  was  modelled  using  the  same  intraindividual  vanability 
model.  A  further  reduction  in  objective  function  was  achieved  but  the  Emax  and  Ce50were 
estimated  with  less  precision  than  the  slope  parameter  of  the  linear  model. 
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N The  individual  parameter  estimates  for  linear  and  Emax  models  are  shown  in  Table  7.8. 
Notably,  the  Keo  and  the  slope  (at  Ce50  i.  e.  Emax/Ce50)  were  largest  for  the  Emax.  The 
reduced  precision  with  the  Emax  model  is  most  likely  due  to  the  largest  predicted  Ce  for 
the  majority  of  individuals  being  much  lower  than  the  estimated  Ceýo  Figures  7.13  -7.15 
show  that  the  Emax  model  is  essentially  linear  over  the  observed  Ce  range  for  most 
individuals  (individuals  43  and  44  are  possible  exceptions).  The  slope  of  the  Emax  model 
at  Ce50  is  therefore  not  comparable  to  the  slope  of  the  linear  model.  The  linear  model  for 
the  prolongation  of  QTc  is  therefore  the  most  appropriate  for  the  majority  of  individuals 
over  the  dose  range  investigated. 
239 Table  7.8  Individual  parameter  estimates  for  QTc  prolongation 
Emax  Model  -  Linear  Model 
ID  Keo  Baseline  Emax  Ce50  Emax/  Keo  Baseline  Linear 
hr-1  msecs  msecs  ng  ml-1  Ce50  hr"  msecs 
msecs.  ml.  msecs.  ml 
I  ng-1  ng-1 
IHD 
1  4.09  -7.01  217.36  6.08  35.74  3.89  1.02  21.07 
2  4.64  -4.81  166.13  10.15  16.36  3.90  0.71  12.49 
3  4.27  -3.06  146.50  8.69  16.85  3.49  1.26  12.54 
4  3.72  -10.77  186.72  7.14  26.15  3.41  0.66  14.43 
5  2.80  -8.40  225.76  6.14  36.75  2.94  0.99  21.09 
6  5.27  -4.77  210.83  4.98  42.33  4.65  2.75  24.60 
7  4.75  -13.53  153.85  7.28  21.13  3.70  0.47  10.76 
8  4.50  -4.39  160.88  5.82  27.66  3.73  1.63  16.72 
13  4.55  -3.90  172.58  3.86  44.75  4.05  16.62  17.73 
15  4.27  -400  186.88  500  37.39  3.78  11.84  17.52 
16  4.84  -7.80  188.66  5.99  31.49  4.25  1.39  18.03 
17  7.78  -11.13  184.33  5.97  30.87  6.07  1.74  15.17 
18  4.82  -1600  215.68  6.62  32.58  4.18  0.95  16.18 
19  3.33  -6.24  191.48  8.77  21.84  2.90  1.18  13.76 
20  4.03  -8.44  202.96  5.13  39.55  3.45  5.32  19.36 
21  4.28  -5.80  188.22  5.73  32.82  3.52  3.51  18.54 
Median  4.39  -6.63  187.55  6.04  32.03  3.75  1.33  17.12 
Mean  4.50  -7.50  187.43  6.46  30.89  3.87  3.25  16.87 
SD  1.07  3.73  23.33  1.63  8.65  0.74  4.55  3.66 
VOL 
37  8.22  -2.44  156.88  8.87  17.69  5.87  3.13  11.91 
38  4.51  -4.90  209.05  6.26  33.40  3.71  7.38  15.71 
39  4.87  -9.07  442.42  14.04  31.50  4.49  0.80  21.80 
40  4.22  -3.99  142.27  4.94  28.82  3.02  4.21  14.83 
41  3.94  -3.78  232.38  7.93  29.31  3.29  3.60  17.72 
42  3.68  -6.11  421.83  14.60  28.90  3.41  0.92  21.11 
43  4.39  -37.58  189.88  2.12  89.74  3.27  0.91  19.58 
44  4.91  -3.01  121.63  1.13  107.61  3.44  30.70  16.71 
Median  4.45  -4.45  199.47  7.09  30.41  3.43  3.36  17.21 
Mean  4.84  -8.86  239.54  7.49  45.87  3.81  6.46  17.42 
SD  1.43  11.79  124.23  4.97  33.26  0.94  10.04  3.34 
All 
Median-  4.44  -5.96  188.44  6.11  31.49  3.71  1.51  17.12 
Mean  4.61  -7.96  204.80  6.80  35.88  3.85  4.32  17.06 
Sd  1.18  7.20  75.38  3.08  20.92  0.79  6.82  3.49 
240 Figure  7.13  Individual  placebo  corrected  QTc  prolongation  and  predicted  Emax  response 
versus  effect  compartment  concentration  for  the  IHD  patient  group  recieving  doses  1,2.4 
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241 Figure  7.14  Individual  placebo  corrected  QTc  prolongation  and  predicted  Emax  response 
versus  effect  compartment  concentration  for  the  IHD  patient  group  recieving  doses  4,6,8 
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Effect  Compartinut  CoacentmOm  nWl Figure  7.15  Individual  placebo  corrected  QTc  prolongation  and  predicted  Emax  response 
versus  effe  ct  compartment  concentration  for  the  health  volunteers  recieving  doses  1,6,10 
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243 7.7.8  Healthy  volunteer  vs  IHD 
Differences  in  the  baseline,  Keo  and  slope  parameters,  between  healthy  volunteers  and 
IHD  patients,  were  formally  tested  using  the  linear  model  (run  21,  Table7.7).  None  of  the 
parameter  differences  between  the  two  groups  were  found  to  be  significantly  different  (runs 
23,24  and  25,  Table  7.9).  Graphical  analysis  did  not  demonstrate  any  correlation  between 
the  investigated  covariates  and  the  individual  parameter  estimates  of  the  pharmacodynamic 
model. 
Table  7.9  Comparison  between  the  population  pharmacodynamic  parameters  for  healthy 
volunteers  and  IHD  patients  using  the  FOCE  with  interaction  estimation  method 
Run  Parameter  Run  21  Parameter  Parameter  Obj  A  Obj  LRT 
3 
Tested  Parameter  Estimate  for  Estimate  for  Fun  Fun 
2 
Estimate  the  IHD  the 
Group  Volunteer 
Group 
23  Keo  (hr-1)  3.79  3.68  3.86  9590  -0.07  p<0.8 
(SE%)  (14)  (19)  (14) 
24  Baseline  1.61  3.02  0.99  9589  -1.26  P<0.3 
(msecs) 
(SE%)  (88)  (71)  (111) 
25  Linear  16.9  17.50  16.60  9590  -0.2  p<0.7 
(msecs.  ml-1) 
(SE%)  (7)  (8)  (8) 
1)  Differences  in  the  parameter  estimates  between  the  groups  are  tested  individually  in 
runs  23  -  25  by  comparing  them  to  run  21. 
2)  Comparison  with  objective  function  from.  run  21  Table7.7 
3)  LRT  =  Likelihood  Ratio  Test 
244 7.8  Predictions  and  simulations 
7.8.1  Comparison  of  a  dose  per  kilogram  regimen  and  a  fixed  dose  regimen 
for  termination  of  arrhythmia  with  an  IV  infusion 
The  influence  of  body  weight  on  Cmax  following  different  0.5  hr  infusion  regimens 
using  the  average  PK  model 
Based  on  the  final  average  PK  model  prior  to  inclusion  of  the  covariates  (run  3),  the 
predicted  average  concentration  time  profiles  after  an  arbitrary  dose  of  12  mcg.  kg-l.  hr-1  are 
shown  for  a  body  weight  range  of  50  to  100  kg  in  Figures  7.16  a.  Since  the  dose  for  the 
100kg  subject  would  be  twice  that  for  the  50  kg  subject,  the  average  peak  concentration 
would  be  predicted  to  be  100%  larger  in  subjects  weighing  100kg  (Figures  7.16  a).  After 
correcting  for  the  relationships  between  body  weight  and  CL  and  Vss  identified  in  the  final 
covariate  model  (Table  7.6  run  18),  the  peak  concentration  was  still  predicted  to  be  70% 
higher  in  subjects  weighing  100kg  in  comparison  to  subjects  weighing  50  kg  (Figure  7.16 
b).  The  range  in  the  predicted  peak  concentration  across  body  weight  could  be  further 
reduced  by  using  a  fixed  dose  regimen.  In  this  case  the  peak  concentration  would  be 
predicted  to  be  17%  lower  in  subjects  weighing  100kg  in  comparison  to  subjects  weighing 
50kg  (Figure  7.16  c).  Therefore,  based  on  the  covanate  model  it  was  predicted  that  the 
narrowest  range  in  peak  concentrations  would  be  achieved  by  using  a  fixed  dose  regimen. 
However,  this  conclusion  depends  on  the  accuracy  of  the  covariate  relationships.  A 
sensitivity  analysis  was  performed  to  test  whether  the  slope  of  the  relationship  between  Vss 
and  body  weight  altered  the  above  conclusion.  Even  when  the  slope  for  the  relationship 
between  Vss  and  body  weight  was  as  high  as  2.4L.  kg-l  (i.  e.  intercept  was  zero)  the  peak 
concentrations  following  the  per  kilogram  dosing  strategy  were  still  predicted  to  be  57% 
higher  in  100kg  subjects  compared  to  50kg  subjects  (Figure  7.17  a). 
245 Figure  7.16  The  populaton  mean  predicted  concentration  time  profiles  over  the  body 
weight  range  of  the  study  for  a  30  minutes  infusion  of  a)  l2mcg.  kg-1.  hr-'  assuming  no 
relationship  between  CL,  Vss,  V,  and  WT,  b)  12mcg.  kg-l.  hr-1  assuming  the  modelled 
relationships  between  WT  and  CL  and  Vss  i.  e.  slopes  of  0.1  14L.  hr-  I  kg-1  andl.  52L.  kg-1,  c) 
a  fixed  dose  (12mcg.  kg-'.  hr-lx  77.9kg  )  assuming  the  modelled  relationships  between  WT 
and  CL  and  Vss  i.  e.  slopes  of  0.1  14L.  hr-l.  kg-1  and  1.52L.  kg-1 
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246 Figure  7.17  The  populaton  mean  predicted  infusion  profiles  for  (a)  a  30  minutes  infusion 
of  12mcg.  kg-l.  hr-1  over  the  body  weight  (WT)  range  for  the  study:  assuming  the  slope  for 
Vss  was  2.4L.  kg-1  and  b)  a  fixed  dose  (12mcg.  kg-l.  hr-lx  77.9kg  )  for  all  weights  assuming 
the  slope  for  Vss  was  2.4L.  kg-'.  The  estimated  slope  for  CL  vs  body  weight  i.  e.  0.1  14L.  hr- 
1.  kg-1  was  used  in  each  case 
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Time  Hours In  companson,  the  peak  concentrations  following  the  fixed  dose  regimen  were  predicted  to 
be  27%  lower  in  100kg  subjects  compared  to  50kg  subjects  (Figure  7.17  b).  While  the 
spread  in  concentration  following  the  dose  per  kilogram  regimen  occurs  over  the  initial 
0.16  hr  (up  to  the  dashed  line  Figures  7.16a,  7.16b  and  7.17.  a),  the  concentrations 
following  the  fixed  dose  regimen  are  narrowest  over  this  period  (up  to  dashed  vertical  line 
Figures  7.16c  and  7.17b).  The  variability  at  the  end  of  the  0.5  hr  infusion  is  more 
dependent  on  the  initial  volume  of  distribution  (VI)  than  Vss  and  therefore,  the  relationship 
between  V,  and  body  weight.  In  the  present  analysis,  V,  was  not  influenced  by  body 
weight,  so  the  predicted  concentration  range  was  narrowest  when  dose  was  fixed  across 
body  weight. 
The  influence  of  body  weight  and  infusion  time  on  peak  QTc  using  the  average 
PK\PD  model 
The  predicted  QTc  following  a  fixed  600  mcg  dose  (Figure  7.18)  and  a  7.7mcg.  kg-1  dose 
(Figure  7.19)  over  infusion  times  of  1,15,30  and  45  minutes  were  compared  using  the 
final  average  PK/PD  model  (combination  of  population  parameters  from  run  18  and  run 
21).  For  mean  study  weight  (77.9  kg),  the  total  amount  administered  is  the  same  for  both 
regimens.  Since  a  linear  pharmacodynamic  model  was  used,  it  rnimicked  the  differences  in 
plasma  concentrations,  so  it  is  not  surprising  that  the  range  of  peak  QTc  intervals  was 
predicted  to  be  narrower  with  the  fixed  dose  regimen.  As  expected,  the  peak  QTc  interval 
was  predicted  to  be  inversely  related  to  the  rate  of  adrninistration  and,  therefore,  the  length 
of  the  infusion.  However,  the  duration  of  infusion  affected  the  expected  range  in  peak 
predictions  for  each  regimen  differently.  While  there  was  a  slight  widening  of  the 
predicted  range  of  peak  QTc's  with  increasing  infusion  duration  with  the  fixed  dose 
regimen  (figure  7.18),  a  considerable  narrowing  was  predicted  for  the  per  kilogram 
regimen  (figure  7.19).  Therefore,  the  difference  in  the  predicted  ranges  of  peak  QTc  was 
less  with  the  longer  infusions. 
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0 The  influence  of  body  weight  and  infusion  time  on  Cmax  and  QTc  via  simulations 
utilising  the  population  parameter  estimates 
As  before,  a  fixed  600  mcg  dose  and  a  7.7mcg.  kg-1  dose  infused  over  1,15,30  and  45 
minutes  were  compared.  However,  in  this  instance  the  full  PK/PD  model  (mean  and 
variance  estimates  from  runs  18  and  21)  was  used  to  simulate  the  Cmax  and  peak  QTc  for 
1000  subjects.  Body  weight  was  randomly  sampled  from  a  normal  distribution  with  mean 
and  SD  equal  to  77.9  and  13.9kg,  respectively.  The  results  are  shown  in  Table  7.10.  In 
contrast  to  the  results  with  the  average  PK/PD  model,  the  differences  between  the  two 
dosing  strategies  were  much  less  obvious.  While  the  SD  and  5-95thpercentile  range  for  the 
Cmax  and  peak  QTc  (%change  QTc)  were  still  larger  for  the  dose  per  kilogram  regimen, 
the  differences  were  less  than  would  be  expected  from  the  comparisons  shown  in  Figures 
7.16  -  7.19.  As  before  the  difference  between  the  SD's  and  5-95  th  percentile  ranges 
became  less  as  the  infusion  time  increased. 
As  previously  discussed  (see  Section  7.1.6),  there  is  an  increased  risk  of  UP  when  QTc 
intervals  are  prolonged  to  greater  than  25%  from  baseline  or  to  absolute  values  Of  greater 
than  560msecs.  The  risk  following  a  fixed  600mcg  dose  and  a  7.74mcg.  kg-l  dose  infused 
over  1,15,30  and  45  minutes  were  compared.  The  percentage  of  subjects  exceeding  the 
criteria  for  increased  risk  of  UP  are  also  shown  in  Table  7.10. 
Following  the  one  minute  infusion,  almost  all  subjects,  regardless  of  dosage  regimen,  were 
predicted  to  be  at  nsk  of  TdP.  As  expected,  the  percentage  at  risk  was  predicted  to 
decrease  with  increasing  infusion  time.  However,  even  the  percentage  at  risk  after  a  45 
minute  infusion  (24-25%\67%-69%)  was  still  unacceptably  large,  and  lower  doses  would 
be  required.  For  this  population,  the  percentage  change  in  QTc  criterion  (>25%)  was  found 
to  be  more  sensitive  than  the  absolute  value  criterion  (>560msecs).  The  percentage  at  risk 
in  the  whole  population  was  very  similar  for  the  two  regimens  across  all  infusion  times. 
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cli The  lack  of  difference  was  due  to  the  overall  shape  of  the  two  resultant  distributions. 
For  example,  the  distribution  of  peak  QTc  following  the  30  minute  infusion  (Figure 
7.20)  demonstrated  that,  although  there  was  a  larger  number  of  patients  with  peak 
QTc  >  670msecs  dosed  according  to  the  per  kilogram  regimen,  a  larger  number  of 
patients  with  peak  QTc  between  560  and  670msecs  were  dosed  according  to  the  fixed 
dose  regimen.  Together,  approximately  the  same  number  of  patients  were  predicted 
to  have  peak  QTc's  >  560msecs.  Nevertheless,  the  relationship  between  percentage 
at  risk  (defined  using  either  criterion)  and  body  weight  was  different  for  the  two 
regimens  and  the  differences  became  more  apparent  as  the  infusion  time  increased 
(Table  7.10).  Not  surpnsingly,  patients  with  high  body  weight  >91.8  Kg  (mean 
+ISD)  were  predicted  to  be  at  much  greater  risk  when  dosed  according  to  the  per 
kilogram  regimen.  Although  patients  with  low  body  weight  <64Kg  (mean  -1SD) 
were  predicted  to  be  at  greater  nsk  when  dosed  according  to  the  fixed  dose  regimen, 
the  increase  over  that  for  the  whole  population  was  small  i.  e.  For  the  30  minute 
infusion  54%  vs  46%  for  the  absolute  value  criterion  and  82%  vs  82%  for  percentage 
change  criterion,,  respectively. 
253 COD 
m 
0 
+-4 
zi 
Cý4 
0 
0 
0 
40- 
U 
F--4 
Cý 
9ý;  8< 
9/-8 
stle 
9[2 
98/ 
99L 
SýV 
969  to 
999 
999 
909 
SL9 
StIg 
9L9 
sev 
991V 
sz;  v 
ýt 
0000  C)  00 
LO  0  LO  0  LO  0  LO 
C\j  C\j  V- 
slc);  alqnS  jo  jaqwnN 7.8.2  Steady  state  infusions  and  risk  of  TdP 
Maintenance  therapy  with  dofetilide  for  the  prevention  of  arrhythmias  will  require  the 
development  of  an  oral  formulation 
. 
While  the  absorption  characteristics  of  dofetilide  are 
needed  to  predict  an  oral  dosage  regimen,  it  is  possible  to  use  the  current  model  to  predict 
the  number  of  subjects  who  would  be  at  risk  of  UP  at  various  Css  concentrations,  and 
thereby  predict  the  maximum  tolerated  Css.  QTc  intervals  were  predicted  for  various 
target  steady  state  concentrations  (I  to  20  ng.  ml-1)  using  the  individual  parameter  estimates 
for  the  linear  pharmacodynamic  model  (Table  7.8).  The  cumulative  percentage  of 
individuals  with  prolongations  greater  than  560msecs  or  +%25  from  baseline  were 
predicted.  These  were  used  to  predict  the  percentage  of  subjects  with  an  increased  risk  of 
UP  (Figure  7.21).  The  steep  slopes  define  tight  upper  liM]ts  for  the  Css.  An  increased 
risk  would  appear  to  occur  with  concentrations  above  4  ng.  ml-1  for  the  >+25%  criteria  and 
above  6  ng.  ml-1  for  the  >560  msecs  criteria  (Figure  7.21).  The  percentage  change  from 
baseline  criteria  was  again  shown  to  be  the  most  sensitive  criteria. 
Figure  7.21  Cummulative  frequency  of  individuals  exceeding  safety  limits  for  QTc 
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This  analysis  has  demonstrated  that  the  dose  concentration  effect  relationship  for  dofetilide 
is  the  same  in  healthy  volunteers  and  IHD  patients.  In  general,  much  of  early  drug 
development  is  based  on  there  being  a  concordance  between  healthy  volunteers  and 
patients  with  IHD.  For  example,  the  maximum  tolerated  dose  and  dose  ranges  for  future 
patient  studies  are  determined  through  investigation  in  healthy  volunteers  (see  chapter  4). 
Furthermore,  clinical  pharmacology  studies  undertaken  throughout  drug  development  (i.  e. 
drug  interaction,  food  effect  and  bioequivalence  studies)  routinely  utilise  healthy  volunteers 
as  substitutes  for  the  target  patient  population  (see  chapter  5).  It  is  therefore  important  that 
potential  differences  in  the  PK/PD  relationship  for  patients  and  healthy  volunteers  are 
investigated  at  an  early  stage  in  the  drug  development  process. 
While  phannacokinetics  and  pharmacodynamics  for  patients  and  healthy  volunteers  are 
similar  for  most  marketed  drugs,  there  have  been  some  notable  exceptions  (Smith  et  al.. 
1983;  Boyd  et  al.  1989).  In  such  cases  it  may  be  possible  to  use  an  integrated  PK/PD 
model  to  adjust  for  differences,  so  that  inferences  for  the  target  population  could  still  be 
made  from  investigations  in  healthy  volunteers. 
7.9.1  Pharmacokinetic  analysis 
The  bias  in  the  fit  of  concentration  data  using  the  FO  method  can  occur  when  models  are 
highly  non-linear  (Chapter  3),  as  demonstrated  with  the  multiple  dose  three  compartment 
model  (chapter  4.5.2).  However,  the  single  dose  two  compartment  model  used  in  this 
Chapter  is  relatively  linear  in  comparison.  The  large  number  of  observations  per  individual 
(average  66  per  patient)  may  have  caused  the  FO  method  to  be  particularly  unstable  and 
sensitive  to  inaccurate  starting  estimates.  Rerunning  the  FO  method  using  the  parameters 
calculated  by  the  FOCE  method  did  not  reduce  the  bias.  The  value  of  the  FOCE  method  in 
population  analysis  is,  therefore,  further  highlighted. 
256 A  combined  exponential  and  additive  model  provided  the  best  fit  to  the  data.  The  SD  of 
the  additive  component  was  estimated  to  be  very  similar  to  the  limit  of  quantification  of  the 
assay  (0.05  ng.  ml-1,  information  supplied  by  Pfizer  Ltd).  As  discussed  in  chapter  4,  this 
result  demonstrates  that  the  combined  error  model  is  useful  when  concentrations  are 
measured  at  or  around  the  limit  of  quantification. 
A  larger  population  is  required  to  substantiate  the  covariate  relationships  which  were 
determined.  However,  model  development  is  a  step-wise  process  where  decisions  are  often 
made  on  limited  data,  so  the  extrapolations  made  here  are  consistent  with  routine  practice. 
The  relationship  between  clearance  and  body  weight  may  reflect  changes  in  renal  and/or 
hepatic  function.  Renal  impairment  has  been  shown  to  greatly  increase  the  exposure  and 
compromise  the  safety  profile  of  sotalol,  a  drug  which  is  structurally  similar  to  dofetilide 
(Dancey  et  al.  1997).  Although  there  were  no  comparative  estimates  of  CL  in  the 
literature,  the  terminal  half-life  for  this  study  (9.  Ohrs)  was  within  the  range  of  7.1  to  9.7hr-I 
previously  estimated  )  (Gemmill  et  al.  1991;  Sedgwick  et  al.  1991;  Tham  et  al.  1993;  Le 
Coz  et  al.  1995). 
The  Vss  estimate  (185L)  was  less  than  that  previously  reported  (228  to  267L)  (Gemmill  et 
al.  1991;  Sedgwick  et  al.  1991;  Tham  et  al.  1993;  Le  Coz  et  al.  1995).  Since  the  average 
body  weight  in  this  study  (77kg)  was  consistent  with  the  other  studies  (68  to  74  kg),  the 
final  covariate  model  cannot  explain  the  lower  Vss. 
The  hydrophilic  nature  of  dofetilide  means  that  it  does  not  readily  distribute  and 
accumulate  into  adipose  tissue.  It  would  therefore  be  expected  that  lean  body  weight 
would  correlate  better  with  Vss,  but  the  covariate  analysis  demonstrated  that  actual  body 
weight  was  the  most  influential  covariate.  It  is  possible  that  the  calculation  of  lean  body 
weight  using  height  alone  was  too  empirical,  and  that  that  an  additional  adjustment  for 
body  frame  size  (which  was  not  available  for  this  study)  may  have  improved  the  estimates 
(Robinson  et  al.  1983). 
257 The  relationship  between  body  weight  and  Vss  was  shown  to  be  entirely  due  to  an  increase 
in  the  peripheral  compartment  volume.  Since  plasma  volume  has  been  shown  to  be  related 
to  body  weight  (Snyder  et  al.  1975)  it  may  be  expected  that  V,  would  also  correlate  with 
body  weight.  However,  there  may  not  be  a  direct  relationship  between  V,  and  plasma 
volume,  since  V,  may  include  distribution  into  the  extravascular  space. 
7.9.2  PK/PD  and  baseline  response 
The  demonstrated  delay  between  the  end  of  the  infusion  peak  dofetilide  concentration  and 
the  maximum  QTc  was  consistent  with  previous  studies  investigating  the  pharmacokinetics 
and  phannacodynamics  of  intravenous  dofetilide  (Gemmill  et  al.  1991;  Sedgwick  et  al. 
1991;  Rasmussen  et  al.  1992;  Le  Coz  et  al.  1995).  The  Tmax  for  the  peak  QTc 
prolongation  was  shown  to  be  independent  of  dose,  so  the  temporal  delay  was  unlikely  to 
be  the  result  of  an  indirect  effect  (Dayneka  et  al.  1993;  Jusko  &  Hui,  1994).  Le  Coz  et  al. 
have  previously  estimated  the  temporal  displacement  of  dofetilide  using  an  effect 
compartment  (Le  Coz  et  al.  1995).  Their  estimate  of  equilibrium  half-life  estimate  was  6-7 
minutes  and  therefore  similar  to  that  estimated  here  (9  Minutes). 
As  previously  discussed,  many  antiarrhythmic  drugs  show  hysteresis  after  IV  dosing 
(Chapter  1.2.4),  and  the  estimation  half-lives  have  been  shown  to  be  remarkably  similar 
e.  g.  2  minutes  for  disopyramide  (Whiting  et  al.  1980),  6  minutes  for  procainamide 
(Galeazzi  et  al.  1976)  and  8  minutes  for  quinidine  (Holford  et  al.  198  1).  The  delay 
mechanism  underlying  the  distribution  into  the  effect  compartment  may  therefore  be 
similar  for  many  antiarrhythmic  drugs  and  related  to  their  shared  activity  on  ion  channels. 
In  contrast  to  beta-blockers,  which  combine  extracellularly  with  adrenergic  receptors,  ion 
channel  blocking  drugs  exert  their  effects  within  the  lipid  membrane  (Herbette  et  al.  1988) 
or  on  the  intracellular  face  of  the  cardiac  ion  channel  (Hondeghem  &  Katzung,  1977). 
Localised  distribution  has  been  postulated  as  an  explanation  of  the  differences  in  the  time 
258 course  of  the  various  antiarrhythmic  effects  of  arniodarone  (Roden,  1993).  While  the 
adrenergic  effects  are  manifested  soon  after  initiation  of  therapy  (Nfitchell  et  al.  1989; 
Kadish  et  al.  1990),  slower  diffusion  to  the  potassium  ion  channel  means  that  prolongation 
of  the  refractory  period  takes  longer  to  develop  akeda  et  al.  1984;  Nhtchell  et  al.  1989).  It 
is  likely  that  a  similar  process  governed  the  delay  in  the  QTc  prolongation  following  the  IV 
administration  of  dofetilide. 
The  importance  of  taking  placebo  response  into  account  in  assessing  the  dose  response 
relationship  (Dobrilla  &  Scarpignato,  1994)  and  its  particular  importance  to  the  assessment 
of  cardiovascular  drugs  (Bienenfield  et  al.  1996)  has  been  well  documented.  Diurnal 
variation  in  QT  as  a  consequence  of  both  temporal  changes  in  sympathovagal  tone  and 
circulating  catecholamines  is  also  well  recognised  (Bexton  et  al.  1986;  Murakawa  et  al. 
1992;  Hohnloser  &  Klingenheben,  1994).  As  previously  discussed,  the  corrected  QT 
interval  (QTc)  was  used  to  account  for  heart  rate  changes  during  and  between  study  days 
(see  section  7.15).  However,  evidence  of  diumal  variation  in  QTc  has  also  been 
demonstrated  (Vervaet  &  Amery,  1993).  The  point  for  point  subtraction  of  the  smoothed 
placebo  QTc  from  QTc  intervals  recorded  during  treatment  with  active  drug  was  used  to 
remove  both  placebo  effects  and  any  diurnal  effects  remaining  after  correction  for  heart 
rate. 
The  baseline  QTc  measurement  was  larger  than  that  estimated  by  Le  Coz  et.  al.  (1995)  (418 
vs  365msecs,  respectively).  Since  resting  QTc  intervals  have  been  shown  to  increase  with 
age  (Goldberg  et  al.  1991;  Reardon  &  Malik,  1996),  the  age  difference  between  the  two 
study  groups  (57.2  vs  23.4  years,  respectively)  may  account  for  the  difference  in  baseline 
QTc.  Age  related  changes  in  the  sympathovagal  tone  and  circulating  catecholarnIne  levels 
may  underlie  this  effect. 
Although  calculating  QTc  prolongation  as  change  from  baseline  has  been  used  to  compare 
the  effects  of  different  doses  of  dofetilide  (Sedgwick  et  al.  1991;  Rasmussen  et  al.  1992 
259 Tham  et  al.  1993),  an  adequate  fit  to  the  baseline  corrected  data  could  not  be  attained  in 
this  analysis.  Holford  and  Sheiner,  have  previously  suggested  that  when  the  baseline 
measurement  is  known  with  the  same  degree  of  certainty  as  other  measurements  it  should 
be  estimated  as  a  parameter  to  prevent  model  mi  s-  specification  (Holford  &  Sheiner,  1982a, 
b).  Correspondingly,  the  intraindividual  variability  was  reduced  by  greater  than  85%  when 
the  placebo  corrected  baseline  was  modelled  as  a  parameter,  rather  than  being  used  to 
correct  the  post  dose  observations. 
In  contrast  to  this  analysis,  Le  Coz  et.  al  (1995)  determined  that  an  Emax  model  was  more 
appropriate  than  a  linear  model  for  the  majority  of  subjects  (for  8/10  subjects).  The  Emax 
and  Ce5o  estimates  (121msecs,  57%  CV  and  2.2  ng.  ml-1,26%  CV,  respectively)  were  less 
than  those  estimated  when  the  Emax  model  was  used  in  this  analysis  (193  38  %CV  and 
6.35 
, 
65%CV,  respectively).  Furthermore,  the  gradient  at  the  Ccýo  (Emax/  Ce50)  was 
55msecs/  ng.  ml-1  in  comparison  to  35msecs/  ng.  ml-1  estimated  in  this  analysis  indicates 
that  the  healthy  volunteers  in  Le  Coz  et  al.  study  were  more  sensitive  to  dofetilide.  Since 
healthy  volunteers  were  used  in  both  studies,  the  age  difference  between  the  two  groups 
(23.4  vs  57.2  years,  respectively)  may  account  for  the  difference.  While  the  effect  of  the 
ageing  process  on  phannacokinetics  of  ant,  arrhythryu  cs  has  been  well  studied,  less  is 
known  about  age  related  changes  in  the  pharmacodynamics  (Storein,  1984;  Nestico  & 
Morganroth,  1986;  Podrid  et  al.  1989;  Hayakawa  &  Ino,  1994;  Kim  et  al.  1994).  Since 
changes  in  the  pharmacokinetics  confound  the  interpretation  of  changes  in  the 
phannacodynamics  (De  Caprio  et  al.  1995)  both  need  to  be  studied  together. 
It  has  been  shown  that  the  sensitivity  of  the  potassium  channel  to  class  III  agents  decreases 
in  patients  with  heart  disease  (Wit  &  Coromilas,  1993).  Physiological  differences  between 
the  aged  and  healthy  heart  have  been  shown  to  parallel  the  progression  of  heart  disease 
(Yamaguchi  &  Ito,  1988;  Assey,  1993).  So  it  is  possible  that  the  difference  in  sensitivity  to 
260 dofetilide  is  due  to  the  correlation  between  age  and  functional  changes  in  the  potassium  ion 
channels,  which  occur  in  the  absence  of  obvious  organic  disease. 
Whether  or  not  this  is  true,  the  older  population  did  achieve  QTc  prolongations  greater  than 
the  maximum  predicted  by  Le  Coz  et.  al.  A  recent  analysis  has  shown  that  data  up  to  95  % 
of  Emax  is  needed  to  obtain  adequate  precision  (Dutta  et  al.  1996).  Therefore,  due  to  the 
safety  implications  of  underestimating  the  QTc  prolongation,  and  therefore  the  associated 
risk  of  UP,  it  would  appear  to  be  more  prudent  to  use  a  linear  pharmacodynamic  model  in 
the  prediction  of  QTc  intervals  following  alternative  dosage  regimens.  Furthermore,  while 
receptor  theory  implies  that  a  finite  maximum  could  be  observed,  the  therapeutic  range  for 
dofetilide  is  likely  to  be  in  the  linear  portion  of  the  concentration  response  relationship. 
7.9.3  Predictions  and  simulations 
Comparison  of  a  dose  per  kilogram  regimen  and  a  fixed  dose  regimen  for 
termination  of  arrhythmia  via  IV  infusion 
Given  that  on  average  only  7%  of  the  total  dose  would  be  eliminated  during  the  initial 
period  of  distribution,  V,  would  have  little  effect  on  the  time  to  steady  state  and  the 
concentration  measured  during  the  later  stages  of  a  steady  state  infusion  (Rowland  & 
Tozer,  1989b).  However,  short  intravenous  infusions  are  generally  used  for  the  abolition  of 
affhythmias,  so  explaining  why  the  variability  In  V,  is  important  in  the  selection  of  a  future 
dosing  strategy.  Since  V,  was  found  not  to  be  related  to  body  weight,  the  only  fixed  factors 
affecting  the  rise  in  concentration  during  the  distribution  phase  were  the  rate  of  infusion 
and  the  administered  dose.  The  relationship  between  Vss  and  body  weight  only  begins  to 
affect  the  rising  concentration  towards  the  end  of  the  distribution  phase  (0.16  hrs  i.  e.  4x 
T1/2(x).  Therefore,  the  shorter  the  infusion,  the  more  the  peak  concentration  would  be 
influenced  by  Vi,  and  the  longer  the  infusion  the  more  the  concentration  would  be 
influenced  by  Vss.  Therefore,  the  relationship  between  body  weight  and  Vss  has  more 
influence  on  the  longer  infusions. 
261 The  interplay  between  covariate  relationships,  duration  of  infusion  and  dosing  regimen  was 
examined  using  predictions  based  on  the  average  PK/PD  model  and  simulations  using  the 
full  PK/PD  model.  Even  with  a  much  larger  slope  for  the  relationship  between  weight  and 
Vss,  the  range  of  peak  concentrations  (predicted  using  the  average  PK\PD  model)  for  the 
per  kilogram  regimen  (following  a  30  minute  infusion),  was  still  twice  that  for  the  fixed 
dose  regimen.  A  fixed  dosage  regimen  was  shown  to  provide  less  variable  Cmax  and  Peak 
QTc  measurements  for  infusions  of  up  to  at  least  45  minutes  of  duration. 
Slower  infusion  rates  resulted  in  smaller  maximal  changes  in  QTc,  and  a  lower  risk  of  UP 
(Table  7.10).  While  the  therapeutic  response  of  other  antiarrhythrmcs  has  not  previously 
been  shown  to  relate  to  the  level  of  QTc  prolongation,  it  may  be  possible  to  determine  this 
for  dofetilide  since  it  has  only  one  mechanism  of  action.  Successful  termination  of  an 
arrhythmia  may  be  related  to  the  peak  QTc  or  the  percentage  change  from  baseline. 
However,  the  rate  of  change  of  QTc  may  also  be  important  for  quick  and  effective 
termination.  An  optimal  infusion  time  and  dose  for  abolishing  arrhythmias  without 
inducing  UP  may  therefore  exist. 
The  remaining  interindividual  and  intraindividual  variabilities  were  large  in  comparison  to 
that  explained  by  the  covariate  model.  So  inclusion  of  these  estimates  along  with  an 
expectation  of  the  body  weight  distribution  provides  a  more  realistic  comparison  of  the 
dosing  regimens.  Although  the  difference  between  the  two  regimens  was  less  than  would 
be  predicted  using  the  average  PK/PD  model,  the  full  simulation  approach  confirmed  that 
adopting  a  fixed  dose  strategy  for  short  infusions  would  reduce  the  variability  in  Cmax  and 
QTc  prolongation.  The  reason  for  this  not  translating  into  an  overall  reduction  In  the  risk 
of  UP  was  found  to  be  due  to  the  differences  in  the  resultant  distributions  of  QTc  (Figure 
7.20).  The  initial  distributions  for  the  PK/PD  parameters  (assumed  to  be  log-normal)  and 
the  weight  distribution  (assumed  to  be  normal)  could  therefore  affect  the  comparison. 
262 The  sensitivity  of  the  >25%  change  from  baseline  criterion  compared  to  the  >  560msecs 
criterion  was  entirely  dependent  on  the  baseline  QTc.  If  the  baseline  was  greater  than 
425msecs  then  the  absolute  QTc  criterion  would  be  evoked  before  the  percentage  change 
for  baseline  was  exceeded  by  25%.  The  absolute  prolongation  has  been  most  often 
correlated  with  an  increased  risk  of  UP  (Neuvonen  et  al.  1979;  Belton  et  al.  1982;  Kuck  et 
al.  1984),  however,  utilisation  of  both  criteria  provides  added  protection  to  the  patient  in 
clinical  practice  (Stratmann  &  Kennedy,  1987). 
An  important  difference  between  the  regimens  is  in  who  they  place  at  risk  The  percentage 
at  risk  of  UP  would  be  particularly  high  for  heavy  patients  dosed  according  to  the  per 
kilogram  regimen.  Conversely,  the  fixed  dosage  regimen  would  associate  a  slightly  higher 
risk  of  UP  with  lighter  patients.  In  deciding  on  the  most  appropriate  regimen, 
consideration  should  be  given  to  potential  correlation's  between  body  weight  and  other  risk 
factors  for  UP  i.  e.  hypokalaernia  and  females.  Furthermore  the  lighter  patients  may  tend 
to  be  frailer  and  consequently  less  likely  to  recover  from  an  episode  of  TdP. 
Steady  state  simulation 
The  steady  state  simulation  indicated  that  steady  state  concentrations  (Css)  above  4  ng.  ml-1 
(mcg.  1-1)  would  be  (based  on  the  >25%  change  from  baseline  criterion)  associated  with  a 
sharp  increase  in  the  percentage  of  patients  at  high  risk  of  developing  TdP.  Oral  dosage 
regimens  for  the  prevention  of  arrhythmias  could  be  designed  with  this  level  as  a  maximum 
for  the  target  concentration  range.  However,  it  has  been  assumed  that  tolerance  does  not 
develop,  in  contrast  Schwartz  et  al.  (1989)  have  previously  shown  that  the  sensitivity  of  the 
myocardium  to  verapamill  measured  by  QTc  prolongation,  decreases  upon  multiple  dosing. 
Thus  further  studies  are  required  to  assess  the  effect  of  duration  of  therapy  on  sensitivity  of 
the  myocardium  to  dofetilide. 
263 7.10  Conclusions 
There  was  no  significant  difference  in  pharmacokinetics  and  pharmacodynarmcs  of 
dofetilide  between  patients  with  IHD  and  age  matched  healthy  volunteers. 
The  population  approach  using  NONMEM  successfully  identified  both  individual  and 
population  PK  and  PD  responses,  while  providing  a  basic  population  model  which  could 
be  used  in  the  prospective  assessment  of  the  factors  which  affect  dofetilide'sQTc  /safety 
profile.  The  FOCE  method  with  "interaction"  gave  the  least  biased  estimates  for  the 
parameters  of  the  pharmacokinetic  model.  A  two  compartment  model  best  described  the 
pharmacokinetics  and  an  effect  compartment  was  used  to  account  for  the  displacement 
between  concentration  and  effect.  A  linear  model  best  described  the  subsequent 
relationship  between  effect  compartment  concentration  and  QTc  prolongation.  The 
inclusion  of  baseline  placebo  QTc  as  a  calculable  parameter  in  the  pharmacodynamic 
model  substantially  reduced  intraindividual  variability. 
Simulations  were  used  to  identify  steady  state  concentrations  which  increased  the 
percentage  of  subjects  with  QTc  prolongations  above  those  associated  with  a  high  risk  of 
TdP.  The  effect  of  dosage  regimen  and  duration  of  infusion  on  Cmax,  peak  QTc  and  risk 
of  UP  was  also  investigated  via  prediction  and  simulation.  While  dosing  on  the  basis  of 
per  kilogram  body  weight  is  routinely  used  in  therapeutics,  this  analysis  would  suggest  that 
for  a  short  infusion,  the  range  and  variability  in  Cmax  and  QTc  measurements  would  be 
narrower  following  a  fixed  dose  regimen.  The  importance  of  V,  and  body  weight  to  this 
conclusion  was  highlighted. 
The  fact  that  lighter  patients  (who  may  also  be  frail  and  elderly)  are  most  likely  to  be 
placed  at  risk  with  the  fixed  dose  regimen  may  favour  the  dose  per  kilogram  regimen. 
Nevertheless,  the  analysis  indicates  that  caution  is  required  when  dosing  heavy  patients  on 
a  per  kilogram  basis,  such  that  a  maximum  total  dose  should  be  imposed  in  subsequent 
264 studies.  Further  investigation  of  the  variability  in  the  PK/PD  relationship  is  required  to 
identify  other  factors  which  can  aid  in  the  predictions  of  concentrations  and  QTc 
measurements  and  therefore  allow  optimisation  of  the  dofetilide  dosage  used  in  the 
treatment  and  prevention  of  cardiac  arrhythmias. 
265 CHAPTER  8 
GENERAL  CONCLUSIONS 
266 The  analyses  discussed  in  thesis  have  raised  some  general  points  to  consider  when 
applying  nonlinear  mixed  effect  modelling  in  the  early  phases  of  drug  development. 
These  are  summarised  in  this  chapter. 
NONMEM  Estimation  Methods 
In  general  the  NONMEM  software  performed  well.  The  FOCE  methods  substantially 
out  performed  the  FO  method  in  the  determination  of  the  most  appropriate  PK/PD 
model  (Chapters  4&  7)  and  of  point  and  interval  estimates  for  a  bioequivalence  test 
(Chapter  5).  The  increase  in  computation  time  was  most  troublesome  when  the 
problem  required  a  complex  nonlinear  model  and  a  large  amount  of  data  was  available 
for  each  subject  (Chapter  4).  Unfortunately  this  is  exactly  the  situation  where  the 
FOCE  methods  are  most  likely  to  be  advantageous.  However,  it  may  be  possible  to 
substantially  reduce  the  extraordinary  run  times  by  utilising  user  defined  code 
(Chapter  4). 
Comparison  to  Standard  Approaches  of  Estimating  Pharmacokinetic 
Parameters 
Noncompartmental  analysis  was  successfully  used  to  determine  the  primary 
pharmacokinetic  and  pharmacodynamic  parameters  of  interest  and  allowed  drug 
accumulation  (Chapter  4),  bioequivalence  (Chapter  5),  dose  response  (Chapter  6)  and 
PK/PD  relationships  (Chapter  7)  to  be  investigated  by  standard  methods.  However, 
model  based  approaches  were  required  in  the  prediction  of  steady  state  concentrations 
(Chapter  4),  and  in  testing  bioequivalence  where  only  a  few  random  plasma  samples 
per  individual  were  available  (Chapter  5).  Furthermore,  a  fuller  understanding  of  the 
relationships  underlying  the  dose  response  could  be  ascertained  by  adopting  the  model 
based  approaches.  In  particular,  a  greater  insight  into  potential  covariate  effects  and  a 
break  down  of  the  variability  into  either  the  PK/PD  component  of  dose  response 
relationship  was  possible  (Chapter  6  &7).  Together  these  provided  a  framework  with 
which  to  predict  and  simulate  responses  to  different  dosage  regimens  in  larger 
populations  (Chapter  4,6  &7). 
267 Identification  of  Structural  and  Covariate  Models 
Although  identification  of  the  "best"  structural  model  is  known  to  be  problematic 
when  the  data  is  sparse  (Chapter  5&  6),  the  average  model  can  also  be  difficult  to 
select  when  the  data  is  rich  (Chapter  4&  7).  While  characterisation  of  individual 
plasma  time  profiles  allows  identification  of  a  range  of  different  structural  models 
(Chapter  4),  the  fit  of  an  individuals  data  to  competing  models  can  be  explored  using 
the  individual  estimates  obtained  from  the  population  approach  (Chapter  7). 
Furthermore,  it  is  likely  that  an  apparent  qualitative  change  in  the  structural  model 
between  subjects  is  more  likely  to  be  an  artefact  of  the  encountered  variability  and, 
therefore,  more  readily  dealt  with  by  adopting  a  population  approach. 
Due  to  the  small  numbers  of  subjects,  it  was  known  from  the  outset  that  it  would  be 
difficult  to  accurately  determine  the  underlying  covariate  relationships.  Nevertheless, 
the  identified  covariate  relationships  allowed  several  hypotheses  to  be  generated  ( 
Chapters  6&  7).  While  these  have  to  be  confirmed  in  larger  Phase  11  or  Phase  III 
studies,  the  approach  is  consistent  with  the  concept  of  Phase  LIII  studies  as  the 
learning  and  theory  testing  stage  of  drug  development.  One  way  of  increasing  the 
confidence  in  the  identified  covariate  effect  is  to  test  assumptions  underlying  the 
relationships.  Sensitivity  analysis  was  found  to  be  useful  in  assessing  the  potential 
impact  if  the  covariate  effect  be  over  or  underestimated  (Chapter  7).  The  subsequent 
clinical  importance  of  these  relationships  was  best  ascertained  through  simulation 
(Chapter  6). 
Study  Design 
Although  the  approach  of  using  mixed  effects  modelling  to  interpret  data  from  studies 
where  the  design  has  been  compromised  should  be  treated  with  caution,  it  was  found 
to  have  utility  in  the  example  presented  in  this  analysis  (Chapter  7).  On  the  other 
hand,  a  model  based  approach  can  also  be  jeopardised  by  studies  designed  without  Its 
application  in  mind  (Chapter  6). 
268 Predictions/Simulations 
Prediction  and  simulation  techniques  are  core  to  developing  the  understanding  gained 
by  applying  a  model  based  approach  to  a  data  problem.  While  a  prediction  using 
individual  or  typical  parameter  estimates  can  be  useful  in  exploring  the  relationships 
uncovered  in  a  particular  analysis  (Chapter  7),  undertaking  a  formal  simulation  is 
recommended  since  it  formally  accounts  for  both  fixed  and  random  effects  (Chapter  4, 
6  and  7).  It  should,  however,  be  remember  that  the  simulation  will  only  allow 
investigation  of  factors  included  in  the  model. 
Model  Assumptions 
While  simulation  allows  you  to  test  for  the  affect  of  modelling  assumptions  on 
potential  clinical  outcomes  (Chapter  6  and  7),  the  assumptions  should  first  be  tested 
during  the  modelling  process.  For  example,  error  structure  was  found  to  change  upon 
changing  from  modelled  baseline  to  percentage  reduction  model  (Chapter  6).  Some 
assumptions  may  limit  the  applicability  of  the  developed  modelling  techniques.  For 
example,  the  Wagner  Nelson  approximation  used  to  directly  estimate  Cmax  from  a 
two  compartment  model,  was  only  valid  for  drugs  where  the  terminal  half-life  was 
much  longer  than  the  distribution  half-life  (Chapter  5). 
Baseline  Correction 
While  baseline  correction  can  reduce  the  model  complexity  (Chapter  6)  it  is  best  to 
start  from  a  model  where  baseline  is  estimated  as  a  parameter  (Chapter  7).  In  Chapter 
7,  when  a  baseline  correction  was  utilised,  the  underlying  variability  in  baseline 
measurement  prevented  the  Emax  relationship  from  being  identified  as  a  potential 
model.  Modelling  the  baseline  greatly  reduced  the  variability  and  allowed  the  Emax 
relationship  to  provide  a  similar  fit  to  the  linear  relationship.  In  Chapter  6,  a  baseline 
correction  was  implicit  in  the  percentage  reduction  model  adopted  to  simplify  the 
original  absolute  reduction  from  baseline  model.  While  this  showed  that  baseline 
total  cholesterol  could  be  a  covariate  of  both  Emax  and  D50  it  did  not  allow  the 
determination  of  which  relationship  was  most  important. 
269 Hypothesis  Testing  - 
Determination  of  statistical  significance  is  generally  based  on  the  ability  to  reject  the 
Null  Hypothesis  in  favour  of  a  suitable  alternative  hypothesis.  Normally  the 
probabililty  ((x)  of  making  a  type  I  error  is  a  preselected  acceptable  level  and  the 
probability  of  making  a  type  11  error  @)  is  minimised  by  choosing  an  appropriate 
sample  size.  While  Phase  1/11  studies  can  be  powered  to  n-iinimise  Type  11  error  in  the 
determination  of  mean  differences,  they  are  not  generally  powered  for  the  purposes  of 
PK/PD  modelling.  This  is  a  particular  problem  with  the  covariate  analyses  undertaken 
(Chapter  6  and  7). 
Population  PK/PD  Modelling  the  Alternative  Paradigm  for  Drug  Development  ? 
In  the  analyses  presented,  the  benefits  of  PK/PD  modelling  in  the  early  phases  of  drug 
development  was  highlighted.  While  the  application  of  nonlinear  mixed  effects 
modelling  to  bioequivalence  testing  (Chapter  5)  may  only  provide  an  advantage  in  a 
limited  number  of  circumstances,  the  presented  applications  in  the  areas  of  drug  safety 
(Chapter  4),  dose  response  (Chapter  6)  and  integrated  PK/PD  problems  (Chapter  7) 
cover  much  of  the  early  development.  It  can  therefore  be  speculated  that  wider 
implementation  of  these  techniques  would  improve  decision  making  and  allow 
inforination  to  be  more  effectively  propagated  across  the  phases  of  drug  development. 
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Chapter  4:  The  NMTRAN  user  supplied  PRED  subroutines  for  implementation  of 
equations  4.2  (run  8)  and  4.5  (run  11). 
Chapter  4  Run8  Chapter  4  Run  11 
$PRED 
TALPH=THETA(l) 
TA=THETA(2) 
TBETA=THETA(3) 
TB=THETA(4) 
TGAM=THETA(5) 
TC=THETA(6) 
TKA=  THETA(7) 
ALPH=TALPH*EXP(ETA(l)) 
A=TA*EXP(ETA(2)) 
BETA=TBETA*EXP(ETA(3)) 
B=TB*EY,  P(ETA(4)) 
GAM=TGAM*EXP(ETA(5)) 
C=TC*EXP(ETA(6)) 
KA=  TKA*EXP(ETA(7)) 
TAU=12 
AI=EXP(-ALPH*T) 
A2=EXP(-N*ALPH*TAU) 
A3=EXP(-ALPH*TAU) 
AIO=A*Al*(I-A2)/(I-A3) 
BI=EXP(-BETA*T) 
B2=EXP(-N*BETA*TAU) 
B3=EXP(-BETA*TAU) 
BIO--B*Bl*(l-B2)/(l-B3) 
CI=EXP(-GAM*T) 
C2=EXP(-N*GAM*TAU) 
C3=EXP(-GAM*TAU) 
C10--C*Cl*(I-C2)/(I-C3) 
$PRED 
TALPH=THETA(l) 
TA=THETA(2) 
TBETA=THETA(3) 
TB=TBETA(4) 
TGAM=THETA(5) 
TC=TBETA(6) 
K=TALPH*EXP(ETA(l)) 
A=TA*EXP(ETA(2)) 
BETA=TBETA*EXP(ETA(3)) 
B=TB*EXP(ETA(4)) 
GAM=TGAM*EXP(ETA(5)) 
C=TC*EXP(ETA(6)) 
TAU=12 
AI=EXP(-K*T) 
A2=EY.  P(-N*K*TAU) 
A3=EXP(-K*TAU) 
A4=A*T*Al 
A5=A*TAU*Al 
A6=A4*(l-A2)/(l-A3) 
A7=1/(I-A3) 
A8=(A3-A2)*A7 
A9=A5*A7*(A8-N*A2+A2) 
AIO=A6+A9 
Bl=EXP(-BETA*T) 
B2=EXP(-N*BETA*TAU) 
B3=EXP(-BETA*TAU) 
B  10=B*B  1  *(l-B2)/(l-B3) 
Cl=EXP(-GAM*T) 
C2=EXP(-N*GAM*TAU) 
C3=EY,  P(-GAM*TAU) 
CIO=C*Cl*(I-C2)/(l-C3) 
KI=EY,  P(-KA*T) 
K2=EXP(-N*KA*TAU) 
K3=EXP(-KA*TAU) 
KIO=-(A+B+C)*Kl*(I-K2)/(I-K3)  K10=-(A+B+C)*Al*(l-A2)/(l-A3) 
F=AIO+BlO+CIO+KIO 
IPRED=F 
Y=F*EXP(EPS(2))+EPS(l) 
F=AlO+Blo+CIO+KIO 
IPRED=F 
Y=F*EXP(EPS(2))+EPS(l) 
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Chapter  5:  The  NMTRAN  $PK  subroutine  for  a  two  compartment  model  with  the 
F 
relative  differencesORDin  -  and  Ka  estimated  using  Equations  5.10  and  5.11, 
V, 
respectively  (Run  12);  and  the  user  supplied  NMTRAN  PRED  subroutine 
parameterising  the  model  in  terms  of  CAmax  using  E.  q.  5.23,5.24,5.26,5.11  and 
5.18  (run  13). 
Chapter  5  Run  12 
$SUBROUTINE  ADVAN4  TRANS5 
$PK 
1=0 
EF(FORM.  EQ.  2)  1=1 
FS2=(I-I)+I*(T]HETA(6)+I) 
FKA=(1-1)+I*(THETA(7)+l) 
TVBETA=THETA(l) 
TVVS2=1/(TIMTA(2)*FS2) 
TVKA=THETA(3)*FKA 
TVAOB=TIMTA(4) 
TALPHA=THETA(5) 
BETA=TVBETA*EXP(ETA(l)) 
S2=TVVS2*EY,  P(ETA(2)) 
KA=TVKA*EXP(ETA(3)) 
ALPHA=TALPHA*EXP(ETA(4)) 
AOB=TVAOB 
$ERROR 
Y=F*EXIP(ERR(l)) 
Chapter  5  Run  13 
$PRED 
IND=O 
IF(FORM.  EQ.  2)  IND=l 
DR=l 
IF(STD.  EQ.  1)  DR=2 
TIM=TIME*(l-IND)+(TIME-  100)  *IND 
TALPHA=TBETA(l) 
CMNAT=TIIETA(2) 
KAN=THETA(3) 
TAOB=TBETA(4) 
TBETA=TBETA(5) 
KCMAX=THETA(6) 
KKA=THETA(7) 
ALPHA=TALPHA*EXP(ETA(l)) 
TCMAX=CMNAT*(I- 
IND)+CMNAT*(I+KCMAX)*IND 
CMAX=(TCMAX/DR)*EXP(ETA(2)) 
TKA=(I-IND)*KAN+IND*KAN*(I+KKA) 
KA=TKA*EXP(ETA(3)) 
AOB=TAOB 
BETA=TBETA*EXP(ETA(4)) 
K21=(AOB*BETA+ALPHA)/(AOB+I) 
Rl=(ALPHA-K21)/(KA-K21) 
IF  (Rl.  LE.  0)  EXIT  11 
TPK=-l/(KA-ALPHA)*DLOG(RI) 
Al=(KA-ALPHA)*(BETA-ALPHA) 
A=(K21-ALPHA)/Al 
Bl=(KA-BETA)*(ALPHA-BETA) 
B=(K21-BETA)/Bl 
AA1=EXP(-ALPHA*TPK) 
AA2=EXP(-ALPHA*TIM) 
BBI=EXP(-BETA*TPK) 
BB2=EXP(-BETA*TIM) 
KA1=EXP(-KA*TPK) 
KA2=EXP(-KA*TIM) 
IZ=A*AA1+B*BBI-(A+B)*KA1 
JZ=CMAX/IZ 
MZ=A*AA2+B*BB2-(A+B)*KA2 
FUN=JZ*W 
Y=FUN*EXP(ERR(l)) 
273 Chapter  5:  The  NMTRAN  $PK  subroutine  for  a  two  compartment  model  with  the 
relative  differencesOInRD(multiplicative  model)  in 
F 
estimated  using  equations  5.11 
V, 
and  5.28,  respectively  (run  14);  and  the  user  supplied  NMTRAN  PRED  subroutine 
parameterising  the  model  in  terms  of  CAmax  using  E.  q.  5.23,5.24,5.26,5.11  and 
5.29  (run  15). 
Chapter  5  Run  14 
$SUBROUTINE  ADVAN4  TRANS5 
$PK 
1=0 
IF(FORM.  EQ.  2)  I=l 
FS2=1*(THETA(6)) 
FKA=(I-I)+I*(THETA(7)+I) 
TVBETA=THETA(l) 
TVVS2=(THETA(2)+FS2) 
TVKA=TIMTA(3)*FKA 
TVAOB=THETA(4) 
TALPHA=THETA(5) 
TVS2=EXP(TVVS2) 
TS2=1/TVS2 
BETA=TVBETA*EXP(ETA(l)) 
S2=TS2*EXP(ETA(2)) 
KA=TVKA*EY,  P(ETA(3)) 
ALPHA=TALPHA*EXP(ETA(4)) 
AOB=TVAOB 
$ERROR 
Y=F*EXP(ERR(l)) 
Chapter  5  Run  15 
$PRED 
IND=O 
IF(FORM.  EQ.  2)  IND=  1 
DR=l 
EF(STD.  EQ.  1)  DR=2 
TIM=TIME*(I-IND)+(TIME-100)*IND 
TALPHA=THETA(l) 
CMNAT=TliETA(2) 
KAN=THETA(3) 
TAOB=THETA(4) 
TBETA=THETA(5) 
KCMAX=THETA(6) 
KKA=THETA(7) 
ALPHA=TALPHA*EXP(ETA(l)) 
TCMAX=CMNAT+(KCMAX*IND) 
TDMAX=EXP(TCMAX/DR) 
CMAX=(TDMAX)*EXP(ETA(2)) 
TKA=(l-IND)*KAN+IND*KAN*(I+KKA) 
KA=TKA*EXP(ETA(3)) 
AOB=TAOB 
BETA=TBETA*EXP(ETA(4)) 
K21=(AOB*BETA+ALPHA)/(AOB+I) 
Rl=(ALPHA-K21)/(KA-K21) 
EF  (Rl.  LE.  0)  EXIT  II 
TPK=-l/(KA-ALPHA)*DLOG(RI) 
Al=(KA-ALPHA)*(BETA-ALPHA) 
A=(K21-ALPHA)/Al 
Bl=(KA-BETA)*(ALPHA-BETA) 
B=(K2  I-BETA)/B  I 
AAI=EXI?  (-ALPHA*TPK) 
AA2=EXP(-ALPHA*TIM) 
BB1=EXP(-BETA*TPK) 
BB2=EXP(-BETA*TIM) 
KAI=EXP(-KA*TPK) 
KA2=EXP(-KA*TIM) 
IZ=A*AAI+B*BBI-(A+B)*KAI 
JZ=CMAX/IZ 
MZ=A*AA2+B*BB2-(A+B)*KA2 
FLTN=JZ*Na 
Y=FUN*EXP(ERR(l)) 
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Chapter  6:  The  NMRAN  user  supplied  PRED  subroutines  for  implementation 
equations  6.1  to  6.5  i.  e.  the  Placebo,  Step,  Steplinear,  Emax  and  Emax  percentage 
reduction  models 
Chapter  6  Step  model  Chapter  6  Steplinear  model 
$PRED 
IND=O 
IF(DOSE.  GT.  0)  IND=  1 
RED=  TI]ETA(2)*EXP(ETA(2)) 
PLAC=THETA(l)*EXP(ETA(l)) 
LR=PLAC-RED*(IND) 
Y=LR*EXP(ERR(l)) 
Chapter  6  Emax  model 
$PRED 
B=THETA(3)+DOSE 
A=THETA(2)*DOSE 
RED=(A/B)*EXP(ETA(2)) 
PLAC=THETA(1)*EXP(ETA(l)) 
LR=PLAC-RED 
Y=LR*EXP(ERR(l)) 
$PRED 
IND=O 
IIF(DOSE.  GT.  0)  IND=l 
RED  1=THETA(2)+TBETA(3)*DOSE 
RED=REDI*EXP(ETA(2)) 
PLAC=THETA(I)*EXP(ETA(l)) 
LR=PLAC-RED*(IND) 
Y=LR*EXP(ERR(l)) 
Chapter  6  Emax  Percentage  Reduction 
model 
$PRED 
B=THETA(2)+DOSE 
A=THETA(1)*DOSE 
RED=(A/B)  *EXP(ETA(l)) 
LR=100-RED 
Y=LR*EXP(ERR(l)) 
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Chapter  7:  The  NMTRAN  $PK  subroutine  for  a  two  compartment  PK  model  with  an 
effect  compartment  and  either  a  linear  or  Emax  PD  model 
Chapter  7  Linear  PD  model  )  model 
$SUBROUTINE  ADVAN5  TRANS  I 
$MODEL 
COMP=(CENTRAL,  DEFDOSE) 
COMP=(PKCOMP) 
COMP=(PDCOMP,  DEFOBS)$PK 
$PK 
KlO=VK1 
K12=VK12 
K21=VK21 
sl=vsl 
K13=  0.01*KlO 
K30=  THETA(1)*EXP(ETA(l)) 
LINE=THETA(2)*EXP(ETA(2)) 
BASE=THETA(3)*EXP(ETA(3)) 
S3=SI*KI3/K30 
$ERROR 
EFFC=F 
IPRE=BASE+(LE,,,;  E*F) 
Y=EPRE+ERR(l) 
$SUBROUTINE  ADVAN5  TRANS  I 
$MODEL 
COMP=(CENTRAL,  DEFDOSE) 
CON[P=(PKCOMP) 
COMP=(PDCOMP,  DEFOBS) 
$PK 
KIO=VK1 
K12=VK12 
K21=VK21 
sl=vsl 
K13=  0.01*KIO 
K30=  THETA(1)*EXP(ETA(l)) 
EMAX=THETA(2)*EXP(ETA(2)) 
D50=THETA(3)*EXP(ETA(3)) 
BASE=TBETA(4)*EXP(ETA(4)) 
S3=Sl*Kl3/K30 
$ERROR 
EFFC=F 
IPRE=BASE+(EMAX*F)/(D50+F) 
Y=IPRE+ERR(l) 
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Definitions:  population  and  Statistical  modelling  theory  terms  and  symbols 
Symbol  Derinition 
Intraindividual  random  effect,  accounts  for  the  error  between  the  model 
prediction  for  the  jth  observation  for  the  ith  individual  and  the  actual 
observation 
the  ith  individual's  vectors  of  E  values 
flki  Interindividual  random  effects;  accounts  for  the  error  between  Pk  and  Pik 
Ili  the  ith  individual's  vectors  of  il  values 
Val  Variance  of  E  's,  related  to  predicted  value  by  function 
2 
Variance  of  "s,  related  to  predicted  value  by  function  1) 
K 
flk 
-)Ok 
Vector  of  population  mean  parameter  estimates;  Kth  parameter  from  the 
vector  of  population  mean  parameter  estimates  ý 
ORD  Relative  difference  between  two  means  using  an  additive  model 
OInRA  Ratio  of  two  means  using  a  multiplicative  model 
aV  =1  (ý=O)  standard  deviation  (in  observation  units) 
2 
V- 
ii 
(C=2)  Coefficient  of  Variation 
For  an  additive  model  the  standard  deviation  (in  observation  units) 
For  exponential  or  proportional  the  coefficient  of  variation  (%) 
92  Variance  -  Covariance  Matrix  of  interindividual  random  effects  71 
C  Fixed  effect  for  the  power  function  intraindividual  variability  model 
X2  Chi  squared  test 
I  Mathematical  symbol  to  represent  sum  of 
Oels  Objective  function  value  (-2  In  likelihood  as  estimated  by  NONMEM 
OFV  or  -2LL) 
Obj.  Fun. 
f  A  general  function  of  all  arguments  listed  which  includes  a  structural  model 
that  relates  the  independent  variables 
g,  0  A  general  function  which  relates  Pk  to  4  throughOk 
S(  A  general  function  incorporating  interindividual  and  intraindividual 
submodels 
Pi  ith  Individuals  vector  of  model  parameters 
kth  parameter  from  the  ith  Individuals  vector  of  model  parameters 
Pik 
the  population  average  or  typical  parameter  of  the  structural  model 
Pk 
S  Variance  -  Covariance  Matrix  of  intraindividual  random  effects 
X  ij 
All  the  independent  variable  information  including  the  time  of  observations 
and  dosage  history 
The  jth  observation  for  the  ith  individual 
Yjj 
The  jth  prediction  for  the  ith  individual 
Yjj 
Represents  the  vector  of  covariates  for  the  ith  individual 
4 
277 Symbol  Definition 
ADD  Additive  component  of  intraindividual  error  model 
AIC  Akaike  Information  Criterion 
%CV  Coefficient  of  variation 
DV  Dependent  variable 
EPS  Ej  in  NONMEM  syntax 
ELS  Extended  least  squares 
EXP  Exponential  component  of  intraindividual  error  model 
F 
Y 
tj 
in  NONMEM  syntax 
FO  First  order  estimation 
FOCE  First  order  conditional  estimation 
GAM  General  additive  model 
GOF  Goodness  of  fit  plots 
Interaction  FOCE  method  where  I  is  based  on  the  conditional  estimates  of 
Method 
No  Interaction  FOCE  method  where  I  is  estimated  based  on  the  mean  parameter  model. 
Method 
11V  Interindividual  variability 
10V  Interoccasion  variability 
IPRED  Individual  predictions 
IRES  Individual  Weighted  Residuals 
IWRES  Individual  Weighted  Residuals 
Likelihood  The  difference  is  approximately  X2  distribution  with  degrees  of  freedom  (df) 
ratio  test  equal  to  the  difference  in  the  number  of  free  parameters.  When  one 
(LRT)  parameter  is  fixed  in  the  reduced  model  a  decrease  in  objective  function 
value  3.84  is  significant  at  p<0.05. 
Posthoc  Individual  posterior  Bayes  parameter  estimates  obtained  after  the  ELS 
problem  has  been  minimised  v 
PRED  Population  predictions 
PROP  Proportional  component 
RES  Residuals 
SD  Standard  Deviation 
SE  Absolute  Standard  error 
SE  Absolute  Standard  error  /population  estimate  *  100 
STS  Standard  Two  Stage  Approach 
WRES  Weighted  Residuals 
Y 
y  ij 
in  NONMEM  syntax 
278 Definitions:  PK\pD  Terms  and  Symbols 
Symbol  Definition 
(X,  Pq  Y9  81)  Initial,  intermediate  and  elimination  rate  constant  (depending  on  number  of 
compartments) 
Ir  The  dosing  interval 
A,  Amount  of  drug  in  the  Central  compartment 
Ae  Amount  of  drug  in  the  effect  compartment 
AT  Total  amount  of  drug  in  the  central  compartment  at  time  T 
A,  B,  C,  D  coefficient  constants 
AUC  Area  under  the  concentration  time  curve 
AUCo-_  (inf)  Area  under  the  concentration  time  curve  between  0  and  infinity 
AUCo,  Area  under  the  concentration  time  curve  between  0  and  T 
Ce  Concentration  at  the  site  of  drug  action  (in  the  effect  compartment) 
Ce,,  Concentration  at  the  site  of  drug  action  at  steady  state  (in  the  effect 
compartment) 
Ce50  Concentration  at  the  site  of  drug  action  which  gives  50%  of  the  maximum 
response 
C,  Cp,  (Ct)  Plasma  concentration  (Plasma  concentration  as  function  of  time) 
CSS  Plasma  concentration  at  steady  state 
CI  Confidence  Interval 
CL  Clearance 
CL/F  Apparent  clearance  (oral  plasma  clearance) 
Cmax  Maximum  concentration 
Cmax. 
D 
the  estimate  of  Cmax,  derived  from  the  modelled  parameters 
CAmax  Maximum  concentration  at  TApk 
Cmax 
E  Estimate  of  Cmax.  obtained  directly  from  the  model 
CAmax 
E  Estimate  of  CAmax.  obtained  directly  from  the  model 
D50  Dose  which  gives  50%  of  the  maximum  response 
Emax.  The  maximum  response 
F  Bioavailability 
Hysteresis  The  temporal  displacement  between  concentration  and  effect  in  a 
counterclockwise  direction 
k  Combined  absorption  and  distribution  rate  constant 
Ka  First  Order  rate  constant  for  absorption 
Ko  Zero  order  constant  for  absorption 
Ke/K10  Elimination  rate  constant 
K121K21  inter-compartmental  rate  constants 
Kle  Rate  constant  governing  the  transfer  to  the  effect  compartment 
Keo  Rate  constant  representing  the  loss  from  the  effect  compartment  and 
accounting  for  the  hysteresis 
LR  Lipid  response 
MRT  Mean  residence  time 
N  Number  of  doses  given 
PD  Pharmacodynamics 
PK 
Proteresis 
Pharmacokinetics 
The  temporal  displacement  between  concentration  and  effect  in  a  clockwise 
direction 
Q  Intercompartmental  clearance 
V  Volume  of  distribution 
279 Symbol  Derinition 
t  time 
TI/2  (half-life)  Terminal  half-life 
Tlag  Lag  time  for  absorption 
Tmax/Tpk  Time  of  maximal  plasma  concentration 
TApk  Time  at  which  the  accumulative  amount  absorbed  /  VI  equals  a  maximum. 
IT  approximates  to  Tpk  when  Ka>cc  >0 
V,  Volume  of  distribution  of  the  central  compartment 
Ve  Volume  of  distribution  of  the  effect  compartment 
Vss  Volume  of  distribution  at  steady  state 
Other  Abbreviations 
Symbol  Derinition 
AGE  Age  of  patient  (years) 
CI-cr  Creatinine  Clearance  (ml.  min-1)  estimated  from  the  Cockcroft  Gault 
relationship* 
FDA  Food  and  Drug  Administration 
HDL  High  density  Lipoproteins  (mmol.  1;  1) 
HMG  COA  3-hydroxy-3-methylglutaryl  Coenzyme  A  inhibitor 
HR  Heart  Rate 
LDL  Low  density  Lipoproteins  (mmol-L) 
LOQ  Limit  of  Quantification 
QT  The  ventricular  refractory  period  i.  e.  the  time  between  the  depolarisation  and 
repolarisation  of  the  ventricular  myocardium,  It  is  measured  from  a  standard 
electrocardiogram  (ECG)  in  msecs 
QTc  QT  corrected  for  heart  rate 
RR  RR  interval  from  the  electrocardiogram 
RBS  Ranitidine  bismuth  subcitrate 
SCRT  Serum  creatinine  concentration  (mg.  dl-1) 
SD  Standard  deviation 
SEX  Gender  (males  0,  females  1) 
UP  Torsade  de  Pointes 
WT  Body  weight  of  patient  (kg) 
VLDL  Very  Low  density  Lipoproteins  (mmol.  L 
VT  Ventricular  Tachycardia 
VF  Ventricular  Fibrillation 
*Cockcroft  Gault  relationýhlýp: 
(140 
-  Age)  x  Weight 
CLcr  = 
serum  creatinine 
.x 
[1.23(male);  orl.  04(female)] 
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Presentations 
A  population  approach  to  dose  vs  response  relationship  for  simvastatin  in  hypertensive 
hypercholesterolearnic  patients 
S.  F.  Marshall,  H.  L.  Elliott,  P.  A.  Meredith 
British  Phannacological  Society 
London  5-7thJanuary  1994 
A  population  approach  to  dose  versus  response  relationship  for  sirnvastatin  in  hypertensive 
hypercholesterolaernic  patients 
S.  F.  Marshall,  H.  L.  Elliott,  P.  A.  Meredith 
Population  Approach  Group  Europe 
London  13-14t"  June  1994 
Prediction  of  simvastatin  pharmacological  response:  a  population  analysis 
S.  F.  Marshall,  H.  L.  Elliott,  P.  A.  Meredith 
Population  Approach  Group  Europe 
Frankfurt  9-  1  OthJune  1995 
Application  of  mixed  effects  modelling  to  bioequivalence  testing 
S.  F.  Marshall.,  P.  A.  Meredith 
NONMEM  intermediate  workshop 
Uppsala  12-13thOctober  1995 
Population  pharmacokinetics  and  Pharmacodynamics  of  a  novel  anti-arrhythmic  drug  in 
healthy  volunteers  and  ischaemic  heart  disease  patients 
S.  F.  Marshall,  H.  L.  Elliott,  P.  A.  Meredith 
PK  UK 
Nottingham,  1-3  rd  November  1995 
Publications 
Marshall  SF,  Elliott  HL,  Meredith  PA.  A  population  approach  to  dose  vs  response 
relationship  for  sirnvastatin  in  hypertensive  hypercholesteroleamic  patients.  1994  Br  J  Clin. 
Phannacol  Vol  37  p494. 
Marshall  SF,  Meredith  PA,  Elliott  HL.  Efficacy  of  low-Density-lipoprotein  lowering  with 
Statins.  1994  Lancet  Vol  344  p683-684. 
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